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ABSTRACT OF THESIS 
Peripheral artery disease (PAD) is the third most prevalent atherosclerotic disorder after 
coronary artery and cerebrovascular disease. Irrespective of how it manifests clinically, PAD 
is consistently linked with excessive rates of major adverse cardiovascular events (MACE) and 
mortality. This thesis examines many contributing factors and provides new insights into the 
management of patients with this condition. 
The introductory chapter considers the evidence for treating individual risk factors and 
the prescription of guideline-recommended medications in PAD. Many prior observational 
studies have found an under-prescription of therapies and suboptimal risk factor control in 
PAD, compared with coronary artery disease-only. It is known from diabetes studies that 
control of multiple risk factors can have a complex interaction, whereby the sum of the parts 
does not equal the whole. Multiple risk factor control is recommended universally, although 
little is known regarding the effect on PAD. 
Chapter 2 is a post hoc analysis of the ACCELERATE trial that included 12,092 
patients with atherosclerotic cardiovascular disease. The rates of MACE are compared between 
PAD and coronary artery disease-only patients in the setting of individual and combined risk 
factor control. 
It is believed that PAD patients have high-risk coronary artery plaque that is more 
critical, diffuse and prone to thrombotic occlusion, but this has not been proven. Chapter 3 
pools data from three clinical trials of lipid-lowering therapy, whereby, coronary artery disease 
was monitored using serial intravascular ultrasound imaging. Plaque burden and disease 




Individual PAD studies indicate that there are gender discrepancies in symptoms, 
functional status, and treatment utilisation. It remains uncertain whether this translates to 
different long-term outcomes. Chapter 4 is a systematic review and meta-analysis to assess 
gender differences in MACE and mortality. Chapter 5 evaluates the gender differences in 
outcomes for the PAD patients from ACCELERATE. 
Lower extremity revascularisation, either through endovascular or surgical means, can 
be complicated by major adverse limb events and mortality. Persisting debate exists as to which 
approach has greater long-term durability and outcomes. Chapter 6 compares the long-term 
outcomes of endovascular and surgical revascularisation in unmatched and propensity-score 
matched groups. 
Dysfunctional high-density lipoprotein cholesterol (HDL-C) is an emerging 
cardiovascular risk factor that could be a therapeutic target. Previously, qualitative 
abnormalities of HDL-C were observed in Indigenous Australians, when they were compared 
to non-Indigenous Australians. Chapter 7 tests for an association between dysfunctional HDL 
and early PAD in Indigenous Australians. 
Significant health disparities are affecting young Indigenous Australians. The 
estimation of cardiovascular risk is especially problematic in this population. Chapter 8 reviews 
a young Indigenous group that was screened for PAD. Their risk of cardiovascular disease is 
estimated using traditional Framingham-based algorithms.  
Questions remain whether all patients with PAD should be treated with the most 
intensive therapies, or if there is a role for a risk-stratified approach akin to atrial fibrillation 
management. Chapter 9 evaluates several CHADS2-based scores for predicting MACE in PAD 
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1.1. Peripheral artery disease introduction 
1.1.1.  Introduction 
Peripheral artery disease (PAD) is the third most prevalent atherosclerotic disorder following 
coronary artery and cerebrovascular disease [1]. There are 237 million PAD cases reported 
worldwide, including 74 million people in the Western Pacific Region. In high-income 
countries, 7% of adults of age 25 years and above are affected. The incidence increases in older 
populations and is 21% for people of age 80 to 85 [2]. PAD is characterised by the accumulation 
of fatty plaque within the arterial vessels supplying the lower extremities [3]. Clinical 
presentations can vary from silent disease, stable intermittent claudication or atypical 
symptoms, to acute or chronic limb-threatening ischaemia [4, 5]. Irrespective of how it 
manifests clinically, PAD has a consistent link with increased mortality and with other 
cardiovascular conditions [3]. Major adverse cardiovascular events (MACE) is a composite 
endpoint used in research, which can include myocardial infarction, stroke, and associated 
mortality. Individuals with PAD have a 2-6-fold higher risk of MACE, compared to age-
matched persons in the general population [6]. Only 20-30% of affected people die from non-
cardiovascular causes, indicating the importance of secondary prevention [7]. Despite these 
issues, PAD remains under-diagnosed [8, 9], under-treated [10-12], less well known [8, 13, 
14], and less well researched than coronary artery disease and stroke [1, 2]. This introductory 
chapter outlines the risk factors, the natural history, the evidence for medical and lifestyle 





1.1.2.  Cardiovascular risk factors and PAD 
A prior meta-analysis evaluated how risk factors correlate with the prevalence of PAD in high-
income countries. A summary of these associations were as followed: age (per 10-year 
increase, odds ratio [OR] 1.65, 95% confidence interval [CI], 1.37 to 1.97), current smoking 
(OR 3.43, 95% CI, 2.58 to 4.58), former smoking (OR 1.94, 95% CI, 1.62 to 2.32), diabetes 
(OR 1.98, 95% CI, 1.77 to 2.22), hypertension (OR 1.59, 95% CI, 1.46 to 1.74), 
hypercholesterolaemia (OR 1.43, 95% CI, 1.18 to 1.74), elevated low-density lipoprotein 
cholesterol (LDL-C) (OR 1.56, 95% CI, 0.79 to 3.10), low high-density lipoprotein cholesterol 
(HDL-C) (OR 1.84, 95% CI 0.98 to 3.44), elevated triglycerides (OR 1.48, 95% CI, 1.17 to 
1.87), body mass index ≥30 kg/m2 (OR 1.07, 95% CI, 0.64 to 1.79), renal impairment (OR 
1.79, 95% CI 1.03 to 3.12), high sensitivity C-reactive protein >3.0 mg/L (OR 2.2, 95% CI, 
1.44 to 3.36) [2]. While this meta-analysis did not identify a significant link between low HDL-
C and PAD, this relationship was evident in other prospective observational studies [15]. 
The role of cardiovascular risk factors in PAD differ from other atherosclerotic 
conditions [16]. Smoking appears to have a more substantial impact in PAD pathogenesis, 
whereas the effects of hypertension and elevated LDL-C, correlate less, than with coronary 




1.2. The natural history of PAD 
1.2.1.  Abnormal ankle-brachial index 
The early stages of PAD are often under-diagnosed, as symptoms can be atypical or absent [4, 
18]. An ankle-brachial index (ABI) is a simple and accurate test that can detect PAD before 
the onset of symptoms [19]. This test involves measurements of the ankle and brachial systolic 
blood pressures using a handheld Doppler device. The ankle blood pressure is taken over the 
posterior tibial and dorsalis pedis artery, with the patient in a prone position. An ABI ≤ 0.9 is 
abnormal, and 0.9 <ABI <1.0 borderline-abnormal for PAD in the tested leg. An ABI >1.4 
suggests the lower limb artery is non-compressible, which occurs with PAD that is heavily 
calcified [19]. 
Population studies have shown that abnormalities of ABI correspond with an increased 
risk of MACE, cardiovascular-related mortality and all-cause mortality [20, 21]. A cohort of 
4,393 American Indians underwent bilateral ABI testing and then followed for 8.3 years. A U-
shaped relationship was observed between mortality and ABI. Low ABI was associated with a 
multivariate-adjusted increase in all-cause mortality (hazard ratio [HR] 1.69, 95% CI, 1.34 to 
2.14) and cardiovascular-related mortality (HR 2.52, 95% CI, 1.74 to 3.64), compared with 
normal ABI. Likewise, a high ABI correlated with an adjusted increase in all-cause mortality 
(HR 1.77, 95% CI, 1.48 to 2.13) and cardiovascular-related mortality (HR 2.09, 95% CI, 1.49 
to 2.94), in comparison with normal ABI. [22]. Similarly, a study of 3,131 patients with 
cardiovascular-related hospital presentations, ABI screening was performed, and these cases 
were followed for 4.8 years. When adjusting for cardiovascular risk factors, low and borderline 
ABI was associated with a higher risk of MACE (HR 1.93; 95% CI, 1.44 to 2.59; HR 1.54; 
95% CI, 1.03 to 2.29, respectively) (Figure 1.1) [23]. 
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Figure 1.1: Kaplan-Meier curve for major adverse cardiovascular events according to 
ABI classification 
 
Reproduced from Miura T, Minamisawa M, Ueki Y, Abe N, Nishimura H, Hashizume N, et al. 2017. Impressive 
predictive value of ankle-brachial index for very long-term outcomes in patients with cardiovascular disease: 
IMPACT-ABI study. PLoS ONE 12(6): e0177609. https://doi.org/10.1371/journal.pone.0177609. Copyright © 
Miura et al. 2017. Open access article under the terms of the Creative Commons Attribution License [23]. 





1.2.2.  Intermittent claudication 
Intermittent claudication is a typical manifestation of PAD, described as an exertional lower 
limb pain of the posterior calf and anterior thigh region. This pain usually restricts walking and 
resolves within minutes of rest [4]. It is estimated that 10-20% of people with PAD experience 
intermittent claudication, while an additional 50% have atypical leg symptoms [8, 9]. 
Symptoms of intermittent claudication can remain stable, although these patients are at high 
risk of MACE and mortality [24]. Where the condition is treated conservatively, the likelihood 
of progression to critical limb ischaemia is considered low [25, 26]. In an observational study 
of 1,107 patients with de novo intermittent claudication, some individuals were initially 
managed conservatively (37.8%) while others underwent lower extremity revascularisation 
(63.1%). The 5-year incidence of adverse outcomes for the entire cohort was as follows: minor 
amputation (0.6%), major amputation (0.2%), critical limb ischaemia (1.1%), worsening 
claudication (14.8%), MACE (36.9%), cardiovascular-related mortality (14.4%), and all-cause 
mortality (26.7%). Where major amputation was at the ankle level or above, and minor 
amputation was below the ankle [24].  
 
1.2.3.  Lower extremity revascularisation 
For patients with intermittent claudication, lower extremity revascularisation has been shown 
to improve walking and pain symptoms. In more advanced disease, revascularisation can 
enhance wound healing and limb salvageability [19]. Despite these potential benefits, this 
procedure is associated with a high risk of complications. Traditionally, revascularisation was 
achieved with open surgical repair where lower extremity disease is removed by 
endarterectomy or bypassed using an autogenous vein or prosthetic graft. In more recent times, 
endovascular repair consisting of balloon dilatation, stent insertion, and atherectomy has 
rapidly gained dominance as the preferred revascularisation procedure, although which of these 
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strategies leads to optimal patient outcomes is unclear [27]. One US study of 381,415 patients 
undergoing peripheral artery revascularisation, the 1-year incidence of adverse outcomes were 
as follows: outpatient endovascular reintervention (11.0%), major amputation (3.5%), acute 
limb ischaemia (6.0%), inpatient surgical reintervention (6.0%), inpatient endovascular 
reintervention (12.8%), acute unplanned rehospitalisation (38.9%), cardiovascular-related 
hospitalisation (12.8%), myocardial infarction (2.0%), and stroke (1.0%) [28].  
 
1.2.4.  Major adverse limb events 
Critical limb ischaemia (CLI) is characterised by severe circulatory disruption complicated by 
rest pain, skin ulceration, gangrenous infection, or the need for a lower extremity amputation 
[29]. For the initial treatment of CLI, 25% of individuals undergo primary amputation, 25% 
have medical treatment-only, and 50% have peripheral artery revascularisation. The one-year 
prognosis of CLI has been reported as resolving in 25%, continuing in 20%, progressing to 
amputation in 30%, and leading to death in 25% [7]. 
Acute limb ischaemia is a sudden thrombotic or embolic occlusion of the peripheral 
artery. Treatment is urgently required, and the 30-day amputation rate is 10-30% [7]. The rates 
of mortality following major amputation are very high, reported as 48% after one year, 61% at 
two years, and 71% at three years [30]. Of the individuals that undergo a below-knee 
amputation, 40% are fully mobile, 15% have a contralateral amputation, 15% have an above-
knee amputation, and 30% die after two years [7].  
Major adverse limb events (MALE) are a composite of clinical endpoints that may 
include CLI, acute limb ischaemia and lower extremity amputation. The COMPASS study 
examined the natural history of 128 PAD patients that experienced MALE and compared their 
outcomes with 6,263 unaffected PAD participants. Individuals that experienced MALE had 
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higher rates of cardiovascular-related hospitalisation (adjusted HR 11.7, p<0.0001), MACE or 
vascular amputation (adjusted HR 7.6, p<0.0001), and all-cause mortality (adjusted HR 3.2, 
p<0.0001), compared to those unaffected with MALE [31]. The natural history of PAD, 






Table 1.1: The natural history of PAD according to clinical presentations 




















Study follow-up  8 years 8 years 5 years 1 year 1 year 1 year 
       
1-Year event-rate*       
   Mortality - - 5.3% - 8.3% 48.3% 
   CV-mortality 2.3% 3.3% 2.9% - - - 
   MACE 3.1% 4.1% 7.4% - 3.7% - 
   MI - - - 2.0% - 5.0% 
   Stroke - - - 1.0% - 4.3% 
   CV-hospitalisation - - - 12.8% 57.6% - 
   MALE - - - 10.3% - - 
   Major amputation - - 0.04% 3.5% 20.5% - 
   CLI - - 0.2% - - - 
   ALI - - - 2.6% - - 
MACE definitions differed across studies. *The 1-year event-rate was estimated from the total 
events during follow-up in the studies cited. †These outcomes were reported from a clinical 
trial, whereby one-third of participants received treatment that significantly reduced MACE 
and MALE. Therefore, they could have been lower-risk than in real-world settings. 
Abbreviations: ABI, ankle-brachial index; ALI, acute limb ischaemia; CLI, critical limb 
ischaemia; CV, cardiovascular; MACE, major adverse cardiovascular events; MALE, major 




1.3. Medical and lifestyle management of PAD 
1.3.1.  Smoking cessation  
Smoking is a modifiable risk factor that progressively contributes to limb morbidity and MACE 
[32]. One study reviewed 739 consecutive patients undergoing peripheral angiography for 
claudication or critical limb ischaemia over a 5-year duration. In the 30% of patients that ceased 
smoking during follow-up, there was a lesser incidence of amputation and mortality, compared 
with individuals that had continued to smoke [33]. For another group of patients undergoing 
infra-inguinal bypass surgery, active smoking correlated with early graft failure after 
multivariate analysis (adjusted odds ratio 1.21, 95% confidence interval [CI], 1.02 to 1.43) 
[34]. Cessation of smoking is an essential treatment for intermittent claudication, associated 
with improved walking performance and less pain. It was demonstrated that participants with 
symptomatic PAD that abstained smoking could achieve a greater maximum treadmill walking 
distance, compared with ongoing smokers, when they were reviewed after ten months [35]. 
Clinicians should routinely offer counselling and pharmacotherapy, as these have been 
shown to improve the success of smoking abstinence [19]. One study randomised 124 
participants with a history of smoking and PAD to intensive counselling intervention or 
standard care. At six months, abstinence from smoking was higher in the intensive group 
(21.3%), compared with standard care (6.8%) [36]. 
There is evidence for safety and efficacy of pharmacotherapy (varenicline, bupropion 
and nicotine replacement therapy) when added to supportive counselling [37-39]. These 
treatments have been extensively studied in the broader population. A Cochrane review 
collated data from 150 trials inclusive of more than 50,000 study participants in randomised 
controlled trials of nicotine replacement. All available forms of nicotine replacement (gum, 
transdermal patch, nasal spray, inhaler and sublingual tablets) were found to be more effective 
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than placebo in achieving smoking abstinence, irrespective of the setting (relative risk 
reduction 1.60, 95% CI, 1.53 to 1.68). Further benefit can be derived from combining different 
forms of nicotine replacement (such as patch and gum), compared to the use of a single type. 
Also, the addition of nicotine replacement therapy to bupropion was more effective than 
bupropion alone [40]. Varenicline, a partial nicotinic acetylcholine receptor agonist, was tested 
in patients with known cardiovascular disease. There were 714 participants, including 179 
people (25.1%) with PAD, that received smoking-cessation with varenicline (1mg twice daily) 
or placebo for 12 weeks. Varenicline appeared safe and was more effective than placebo, with 
an uninterrupted abstinence rate between weeks 9 to 52 (19.2% versus 7.2%, p<0.0001) [38].  
 
Recommendation: Smoking cessation counselling and pharmacotherapy (nicotine 
replacement therapy, bupropion, or varenicline) is strongly recommended. 
 
 
1.3.2.  Exercise therapy 
Regular physical activity is inversely correlated with the risk of mortality in people with PAD 
[41]. Exercise is the most effective non-invasive therapy for symptoms of intermittent 
claudication. The American Heart Association recommends a supervised exercise program 
comprising at least three walking sessions per week (30 to 60 min each) for a minimum duration 
of 12 weeks [19]. A systematic review evaluated the effect of supervised walking therapy on 
ambulation, with a pool of 25 randomised controlled trials and 1,054 participants having 
intermittent claudication. Supervised walking therapy was associated with an increase in 
maximum walk distance (180 metres, 95% CI, 130 to 340 metres) and pain-free walk distance 
(128 metres, 95% CI, 92 to 165 metres), compared with non-intervention [42]. Comparisons 
32 
 
have been made between supervised and unsupervised training. A meta-analysis combined 14 
PAD studies, where these interventions were directly compared. Unsupervised exercise 
differed between these studies and included walking advice and home-based programs. 
Supervised exercise therapy led to significant improvement in maximal walking and pain-free 
walking distance at 12-months, compared with unsupervised training. The maximal walk 
distance increase amounted to 180 metres, but there was no significant effect on the quality of 
life scores. The authors of this meta-analysis suggested that direct supervision might enhance 
the workload and adherence to training, although this has not been conclusively proven [43]. 
Supervised exercise therapy is recommended as an initial treatment for intermittent 
claudication before consideration for lower limb revascularisation [19]. The CLEVER study 
randomly divided patients with aortoiliac disease into three groups: control, supervised 
exercise therapy and stent revascularisation; all receiving optimal medical therapy. From 
baseline to 18 months, both interventions improved peak walk time and quality of life scores, 
compared with control. There was no significant difference in peak walk time between 
supervised exercise and stent revascularisation. There was a demonstrable increase of 
claudication onset time for supervised exercise but not for stent revascularisation, in 
comparison with control. Overall, the CLEVER study established exercise as a viable initial 
treatment for intermittent claudication [44]. The combination of revascularisation and 
supervised exercise therapy could be more effective than either treatment alone. In a meta-
analysis, which included eight clinical trials, combined therapy led to a favourable increase in 
the maximal walk (mean difference [MD] range 82 to 321 metres) and pain-free walk distance 
(MD range 38 to 408 metres), compared with revascularisation or supervised training alone 
[45]. However, supervised exercise therapy is usually the initially preferred, as 
revascularisation is often associated with procedural risks, and long-term outcomes have not 
been well characterised [19, 28]. 
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Supervised exercise therapy is safe for most patients with PAD, but implementation can 
be challenging. Cardiovascular disease, lower limb rest pain, ulceration or amputation and 
other medical comorbidities can restrict the ability to exercise [46]. One study examined the 
participation of 201 patients with stable claudication at three physical rehabilitation centres. 
Physical contraindications significantly limited approximately one-third of people. An 
additional third of the cohort was unable to attend, with transport and time issues commonly 
being reported [47]. While studies of supervised exercise have been mostly walking-based, 
there are other possibilities, including cycling, strength training and arm-cranking. These could 
be useful when a walking-based program is not feasible. One review found no significant 
differences in the benefits of supervised walking and other training methods. Both interventions 
improved the quality of life scores. More evidence is needed to clarify the differences in these 
training methods [48].  
Transportation options can limit supervised exercise therapy at facilities [49]. There is 
increasing attention to alternative structured exercise programs, that require less travelling to 
centres. Structured community or home-based exercise programs utilise clinician-supported 
and instruction-based techniques. A clinical study of 180 patients examined the effect of a step-
monitored home exercise program on walking. Participants with mild-to-moderate severity 
intermittent claudication were randomised to step-monitored home exercise, supervised 
exercise or the control group for 12 weeks. The step-monitored home exercise was comparable 
to supervised training, with regards to walking performance and participant compliance [50]. 
 
Recommendation: Supervised exercise therapy is recommended for intermittent 
claudication, wherever practical. Home- and community- based exercise programs can 
be implemented as an alternative. 
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1.3.3.  Antiplatelet therapy 
The American Heart Association recommends antiplatelet monotherapy for all patients with 
symptomatic PAD [19]. In a previous meta-analysis, aspirin monotherapy was associated with 
a reduction in stroke (HR 0.64, 95% CI, 0.42 to 0.99), but no significant difference in major 
adverse cardiovascular events, cardiovascular mortality, myocardial infarction or major 
bleeding, compared with placebo. However, differences might have been observed in these 
studies if they were more extensive [51]. The CAPRIE study compared the relative efficacy of 
clopidogrel (75mg daily) and aspirin (325mg daily) in reducing MACE (composite of 
cardiovascular mortality, myocardial infarction and stroke). Of the total 19,185 participants, 
there was a cohort of 6,452 (33.6%) persons classified as having symptomatic PAD. In this 
subgroup, clopidogrel was associated with a 23.8% relative risk reduction in MACE compared 
to aspirin. Both treatments had comparable rates of major bleeding [52]. While clopidogrel was 
more efficacious than aspirin in the CAPRIE study, the American Heart Association does not 
have a preference. Also, dual antiplatelet therapy for people with intermittent claudication is 
not usually recommended [19]. The CHARISMA trial randomised 15,603 patients with stable 
atherosclerotic disease (or multiple cardiovascular risk factors) to aspirin and clopidogrel 
combination or aspirin monotherapy. In a post hoc analysis of 3,096 participants with PAD, 
there was no difference between dual antiplatelet therapy and aspirin alone in MACE 
(composite of myocardial infarction, stroke and cardiovascular mortality), stroke, all-cause 
mortality or severe bleeding. Among other secondary endpoints, combination therapy reduced 
myocardial infarction (HR 0.63, 95% CI, 0.42 to 0.96), and rate of hospitalisation for ischaemic 
events (HR 0.81, 95% CI, 0.68 to 0.95), but was associated with increased minor bleeding (HR 
1.99, 95% CI, 1.69 to 2.34) [53] (outlined in Table 1.2). 
There is some evidence for prescribing dual antiplatelet therapy following lower limb 
revascularisation, although the relevant studies were too small to evaluate cardiovascular 
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outcomes. One randomised controlled trial of 80 participants found that dual antiplatelet 
therapy was associated with lower disease restenosis and target revascularisation following 
elective femoropopliteal angioplasty, compared with aspirin alone. However, these benefits did 
not extend to one year, where clopidogrel was ceased at six months. Therefore, prolonged dual 
antiplatelet therapy (> 6months) should be considered for patients who are deemed at high risk 
of restenosis [54]. In another study, the addition of clopidogrel to aspirin significantly improved 
limb outcomes in the subgroup undergoing below-knee prosthetic graft operation, but not those 
receiving a venous graft [55].  
Alternative antiplatelet therapy has been evaluated in patients with symptomatic PAD. 
Ticagrelor is a P2Y12 inhibitor, indicated for acute coronary syndrome [56]. The EUCLID study 
randomised 13,885 patients with symptomatic PAD to ticagrelor (90mg twice daily) or 
clopidogrel (75mg daily). There was no significant difference between groups in MACE, acute 
limb ischaemia, or major bleeding [57] (outlined in Table 1.3).  
 
Recommendation: Clopidogrel is preferable to aspirin monotherapy for all patients. 
Prolonged dual antiplatelet therapy (> 6months) should be considered following 
revascularisation in those at high risk of restenosis. The evidence for the use of dual 
antiplatelet therapy to reduce MACE is lacking, although clinicians should follow 
relevant guidelines when there is co-existent coronary artery disease.  
 
1.3.4.  Anticoagulant therapy 
Warfarin, unfractionated heparin and low-molecular-weight heparin have not been 
demonstrated to reduce ischaemic events, and they increase bleeding risk when compared with 
antiplatelet monotherapy [58]. The WAVE trial randomised 2,161 patients with PAD to an 
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antiplatelet alone or the combination of an antiplatelet with warfarin (target international 
normalised ratio [INR] 2.0 to 3.0). Combined antithrombotics did not reduce MACE, and there 
was an increase in life-threatening bleeding (HR 3.41, 95% CI, 1.84 to 6.35) [59]. The BOA 
trial compared warfarin (INR target 3.0 to 4.5) with aspirin alone in 2,690 patients that 
underwent an infrainguinal bypass operation. There was no difference in the rate of MACE or 
graft occlusion, and anticoagulation was associated with higher bleeding events [60]. In the 
absence of another indication, these anticoagulants are not recommended in patients with PAD 
[19]. 
While current guidelines recommend antiplatelet monotherapy to reduce the risk of 
MACE and major adverse limb events in PAD [19, 61], these could be revised, in light of more 
recent evidence. Rivaroxaban is a direct-acting anticoagulant which has been researched in 
stable and unstable cardiovascular presentations [31, 62, 63]. ATLAS ACS 2-TIMI 51 was a 
randomised controlled trial that investigated the effect of additional rivaroxaban to standard 
antiplatelet therapy immediately following an acute coronary syndrome. A total of 15,526 
patients were randomised to rivaroxaban 2.5mg twice daily, 5mg twice daily or placebo for a 
mean of 13 months and up to 31 months. Rivaroxaban  (pooled doses) was associated with 
reduced major adverse cardiovascular events (HR 0.84, 95% CI, 0.74 to 0.96), increased risk 
of major bleeding (HR 3.96, 95% CI, 2.46 to 6.38) and intracranial haemorrhage (HR 3.28, 
95% CI, 1.28 to 8.42), but not fatal bleeding (HR 1.19, 95% CI, 0.54 to 2.59, p=0.66) [62]. 
Excessive major bleeding has precluded rivaroxaban from being recommended for acute 
coronary syndrome management.  
COMPASS was a randomised controlled trial that investigated MACE and limb 
outcomes in 27,395 people with stable atherosclerotic vascular disease, including 6,391 
persons with PAD. Participants were randomised to three groups, rivaroxaban alone (5mg 
twice daily), the combination of rivaroxaban (2.5mg twice daily) plus aspirin (100mg daily) or 
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aspirin alone (100mg daily). The PAD subgroup appeared to benefit more than the other high-
risk participants [31, 63, 64]. Combined low-dose rivaroxaban and aspirin was associated with 
a reduction in MACE (HR 0.67, 95% CI, 0.52 to 0.87) [63], major adverse limb events (HR 
0.57, 95% CI, 0.37 to 0.88), and major amputation (HR 0.33, 95% CI, 0.12 to 0.92), at the 
expense of increased major bleeding (HR 1.60, 95% CI, 1.09 to 2.36), compared with aspirin 
alone [31]. Of note, COMPASS recruited people with stable PAD, where the risk of major 
adverse cardiovascular and limb events is significantly less than with critical limb ischaemia 
[24, 31]. The reduction in MACE was driven predominantly by fewer ischaemic stroke [63]. It 
could be argued that combined low-dose rivaroxaban and aspirin had a modest absolute 
reduction in stroke and major adverse limb events, compared to aspirin alone (approximately 
1.0% and 1.1%, respectively) [31, 63]. Therefore, when prescribing combined low-dose 
rivaroxaban and aspirin, the net benefit of MACE and major adverse limb events needs to be 
weighed against the risk of major bleeding. In COMPASS, rivaroxaban alone did not improve 
cardiovascular or limb outcomes and was associated with increased major bleeding, compared 
to aspirin alone [63]. 
Patients presenting with critical limb ischaemia have a high risk of subsequent MACE 
and major adverse limb events [31]. Critical limb ischaemia leads to amputation in 10-40% of 
presentations, and this is a contributor to permanent disability and exceptionally high mortality 
rates, estimated at 40-70% within five years [6]. Few studies have investigated antithrombotic 
use in this setting to guide clinical practice. Likewise, lower extremity revascularisation is 
another clinical driver of MACE and major adverse limb events [28, 31]. The EPAD study 
compared edoxaban with clopidogrel, in addition to aspirin in 203 participants following a 
femoropopliteal endovascular intervention. This was a proof-of-concept study, which 
suggested edoxaban could be associated with lower bleeding and restenosis or occlusion, in 
comparison with clopidogrel [65]. VOYAGER PAD is an upcoming cardiovascular outcome 
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study. A total of 6,500 participants are being randomised to rivaroxaban 2.5mg twice daily or 
placebo following lower extremity revascularisation [66].  
 
Recommendation: In patients at high risk of ischaemic cardiovascular or lower limb 
events, where bleeding risks are low, a combination of low-dose rivaroxaban and aspirin 
should be considered. 
 
1.3.5.  Antihypertensive therapy 
Treatment of hypertension reduces the risk of MACE in the general population [67]. In one 
meta-analysis, patients with a higher baseline cardiovascular risk that were treated with 
antihypertensive therapy had a greater absolute risk reduction [68]. Few of these studies 
specifically included people with PAD. The HOPE study was a randomised controlled trial 
where ramipril therapy in the PAD cohort led to a 22% relative risk reduction in major adverse 
cardiovascular events [69]. ON TARGET (Ongoing telmisartan alone and in combination with 
ramipril global endpoint trial) included 3,468 patients with PAD. The study generally found no 
difference in MACE (composite endpoint of cardiovascular-related mortality, myocardial 
infarction, stroke or hospitalisation for heart failure) between the telmisartan and ramipril 
therapy groups, indicating they have comparable benefits [70]. Angiotensin-converting 
enzyme (ACE) inhibitors can improve walking performance in patients with symptomatic 
PAD. One meta-analysis, which pooled six randomised controlled trials found that ACE 
inhibitors were associated with an increase in maximum walk distance and pain-free walk 
distance, compared with placebo [71]. Overall, ACE inhibitors or angiotensin-2 receptor 
blockers may be preferred antihypertensives, as they may have potential additional benefits. 
Beta-blockers are considered safe, despite theoretical concerns that this can exacerbate lower 
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extremity ischaemia  [72]. Treatment-resistant hypertension is a condition that shares many 
risk factors with PAD, including older age, renal impairment and diabetes [73]. In a previous 
single-centre study of 491 patients undergoing lower extremity angiography for PAD, renal 
artery stenosis was evident in 26% [74]. Given the high prevalence of these comorbidities 
among PAD patients, at least two antihypertensive agents are usually required [7, 75].  
The ideal blood pressure target for high-risk patients has been a point of contention [76-
80]. Lowering blood pressure to below 140/90 mmHg was the standard recommendation [81]. 
The ACCORD BP study found no cardiovascular benefit of more intensive control (target 
systolic blood pressure <120 mmHg) in patients in type 2 diabetes, compared with standard 
control (target systolic blood pressure <140 mmHg). Intensive therapy was also associated with 
a higher incidence of severe adverse events, including hypotension, syncope, bradycardia, 
hyperkalaemia, and acute kidney injury [82]. Subsequently, a meta-analysis evaluated 
cardiovascular outcomes from 31 antihypertensive intervention studies in patients with 
diabetes. More intensive blood pressure reduction was associated with a 9% lower incidence 
of stroke, compared with lower intensity therapy. For each 5-mmHg reduction in systolic blood 
pressure, the risk of stroke decreased by 13%. However, there was no association between the 
extent of blood pressure reduction and the risk of myocardial infarction [83]. 
SPRINT examined hypertension management in patients without diabetes and had 
similar blood pressure goals to ACCORD BP. Intensive treatment reduced the incidence of the 
MACE, compared with standard treatment (HR 0.75, 95% CI, 0.64 to 0.89), at the expense of 
increased incidence of severe adverse events. While SPRINT did demonstrate the efficacy of 
intensive blood pressure control, there are concerns with how these findings can be 
extrapolated to different populations. This study did not specifically investigate PAD, and 
people with diabetes, end-stage renal disease, age of 75 years or older or prior stroke were 
excluded [84]. Therefore, it could be argued that patients of a higher complexity were not 
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evaluated. These types of patients might be more susceptible to the side effects of blood 
pressure-lowering [85]. Worsening renal function is an adverse event that is especially relevant 
for people with existing chronic kidney disease. The subgroup of SPRINT with stage 3 to 4 
chronic kidney disease (estimated glomerular filtration rate [GFR] between 20 and 60 
ml/min/1.73 m2) did appear to benefit from intensive blood pressure control. Nevertheless, 
blood pressure reduction in chronic kidney disease should be performed gradually and with 
caution, given the risk of worsening GFR and electrolyte abnormalities [73]. 
Dizziness and other side effects from intensive blood pressure reduction can limit 
treatment adherence. Some factors affecting compliance include increasing age (≥80 years), 
previous non-adherence, side effects, presence of multiple medical comorbidities, 
polypharmacy and excessive cost burden [75]. Many experts advocate for a more 
individualised blood pressure target in elderly patients, with the aid of frailty-defining scores 
[85]. Overall, it is reasonable for the clinician to treat hypertension intensively (target systolic 
blood pressure of 120 mmHg) for patients with PAD, in the absence of risk factors associated 
with safety and non-adherence. 
 
Recommendation: It is reasonable to treat hypertension intensively (systolic blood 
pressure goal of 120 mmHg), where it is perceived to be safe and well-tolerated. 
Otherwise, treat with a more conservative target (blood pressure <140/90 mmHg). 





1.3.6.  Lipid-lowering therapy 
Statins are clinically indicated for all patients with PAD, regardless of lipid levels [19]. In the 
Heart Protection Study 20,436 high-risk participants, including 6,748 with PAD, were 
randomised to receive simvastatin 40mg daily or placebo. Simvastatin in the PAD subgroup 
was associated with a 22% relative risk reduction in the incidence of MACE. The observed risk 
reduction for participants with a baseline total cholesterol less than 5.0 mmol/L or low-density 
lipoprotein cholesterol (LDL-C) less than 3.0 mmol/L was comparable to those with more 
elevated lipids [86]. The REACH registry found that statin therapy was associated with less 
cardiovascular and limb events. Of the total 68,236 participants enrolled, there was a cohort of 
5,861 patients with symptomatic PAD prospectively followed for four years. In a multivariate 
analysis, patients on statins at baseline (62.2%) were compared with those who were not 
(37.8%). Statin therapy was associated with a reduced composite of adverse limb events (HR 
0.82, 95% CI, 0.72 to 0.95) and MACE (HR 0.83, 95% CI, 0.73 to 0.96). Specifically, patients 
on statins had a lower incidence of worsening claudication or development of new critical 
ischaemia, new lower extremity percutaneous or surgical revascularisation, and new ischaemic 
amputation, compared with those who were not [87]. High-intensity statin therapy is preferable. 
In one meta-analysis that pooled 39,612 participants from secondary prevention studies, high-
intensity statin was associated with a 15% relative risk reduction in major vascular events, 
compared with low-intensity therapy. This MACE benefit correlated with the level of LDL-C 
reduction across all studied patient types, even those with an LDL-C less than 2 mmol/L. 
Overall, a lowering of LDL-C by 2-3 mmol/L approximated to a 40-50% risk reduction [88]. 
In a study of 909 PAD patients that underwent peripheral angiography, high-intensity statin 
use was associated with improved survival (HR 0.52, 95% CI, 0.33 to 0.81) and lesser MACE 
(HR 0.58, 95% CI, 0.37 to 0.92), compared with a lower-intensity statin. This divergence in 
outcomes was observed despite the group similarities in demographics, mean LDL-C level, 
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and other cardiovascular risk factors [89]. Statins also improved walking performance and pain 
symptoms in small randomised controlled trials of patients with intermittent claudication [90, 
91]. In one study, 69 participants with symptomatic PAD were randomised to simvastatin 
40mg/day or placebo for one year. The simvastatin group had a more prolonged treadmill 
exercise time until claudication of 54 seconds (24% increase) and 94 seconds (42% increase) 
when studied at 6 and 12 months respectively [90].  
There is evidence for other LDL-C lowering therapies, including ezetimibe and protein 
convertase subtilisin/kexin type 9 (PCSK9) inhibitors in high-risk populations [92]. In the 
FOURIER study, there were 3,642 patients with PAD that were randomised to receive 
evolocumab (PCSK9 inhibitor) or placebo. For PAD patients treated with evolocumab, there 
was significant relative risk reduction in MACE (HR 0.79, 95% CI, 0.66 to 0.94), but not for 
major adverse limb events (HR 0.63, 95% CI, 0.39 to 1.03). However, in all 27,564 
participants, evolocumab was associated with reduced major adverse limb events (HR 0.58, 
95% CI, 0.38 to 0.88). There was a linear correlation between LDL-C reduction and lesser limb 
events that continued even to levels below 10 mg/dL (0.26 mmol/L) [93]. PCSK9 inhibitors 
are not commonly used at this time. Some caveats include a lack of long-term safety data, as 
well as some economic considerations [94]. Lipid targets are recommended to guide the 
prescription of non-statin treatments. For individuals on maximally tolerated statin therapy, it 
is reasonable to add ezetimibe or PCSK9 inhibitors with a goal of a ≥50% LDL-C reduction, 
or LDL-C <1.8 mmol/L and non-high-density lipoprotein cholesterol (non-HDL-C) <2.6 
mmol/L. Ezetimibe is a commonly prescribed LDL-C lowering treatment that is currently more 
accessible than PCSK9 inhibitors [92]. The clinician should also consider additional risk 
factors that warrant intensive lipid-lowering including age ≥65 years, prior myocardial 
infarction or ischaemic stroke, current smoking, history of coronary revascularisation or 
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residual multi-vessel coronary artery disease, metabolic syndrome or high sensitivity C-
reactive protein >2mg/L [92, 94]. 
 
Recommendation: Maximally tolerated statins are recommended for all patients, 
irrespective of lipid levels. Consider the addition of ezetimibe or PCSK9 inhibitors to 
achieve a goal of ≥50% LDL-C reduction, or LDL-C <1.8 mmol/L and non-HDL-C <2.6 
mmol/L. 
 
1.3.7.  Glycaemic control in diabetes 
The benefit of intensive glycaemic control for patients with diabetes and PAD is unclear. 
Diabetes is a major risk factor for cardiovascular disease and PAD [95]. The duration and 
degree of hyperglycaemia have been linked with disease burden. In the UKPDS, each 1% 
increase in glycated haemoglobin was associated with a 28% increased incidence of PAD, 
independent of other risk factors [96]. Individuals affected with PAD and diabetes are more 
likely experience aggressive manifestations of the disease, such as worsening lower extremity 
function, sudden arterial thrombosis, and ischaemic ulceration, compared to those with PAD 
alone [97]. This pathophysiology contributes between 5- to 10-fold increased likelihood of 
major lower limb amputation [7]. Small observational studies have examined clinical outcomes 
in patients with diabetes undergoing lower extremity revascularisation. Poor glycaemic control 
correlated with decreased arterial patency rates and increased risk of major adverse limb events 
[98, 99]. A post hoc analysis of patients with diabetes and PAD in the EUCLID trial showed 
that every 1% increase in HbA1c, was associated with a 14% increased relative risk for MACE 
[100]. However, intensive glycaemic control in patients with established atherosclerotic 
cardiovascular disease has not been shown to improve cardiovascular outcomes in randomised 
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clinical trials. One meta-analysis pooled four large randomised controlled trials, comparing 
intensive and standard glycaemic control in patients with diabetes. Intensive therapy led to a 
mean reduction of HbA1c by 0.88% at the final visit, and a 9% relative risk reduction (95% 
CI, 1-16%) of major adverse cardiovascular events, compared with standard therapy. However, 
for the subgroup with a history of vascular disease, intensive glycaemic control did not 
significantly improve macrovascular outcomes. Also, intensive therapy for all participants was 
associated with an increased incidence of severe hypoglycaemia (HR 2.48, 95% CI, 1.91 to 
3.21), compared with standard therapy [101]. Another meta-analysis examined the effect of 
tight glycaemic control for patients with diabetes on microvascular complications. Intensive 
therapy reduced renal events (HR 0.80, 95% CI, 0.72 to 0.88), and there was a trend towards 
lesser ophthalmic events (HR 0.87, 95% CI, 0.76 to 1.00). There was no reduction in 
neuropathy with intensive-treatment in comparison with standard therapy, although assessment 
was limited to variable and subjective methods in these studies [102]. 
The risks of hypoglycaemia should always be considered when setting glycaemic 
targets. Hypoglycaemia is frequent and under-recognised in the elderly. It is associated with 
falls, cognitive impairment and hospitalisation. The use of a longer-acting sulfonylurea or an 
intensive insulin regimen, polypharmacy, renal disease, cognitive impairment, malnutrition 
and physical frailty all increase the likelihood of hypoglycaemia [103, 104].  
Sodium-glucose cotransporter 2 inhibitors (SGLT2) have emerged as new 
hypoglycaemic agents, with broad metabolic effects. In addition to glycaemic control, they 
have been associated with a reduction in weight, waist circumference, blood pressure and 
increases in LDL and HDL cholesterol. In the CANVAS Program study, canagliflozin therapy 
was associated with a relative risk reduction in MACE (HR 0.86, 95% CI, 0.75 to 0.97), 
compared with placebo. However, the canagliflozin group had a higher risk of lower limb 
amputation (HR 1.97, 95% CI, 1.41 to 2.75). Currently, the mechanism and clinical 
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implications of this finding are unclear [105]. This unexpected safety signal was not evident in 
studies of other SGLT2 inhibitors. EMPA-REG was a randomised controlled trial of 
empagliflozin, where 7,020 patients (including 1,461 patients with a history of PAD). 
Empagliflozin reduced MACE (HR 0.86, 95% CI, 0.74 to 0.99), and this was driven by a 38% 
relative risk reduction in cardiovascular-related mortality [106]. SGLT2 inhibitors appear to 
have broad metabolic benefits and reduce major adverse cardiovascular events. Nevertheless, 
caution would be advised in patients with PAD, given the correlation between canagliflozin 
therapy and an increased incidence of lower limb amputation. The recommendations for 
management of PAD is summarised in Table 1.4. 
 
Recommendation: Glycaemic goals should be individualised in patients with diabetes. A 






Table 1.2: Earlier cardiovascular outcome trials 
 CHARISMA 
N = 3,096 
WAVE 
N = 2,161 
HOPE 
N = 4,051 
HPS 
N = 6,748 
Treatment Antiplatelet Anticoagulation Hypertension Dyslipidaemia 
Study Type RCT RCT RCT RCT 
Study Group PAD cohort Symptomatic PAD 
or cerebrovascular 
disease 











(75mg once daily) 
(1) Warfarin 
(target INR 2.0 to 
















3-point MACE 3-point MACE 3-point MACE 3- point MACE 




CV Mortality 0.92 (0.65-1.28) 1.04 (0.74-1.46) - - 
All-Cause 
Mortality 
0.89 (0.68-1.16) 1.04 (0.79-1.38) - - 
MI 0.63 (0.42-0.96) 0.82 (0.57-1.18) - - 
Stroke 0.79 (0.51-1.21) 1.01 (0.65-1.59) - - 
Major 
Bleeding 
0.97 (0.56-1.66) 3.41 (1.84-6.35) - - 
Minor 
Bleeding 
1.99 (1.69-2.34) 3.63 (3.01-4.38) - - 
 
All relative risks are expressed as a hazard ratio (HR) and (95% confidence intervals), with placebo as the 
reference group. Data is from the following trials: CHARISMA [53], WAVE [59], HOPE [69], HPS [86]. 
Definitions of MACE are as follows: CHARISMA (CV mortality, MI and stroke); WAVE (CV mortality, MI and 
stroke); HOPE (CV mortality, MI and stroke); HPS (MI, stroke, coronary or non-coronary revascularisation).  
Abbreviations: ACS, acute coronary syndrome; ALI, acute limb ischaemia; BD, twice daily; CV, cardiovascular; 
HR, hazard ratio; LLA, lower limb amputation; MACE, major adverse cardiovascular events; MI, myocardial 




Table 1.3: Contemporary cardiovascular outcome trials 
 EUCLID 
N = 13,885 
COMPASS PAD 
N = 7,470 
SPRINT 
N = 9,361 
FOURIER 
N = 3,642 
EMPA-REG 
N = 1,461 
Treatment Antiplatelet Anticoagulation Hypertension Dyslipidaemia Diabetes 
Design RCT RCT RCT RCT RCT 






































































































































- - - 


















All relative risks are expressed as a hazard ratio (HR), with placebo as the reference group. Data is from the 
following trials: EUCLID [57], COMPASS [31, 63], SPRINT [84], FOURIER [93], EMPA-REG [107]. 
Definitions of MACE are as follows: EUCLID (CV mortality, MI and ischaemic stroke); COMPASS PAD (CV 
mortality, MI and stroke); SPRINT (MI, stroke, heart failure and mortality); FOURIER (CV mortality, MI, stroke, 
and hospitalisation for ACS or coronary revascularisation); EMPA-REG (CV mortality, MI, stroke, and 
hospitalisation for ACS). Abbreviations as per Table 1.2.  
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Table 1.4: Summary of recommendations for the management of PAD 
 Recommendations in peripheral artery disease 
Smoking cessation Smoking cessation counselling and pharmacotherapy (nicotine 
replacement therapy, bupropion, or varenicline) is strongly 
recommended. 
Exercise therapy Supervised exercise therapy is recommended for intermittent 
claudication, wherever practical. Home- and community- based 
exercise programs can be implemented as an alternative. 
Antiplatelet therapy 
 
Clopidogrel is preferable to aspirin monotherapy for all patients. 
Prolonged dual antiplatelet therapy (> 6months) should be 
considered following revascularisation in those at high risk of 
restenosis. The evidence for the use of dual antiplatelet therapy to 
reduce MACE is lacking, although clinicians should follow relevant 
guidelines when there is co-existent coronary artery disease.  
Anticoagulant 
therapy 
In patients at high risk of ischaemic events, where bleeding risks are 




It is reasonable to treat hypertension intensively (systolic blood 
pressure goal of 120 mmHg), where it is perceived to be safe and 
well-tolerated. Otherwise, treat with a more conservative target 
(blood pressure <140/90 mmHg). Generally, the preference is for 




Maximally tolerated statins are recommended for all patients, 
irrespective of lipid levels. Consider the addition of ezetimibe or 
PCSK9 inhibitors to achieve a goal of ≥50% LDL-C reduction, or 
LDL-C <1.8 mmol/L and non-HDL-C <2.6 mmol/L. 
Glycaemic control in 
diabetes 
Glycaemic goals should be individualised in patients with diabetes. 
A target HbA1c <7.0% could be considered, in patients without a 




1.4. Other areas for further investigation in PAD 
1.4.1.  Critical limb ischaemia management 
Critical limb ischaemia (CLI) is characterised by a significant disruption in limb perfusion, 
which can be complicated by rest pain, ulceration, gangrenous infection, and could necessitate 
a lower extremity amputation [7]. Management of CLI is distinct from earlier stages of PAD. 
For intermittent claudication, the emphasis is usually to provide non-invasive treatments, 
whereas, in CLI, there is a greater dependency on lower extremity intervention [7, 28]. The 
consequences of delayed diagnosis can be devastating, as the salvageability of a lower limb 
can depend on the timeliness of revascularisation and wound care [108, 109]. Traditionally, 
revascularisation was achieved with open surgical repair where lower extremity disease is 
removed by endarterectomy or bypassed using an autogenous vein or prosthetic graft. In more 
recent times, endovascular repair consisting of balloon dilatation, and stent insertion has gained 
dominance as the preferred revascularisation procedure, although which of these strategies 
leads to optimal long-term patient outcomes is unclear [19]. 
A diverse and well-connected team approach is required to cater for a variety of patient 
needs [29]. One single-centre study compared outcomes of standard care with multidisciplinary 
care in 146 consecutive cases of CLI. Standard care was defined as input from different medical 
providers, without an appointed case manager or a system for open communication and referral. 
Multidisciplinary care featured regular collaborations between vascular, plastic and podiatry 
surgeons, and further consultation from infectious disease, internal medicine and cardiology 
specialists. The investigators of this study described an inefficiency and lack of medical 
continuity with the standard approach. Multidisciplinary care was associated with a two-fold 
improvement in amputation-free survival [110]. 
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CLI is associated with very high rates of MACE and mortality, although the evidence 
for risk factor control is limited [19]. CLI is associated with frailty and renal impairment [111, 
112], and there can be a high susceptibility to adverse events when hypertension and diabetes 
are treated intensively [85, 103, 104]. The evidence of benefit from pharmacotherapies in PAD 
has been mostly extrapolated from lower risk cohorts [29]. There is no consensus regarding the 
role of intensive medical therapy, and more research is needed to guide clinical practice.  
 
1.4.2.  Weight loss in obesity 
Weight loss for people with obesity is recommended for the general population. Many potential 
benefits relate to a reduction in blood pressure, hypertriglyceridaemia, hyperglycaemia, 
inflammation and obstructive sleep apnoea [113]. Whether such benefits translate to improved 
long-term cardiovascular outcomes in PAD is unclear. A meta-analysis combined seven 
observational studies of PAD and showed that obesity was associated with a 9% increased risk 
of MACE [114]. Similar to coronary artery disease, an obesity paradox has been described in 
PAD [115]. A study of 2,392 patients that underwent major vascular surgery found an inverse 
relationship between the body mass index (BMI) and mortality. Obese (BMI >30) and 
overweight (BMI =25-30) patients had more favourable outcomes than normal (BMI =18.5-
24.9) and underweight (BMI <18.5) people. However, there was an over-representation of 
chronic respiratory disease in normal and underweight people, where a low BMI can be 
detrimental [116]. PAD has an association with chronic respiratory disease, primarily due to 
high smoking use in these patient populations [117]. Therefore, medical comorbidities, such as 
chronic respiratory disorders, are relevant when considering a weight loss intervention. More 




1.4.3.  Inflammatory control 
Elevated inflammation, as quantified by high-sensitivity C-reactive protein (hs-CRP), 
correlates with an increased incidence of MACE and mortality [118, 119]. Some cardiovascular 
benefits of statins have been related to a reduction in hs-CRP [120]. CANTOS was a recent 
cardiovascular outcome study that investigated the efficacy of canakinumab, which directly 
acts in lowering inflammation. A total of 10,061 participants with previous myocardial 
infarction and elevated hs-CRP (> 2mg/L) were randomised to canakinumab or placebo. In the 
canakinumab-treated individuals that achieved a hs-CRP <2 mg/L, there was a 25% relative 
risk reduction in MACE, compared to on-treatment participants that had persistently elevated 
hs-CRP. These findings demonstrate the efficacy of lower inflammation in high-risk patients 
[121, 122]. However, canakinumab is not yet commercially available and has not been studied 
in PAD patients. 
 
1.4.4.  High-density lipoprotein cholesterol 
Low high-density lipoprotein cholesterol (HDL-C) is a widely accepted risk factor for 
cardiovascular disease [123] and has been associated with symptomatic PAD [15, 124, 125]. 
Where LDL-C lowering therapies have been shown to reduce MACE, medications targeting 
an increase in HDL-C have been ineffective [126]. One hypothesis is that these treatments do 
not address the qualitative abnormalities of HDL-C, which is common in coronary artery 
disease [127]. Dysfunctional HDL, as defined by a low HDL-mediated cholesterol efflux 
capacity (HDL CEC), is an independent predictor of MACE [128, 129]. The infusion of 
reconstituted HDL into patients has been shown to increase cholesterol efflux capacity [130], 
and the effect on MACE is being tested in a randomised controlled trial [131]. No link has been 
established between dysfunctional HDL and atherogenesis in the peripheral arteries. 
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1.4.5.  Multiple risk factor control 
The evidence for prescribing preventative medications and achieving individual risk factor 
control in PAD has been discussed. However, the effect of intensive multiple risk factor control 
is not well understood. In the Steno-2 study, 160 people with type 2 diabetes and 
microalbuminuria were randomised to receive either a multifactorial intervention or standard 
care for 7.8 years. These participants were subsequently followed for 13.4 years after this 
intervention (21.2 years following randomisation) [132, 133]. The risk factor targets that were 
set were a glycosylated haemoglobin <6.5%, fasting total cholesterol <4.5 mmol/L (175 
mg/dL), fasting triglyceride level <1.7 mmol/L (150 mg/dL), systolic blood pressure <130 
mmHg, and diastolic blood pressure <80 mmHg. The multifactorial intervention included: 
dietary modification with an emphasis on limiting saturated fat intake; light-to-moderate 
exercise for at least 30 minutes three to five times weekly; smoking cessation counselling for 
participants and their partners; daily vitamin and mineral supplementation; and a stepwise 
escalation in the pharmacological treatment of hyperglycaemia, hypertension, and 
dyslipidaemia. Angiotensin-converting enzyme (ACE) inhibitor or an angiotensin 2-receptor 
blocker were routinely prescribed [134]. Patients that were randomised to intensive treatment 
were more likely to achieve control of individual risk factors than those that were not, although 
these differences mostly attenuated after the intervention had ended [134]. At 21.2 years after 
randomisation, the multifactorial intervention was associated with a lower risk of mortality 
(HR 0.54, 95% CI, 0.32 to 0.89), major adverse cardiovascular or limb events (HR 0.41, 95% 
CI, 0.25 to 0.67), and the end-stage progression of diabetic nephropathy and retinopathy [132]. 
There was a delayed impact of intensive treatment on all-cause mortality (Figure 1.2). The 
divergence in outcomes, according to treatment groups, was more pronounced in the years after 
the intervention, indicating a legacy effect (Figure 1.3) [132, 133].  
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The Steno-2 study highlighted the benefits of addressing cardiovascular risk through 
the implementation of multiple strategies. However, there are limitations in extending these 
observations to PAD management today. The Steno-2 study began in 1993 when now proven 
treatments, such as ACE inhibitors and statins, may not have been as commonly prescribed. 
Since that time, risk factor control has evolved, with lower blood pressure and LDL-C targets, 
and new possibilities for lowering hs-CRP and triglycerides [135]. Given the walking 
constraints ascribed to intermittent claudication, a lifestyle intervention for PAD should differ 
from uncomplicated diabetes. The clinical phenotype of PAD, as it relates to functional status, 
concomitant risk factors and medical comorbidities, can vary from other high-risk conditions 
[1, 17, 136-139]. REACH was a prospective international study that followed 8,322 people 
with PAD for up to four years, among other high-risk individuals. A post hoc analysis of PAD 
patients found multiple risk factor control to be associated with a reduction in 1-year MACE. 
Like with the Steno-2 study, this analysis was in an era where risk factor control was less 
stringent [10]. Therefore, the risks and benefits of implementing a multifactorial intervention 





Figure 1.2: Kaplan-Meier survival curve from randomisation, according to Steno-2 
treatment group 
 
Reproduced from Gaede P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in 
patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. 
Diabetologia. 2016;59(11):2298-307. Published online 2016 Aug 16. DOI: 10.1007/s00125-016-4065-6. 
Copyright © Gaede et al. 2016. Open access article under the terms of the Creative Commons Attribution License. 





Figure 1.3: Kaplan-Meier event curves after intervention, according to Steno-2 treatment 
group 
 
Panel A shows the cumulative incidence of all-cause mortality during the 13.3-year study 
period. Panel B shows the cumulative incidence of major adverse cardiovascular or limb event 
(composite of cardiovascular-related mortality, non-fatal stroke, non-fatal myocardial 
infarction, coronary artery bypass graft operation, percutaneous coronary intervention, 
peripheral artery revascularisation, lower extremity amputation). 
Reproduced with permission from Gaede et al. Effect of a multifactorial intervention on mortality in type 2 
diabetes, N Engl J Med 2008 Feb 7;358(6):580-91. DOI: 10.1056/NEJMoa0706245. Copyright © Massachusetts 
Medical Society 2008 [132].  
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1.4.6.  Gender differences 
There are many issues in PAD that weigh against women. Females are more likely to be 
asymptomatic or have atypical symptoms, further challenging clinical diagnosis [140, 141]. In 
observational studies, women with PAD had a more significant walking impairment and 
functional decline than their male counterparts [141, 142]. The efficacy of medical and lifestyle 
treatments is less well established in females, as they were commonly under-represented in 
clinical studies [140]. With potential differences in diagnosis, clinical manifestations and 
treatment, a divergence in long-term outcomes might occur. Gender differences in long-term 
MACE and mortality need further investigation, as this can provide further insights into PAD 
management.  
 
1.4.7.  Diagnosis and screening 
The early stages of PAD are frequently asymptomatic and under-diagnosed [8, 9]. An ankle-
brachial index (ABI) is a simple bedside test that has high sensitivity and specificity for PAD 
[19]. Population studies have demonstrated that an abnormal ABI corresponds with the risk of 
mortality, independent of Framingham-based risk score [20]. The national guidelines 
recommend a risk-stratified approach to manage cardiovascular risk factors, but they do not 
endorse screening for asymptomatic PAD [143, 144]. A compelling indication for PAD 
screening would be in populations where it is highly prevalent, while the estimation of 
cardiovascular risk is difficult. There are striking health disparities that affect Indigenous 
people, including premature atherosclerotic cardiovascular disease [145]. The utility of 
screening for PAD to improve cardiovascular risk-stratification in Indigenous Australians is 
not well understood.  
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1.5. Aims of the research study 
The aims of this research concerning PAD are: 
1. To identify factors that drive MACE and mortality and how this differs from coronary 
artery disease. 
2. To identify associations with novel cardiovascular risk factors. 
3. To evaluate gender differences in long-term outcomes. 
4. To identify factors associated with major adverse limb events. 
5. To evaluate the use of risk algorithms for managing patients. 
6. To identify strategies for improving cardiovascular and mortality outcomes. 
 
1.6. Hypotheses 
The hypotheses regarding PAD are: 
1. There are differences in clinical complexity compared to coronary artery disease 
patients that drive MACE and mortality. 
2. Dysfunctional high-density lipoprotein cholesterol contributes to the pathogenesis. 
3. Clinical factors that weigh against PAD-affected women translate into a higher 
likelihood of MACE and mortality. 
4. There are differences in lower limb and mortality outcomes depending on the type of 
lower extremity revascularisation performed. 
5. Screening for early disease can improve cardiovascular risk-stratification. 
6. Risk algorithms can improve management decisions. 














CHAPTER 2: CARDIOVASCULAR RISK FACTOR CONTROL AND OUTCOMES 





Introduction: Prior studies have demonstrated adverse cardiovascular risk in patients with 
peripheral artery disease (PAD) and suboptimal control of risk factors. The impact of intensive 
risk factor control on outcomes in PAD patients has not been well characterised.  
Methods: ACCELERATE was a randomised trial of evacetrapib and placebo in 12,092 statin-
treated patients with atherosclerotic cardiovascular disease followed for a median of 28 months. 
Major adverse cardiovascular events (MACE) and all-cause mortality rates were compared in 
patients with PAD (n = 2,355) and coronary artery disease (CAD)-only (n = 9,274), in the 
setting of intensive risk factor control. The association between the individual or multiple risk 
factor control and MACE was evaluated in the PAD patients.  
Results: In patients with PAD, there was a higher rate of MACE (17.0% vs 13.3%, p<0.001), 
cardiovascular mortality (5.3% vs 2.2%, p<0.001), non-fatal myocardial infarction (2.7% vs 
1.5%, p=<0.001), non-fatal stroke (2.7% vs 1.5%, p=0.002) and all-cause mortality (8.2% vs 
3.6%, p<0.001), when compared with CAD-only. An increase in MACE for PAD was observed 
even in the setting of an HbA1c <7.0% (12.8% vs 10.7%, p=0.02), LDL-C <70mg/dL (15.7% 
vs 11.4%, p<0.001), systolic BP <130 mmHg (13.8% vs 11.0%, p=0.01), diastolic BP <80 
mmHg (15.9% vs 12.0%, p<0.001), triglycerides <150 mg/dL (14.1% vs 11.9%, p=0.02), non-
smoking (15.6% vs 12.3%, p<0.001), and multiple risk factor control (14.0% vs 11.1%, 
p=0.004), in comparison with CAD-only. For PAD patients that achieved optimal glycaemia, 
LDL-C, systolic BP, diastolic BP, triglycerides, BMI, and smoking abstinence, individually or 
in combination, there was no associated relative risk reduction in MACE. Optimal hs-CRP 
levels were the lone risk factor that correlated with improved cardiovascular outcomes (HR 
0.78, 95% CI, 0.61 to 0.99, p=0.05). 
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Conclusions: Despite intensive risk factor modification, elevated MACE rates continued to be 
observed in PAD, suggesting the need to develop new approaches to reducing cardiovascular 





Peripheral artery disease (PAD) is estimated to affect 5 to 10% of people in Western countries, 
and this number increases to 20% of the population above 70 years of age [6]. The diagnosis 
of PAD is associated with a high risk of major adverse cardiovascular events (MACE) [93]. 
The American Heart Association (AHA) and the European Society of Cardiology recommend 
several medical and lifestyle therapies for all PAD patients to improve cardiovascular outcomes 
[19, 61]. The introductory chapter reviewed the evidence for these guidelines. PAD patients 
were studied in randomised controlled trials of antiplatelets, anticoagulants, statins, 
angiotensin-converting enzyme inhibitors (ACEI), angiotensin-2 receptor blockers (ARB), and 
protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [52, 53, 59, 63, 69, 70, 86, 146]. 
However, the role of intensive multiple risk factor control of hypertension, dyslipidaemia, 
diabetes, and inflammation is still unclear. Previous diabetes studies have shown that multiple 
risk factor control can improve cardiovascular outcomes, in a way, where the sum of the parts 
does not equal the whole [132, 134]. The REACH registry was a prospective international study 
that followed 8,322 people with PAD for up to four years, among other high-risk individuals. 
For these PAD participants, multiple risk factor control was associated with a relative risk 
reduction in 1-year MACE. However, this cohort was followed over a decade ago, and only 
5% of PAD patients achieved optimal control of all cardiovascular risk factors [10]. Today, 
there is more evidence for intensive blood pressure and lipid-lowering for cardiovascular 
disease, below the targets that were standard at that time [147]. High-sensitivity C-reactive 
protein (hs-CRP) could be a target for preventative therapies [135]. Therefore, the impact of 
contemporary multiple risk factor control on cardiovascular outcomes in PAD has not been 
well characterised. 
ACCELERATE (Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein 
Inhibition with Evacetrapib in Patients at High Risk for Vascular Outcomes) was a phase 3 
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clinical study, which investigated the effects of evacetrapib therapy on MACE. In this analysis 
of the ACCELERATE trial, MACE rates were compared between patients with PAD and 
coronary artery disease (CAD)-only, in the setting of intensive risk factor control. Furthermore, 
we examined whether risk factor control correlated with more favourable cardiovascular 
outcomes in PAD.  
 
2.2. Methods 
2.2.1.  Trial design 
ACCELERATE was a multicentre, randomised, double-blind, placebo-controlled trial, which 
compared the effects of evacetrapib and placebo in 12,092 statin-treated patients with 
atherosclerotic cardiovascular disease. Details of the study design, objectives, methods, and 
endpoints have previously been published [148]. The trial was sponsored by Eli Lilly and was 
coordinated by the Cleveland Clinic Coordinating Center for Clinical Research (C5Research) 
and Covance (Princeton, NJ). 
 
2.2.2.  Trial population 
For inclusion, participants had at least one of the following conditions: an acute coronary 
syndrome within the previous 30 to 365 days, atherosclerotic cerebrovascular disease, PAD, or 
diabetes with coronary artery disease. The criteria for inclusion as PAD was defined as current 
intermittent claudication or resting limb ischaemia and either an ankle-brachial index ≤0.90 or 
history of atherosclerotic limb ischaemia leading to previous non-coronary revascularisation or 
amputation. Some people with a PAD history were included based on other study eligibility 
criteria. Participants were required to receive the maximally tolerated dose for at least 30 days 
before screening. Statin-use was required for participation unless there was a history of side 
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effects or contraindications. Participants were required to have a high-density lipoprotein 
cholesterol (HDL-C) level of less than 80 mg/dL (2.10 mmol/L) and a triglyceride level of less 
than 400 mg/dL (4.52 mmol/L). The low-density lipoprotein cholesterol (LDL-C) levels at 
enrolment were to be no more than 10 mg/dL (0.25 mmol/L) or above target levels that were 
specified at the investigator’s discretion. 
 
2.2.3.  Study aims 
The primary endpoint of ACCELERATE was the first occurrence of a MACE, as a composite 
of cardiovascular-related mortality, non-fatal myocardial infarction, non-fatal stroke, coronary 
revascularisation, or hospitalisation for unstable angina. There was no significant difference in 
the primary outcome between patients receiving evacetrapib and placebo, and the study was 
terminated after a mean duration of follow-up of 28 months.  
The aims of this analysis of ACCELERATE were to (1) compare the incidence of 
MACE and mortality in PAD and coronary artery disease (CAD)-only patients, (2) evaluate 
MACE in the setting of intensive individual and combined risk factor control, and (3) use 
logistic regression to test for associations between risk factor control and MACE in PAD.  
 
2.2.4.  Stratification of optimal risk factor control 
Risk factors were evaluated at baseline and throughout the study. Each risk factor was 
categorised as “controlled” if the target was achieved at the three-month review. This analysis 
focused on the following seven risk factor targets: glycated haemoglobin (HbA1c) <7.0%, 
systolic blood pressure <130 mmHg, diastolic blood pressure <80 mmHg, LDL-C <70 mg/dL 
(1.80 mmol/L), triglycerides <150 mg/dL (1.70 mmol/L), high-sensitivity C-reactive protein 
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(hs-CRP) <2.0 mg/L, and smoking abstinence [19, 61, 135]. Smoking abstinence was defined 
as cessation from smoking for at least three months preceding assessment. Where ≥4 of 7 
targets were realised, patients were classified as having “more optimal” control; whereas <4 of 
7 targets met was consider “less optimal” control. A body mass index (BMI) <25 was an 
additional target in further analysis of PAD patients. 
 
2.2.5.  Statistical analysis 
Clinical characteristics of participants were compared using the Wilcoxon test for continuous 
variables and chi-square test for categorical variables. Kaplan-Meier survival curves were 
created for the rate of the first occurrence of MACE. Comparisons were made between the 
incidence of MACE in PAD patients that achieved individual or multiple risk factor control, 
with those that did not. The adjusted analysis corrected for group differences in other 
significant variables identified with Cox regression. The associations were reported as hazard 
ratios (HR) with a 95% confidence interval, where p<0.05 was considered significant. All 
analyses used STATA 15.1 (StataCorp, College Station, TX). 
 
2.3. Results 
2.3.1.  Patient characteristics 
Of 12,092 total patients, 2,355 (19.5%) had PAD, including 752 (6.2%) PAD-only and 1,603 
(13.3%) with concomitant PAD and CAD. There were 9,234 (76.4%) patients with CAD-only. 
The median overall duration of follow-up was 28 months (interquartile range, 26 to 30 months). 
The baseline demographics, disease-specific diagnoses, and medication-use are summarised in 
Table 2.1. Patients with PAD were older (mean age, 66.5 vs 63.9, p<0.001), more frequently 
female (26.6% vs 21.5%, p<0.001), less likely to have diabetes (58.3% vs 72.1%, p<0.001), 
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and higher current smoking (25.8% vs 13.8%, p<0.001) and cerebrovascular disease (36.4% 
vs 15.7%, p<0.001), compared with CAD-only. In PAD patients with concomitant CAD, there 
was lesser history of acute coronary syndrome (36.6% vs 69.6%, p<0.001) and percutaneous 
coronary intervention (62.0% vs 73.0%, p<0.001). PAD patients had higher use of anti-
hypertensive agents (89.5% vs 86.8%, p<0.001) but were less likely to be treated with aspirin 
(74.2% vs 85.7%, p<0.001), statins (95.5% vs 96.6%, p=0.01), and ACEI or ARB (76.0% vs 




Table 2.1: Baseline characteristics 
Characteristic PAD 
(N = 2,355) 
CAD-only 
(N = 9,274) 
p value 
Age (mean years) 66.5 ± 8.8 63.9 ± 9.5 <0.001 
Males (%) 73.4 78.5 <0.001 
White (%) 87.7 80.5 <0.001 
BMI (mean) 29.6±5.4 30.4±5.8 <0.001 
Current smoking (%) 25.8 13.8 <0.001 
Diabetes (%) 58.3 72.1 <0.001 
Cerebrovascular disease (%) 36.4 15.7 <0.001 
Coronary artery disease (%) 68.1 100.0 <0.001 
Prior acute coronary syndrome 36.6 69.6 <0.001 
Prior percutaneous coronary 
intervention 
62.0 73.0 <0.001 
Prior CABG 43.5 26.8 <0.001 
Peripheral artery disease (%) 100.0 0.0  
PAD criteria inclusion 71.1 -  
Ankle brachial index ≤0.9 84.6 -  
Non-coronary revascularisation 
in response to ischaemia 
44.4 -  
Prior amputation 4.9 -  
Baseline medication use (%)    
Statin 95.5 96.6 0.01 
ACE inhibitor or ARB 76.0 78.6 <0.001 
Aspirin 74.2 85.7 <0.001 
Beta blocker 65.6 78.8 <0.001 
Calcium channel blocker 34.3 26.7 <0.001 
Diabetic medication 53.0 63.3 <0.001 
Anti-hypertensive medication 89.5 86.8 <0.001 
 
Age and BMI expressed as mean±standard deviation. ACE inhibitor, angiotensin-converting 
enzyme inhibitor; ARB, angiotensin 2 receptor blocker; BMI, body mass index; CABG, 





2.3.2.  Risk factor control 
Table 2.2 summarises the risk factor control of participants with PAD and CAD-only. The 
patients with PAD were more likely to achieve a HbA1c <7.0% (61.2% vs 53.8%, p<0.001), 
but less likely to achieve a LDL-C <70 mg/dL (55.4% vs 58.0, p=0.03), systolic BP <130 
mmHg (39.6% vs 50.3%, p=0.001), smoking abstinence (74.2% vs 86.2%, p<0.001) and hs-
CRP <2 mg/L (49.2% vs 60.4%, p<0.001), compared to those with CAD-only. A lower 
percentage of patients with PAD were classified as achieving more optimal control compared 
to those without (68.0% vs 72.9%, p<0.001). 
 
Table 2.2: Percentage of people achieving risk factor control at 3-month follow-up 
Risk Factor 
(% of people) 
PAD 
(N = 2,355) 
CAD-only 
(N = 9,274) 
p value 
HbA1c <7%  61.2 53.8 <0.001 
LDL-C <70 mg/dL  55.4 58.0 0.03 
Triglycerides <150 mg/dL 65.8 65.6 0.89 
Systolic BP <130 mmHg 39.6 50.3 0.001 
Diastolic BP <80 mmHg  66.9 65.0 0.09 
Hs-CRP <2 mg/L  49.2 60.4 <0.001 
Non-smoker  74.2 86.2 <0.001 
    
Risk factor control   <0.001 
Less optimal (<4 of 7) 32.0 27.1  
More optimal (≥4 of 7) 68.0 72.9  
 
BP, blood pressure; HbA1c, glycated haemoglobin; hs-CRP, high-sensitivity C-reactive 





2.3.3.  Incidence of MACE and all-cause mortality 
There was a higher rate of MACE (17.0% vs 13.3%, p<0.001), cardiovascular mortality (5.3% 
vs 2.2%, p<0.001), non-fatal myocardial infarction (2.7% vs 1.5%, p<0.001), non-fatal stroke 
(2.7% vs 1.5%, p=0.002) and all-cause mortality (8.2% vs 3.6%, p<0.001) in patients with 
PAD compared with CAD-only (see Table 2.3 and Figure 2.1). Greater MACE rates were 
observed in PAD patients even in the setting of HbA1c <7.0% (12.8% vs 10.7%, p=0.02), LDL-
C <70mg/dL (15.7% vs 11.4%, p<0.001), systolic BP <130 mmHg (13.8% vs 11.0%, p=0.01), 
diastolic BP <80 mmHg (15.9% vs 12.0%, p<0.001), triglycerides <150 mg/dL (14.1% vs 
11.9%, p=0.02), non-smoking (15.6% vs 12.3%, p<0.001), and hs-CRP <2 mg/L (13.2% vs 
11.3%, p=0.10), compared to those without PAD (see Table 2.4 and Figure 2.2). Patients with 
PAD classified as having more optimal control had a higher incidence of MACE than the 
matched CAD-only group (14.0% vs 11.1%, p=0.004). 
 
Table 2.3: Incidence of first occurrence MACE and all-cause mortality 
Event PAD 
(N = 2,355) 
CAD-only 
(N = 9,274) 
p value 
Major adverse cardiovascular events (%) 17.0 13.3 <0.001 
     Cardiovascular mortality 5.3 2.2 <0.001 
     Non-fatal myocardial infarction 6.2 4.3 <0.001 
     Non-fatal stroke 2.7 1.5 0.002 
     Hospitalisation for unstable angina 2.9 2.8 0.89 
     Coronary revascularisation 8.4 9.0 0.25 





Table 2.4: Incidence of first occurrence of MACE, according to risk factor control  
Risk factor control PAD 
(N = 2,355) 
CAD-only 
(N = 9,274) 
p value 
Diabetes (%)    
     HbA1c <7.0% 12.8 10.7 0.02 
     HbA1c ≥7.0% 16.2 13.4 0.03 
LDL-C (%)    
     LDL-C <70 mg/dL 15.7 11.4 <0.001 
     LDL-C ≥70 mg/dL 13.3 13.0 0.75 
Systolic BP (%)    
     Systolic BP <130 mmHg 13.8 11.0 0.01 
     Systolic BP ≥130 mmHg 15.4 13.2 0.03 
Diastolic BP (%)    
     Diastolic BP <80 mmHg 15.9 12.0 <0.001 
     Diastolic BP ≥80 mmHg 12.5 12.3 0.86 
Triglycerides (%)    
     Triglycerides <150 mg/dL 14.1 11.9 0.02 
     Triglycerides ≥150 mg/dL 15.9 12.0 0.002 
Hs-CRP (%)    
     Hs-CRP <2 mg/L 13.2 11.3 0.10 
     Hs-CRP ≥2 mg/L 17.0 13.7 0.01 
Smoking (%)    
     Non-smoker 15.6 12.3 <0.001 
     Current smoker 13.5 13.0 0.79 
Multiple risk factor control    
     More optimal (4 to 7) 14.0 11.1 0.004 
     Less optimal (0 to 3) 15.8 14.2 0.31 
 
BP, blood pressure; HbA1c, glycated haemoglobin; hs-CRP, high-sensitivity C-reactive 









Number at risk 
PAD       2,355      2,239          2,146                 2,055                1,782                  463  






Figure 2.2: Incidence of MACE for PAD and CAD-only patients, in the setting of optimal 
risk factor control 
 
DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; HSCRP, high-sensitivity C-
reactive protein; LDL, low-density lipoprotein cholesterol; RF, risk factor; SBP, systolic blood 
pressure; TRIG, triglycerides. 
 
2.3.4.  Associations between risk factor control and MACE in PAD 
Logistic regression analysis was performed to assess the impact of individual or multiple risk 
factor control on MACE in the PAD patients (Table 2.5). Optimal control of glycaemia 
(adjusted [adj.] HR 0.96, 95% CI, 0.73 to 1.26, p=0.75), LDL-C (adj. HR 1.05, 95% CI, 0.84 
to 1.32, p=0.67), systolic BP (adj. HR 0.90, 95% CI 0.72 to 1.13, p=0.36), diastolic BP (adj. 
HR 1.09, 95% CI 0.85 to 1.39, p=0.50), triglycerides (adj. HR 0.85, 0.66 to 1.13, p=0.16), BMI 
(adj. HR 0.91, 95% CI, 0.68 to 1.21, p=0.51), and smoking abstinence (adj. HR 1.00, 95% CI, 
0.77 to 1.29, p=0.99), were not associated with reduced MACE. Multiple risk factor control, 
as defined in Table 2.5, did not significantly correlate with less MACE (adj. HR 1.13, 95% CI, 
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0.88 to 1.45, p=0.36). Hs-CRP was the lone risk factor target that was independently associated 
with improved cardiovascular outcomes (adj. HR 0.78, 95% CI, 0.61 to 0.99, p=0.05). 
 
Table 2.5: Adjusted* hazard ratio for risk factor control and MACE in PAD 
Risk factor control MACE 
 HR 95% CI p value 
HbA1c <7.0% vs ≥7.0% 0.96 0.73 – 1.26 0.75 
LDL-C <70 mg/dL vs ≥70 mg/dL 1.05 0.84 – 1.32 0.67 
Systolic BP <130 mmHg vs ≥130 mmHg 0.90 0.72 – 1.13 0.36 
Diastolic BP <80 mmHg vs ≥80 mmHg 1.09 0.85 – 1.39 0.50 
Triglycerides <150 mg/dL vs ≥150 mg/dL 0.85 0.66 – 1.13 0.16 
Hs-CRP <2 mg/L vs ≥2 mg/L 0.78 0.61 – 0.99 0.05 
Smoking abstinence vs smoking 1.00 0.77 – 1.29 0.99 
BMI ≤ 25 vs >25 0.91 0.68 – 1.21 0.51 
4 to 8 vs 0 to 3 risk factors controlled † 1.13 0.88 – 1.45 0.36 
 
* Adjusted for significant variables identified using Cox regression (age, amputation for PAD, 
non-coronary revascularisation in response to limb ischaemia, cerebrovascular disease, 
coronary artery disease, acute coronary syndrome, diabetes, and statin-use). † BMI ≤ 25 was 
an additional risk factor target added for Table 2.5. Abbreviations: BMI, body mass index; BP, 
blood pressure; HbA1c, glycated haemoglobin; hs-CRP, high-sensitivity C-reactive protein; 







In this analysis of the ACCELERATE trial, higher rates of MACE were seen for PAD, even in 
the setting of smoking abstinence, or optimal glycaemic, lipid, blood pressure, and 
inflammatory control, compared to CAD-only. These PAD patients appeared relatively well-
managed, compared to prior observational studies [10, 12]. Here, more intensive individual 
and multiple risk factor control were not independently associated with more favourable 
cardiovascular outcomes. These findings underscore the challenges with altering the clinical 
course of PAD and indicate a need for new strategies, including inflammatory control.  
These findings differ from many prior observations of PAD patients, where an under-
prescription of medical therapies has been previously described [10, 13, 149, 150]. One study 
audited the usage of guideline-recommended therapies for PAD patients in 1,982 US clinic 
visits between 2005 and 2012. There was strikingly low utilisation of antiplatelets (35.7% of 
visits), statins (33.1%), ACEI or ARB (28.4%), and counselling or medication for smoking 
cessation (35.8%) [12]. In that setting, high rates of MACE can be expected. A strength of 
analysing ACCELERATE was that the PAD patients were frequently prescribed statins (94%), 
ACEI or ARB (72%), and anti-hypertensives (90%), and were mostly non-smokers (74%). The 
benefits of smoking abstinence and these medical treatments are not in question [147]. 
However, intensively treating hypertension, dyslipidaemia, diabetes, obesity, elevated 
inflammation, alone and in combination, in PAD patients has not been well researched. The 
high MACE rates in ACCELERATE were not attributable to smoking or an under-prescription 
of proven therapies, as often occurs with studies in this space. 
Prior diabetes studies have demonstrated the potential benefits of intensive multiple 
risk factor control. In the Steno-2 study, 160 people with type 2 diabetes and microalbuminuria 
were randomised to receive either a multifactorial intervention or standard care for 7.8 years. 
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These participants were subsequently followed for 13.4 years after this intervention (21.2 years 
following randomisation). The risk factor targets that were set were an HbA1c <6.5%, fasting 
total cholesterol <4.5 mmol/L (175 mg/dL), fasting triglyceride level <1.7 mmol/L (150 
mg/dL), systolic BP <130 mmHg, and diastolic BP <80 mmHg. At 21.2 years after 
randomisation, the multifactorial intervention was associated with a lower risk of mortality 
(HR 0.54, 95% CI, 0.32 to 0.89), major adverse cardiovascular or limb events (HR 0.41, 95% 
CI, 0.25 to 0.67) [132-134]. The Steno-2 study highlighted the benefits of addressing 
cardiovascular risk through the implementation of several strategies. However, there are 
drawbacks to extending these observations to PAD management today. The study began in 
1993 when now established treatments, including ACE inhibitors and statins, may not have 
been as commonly prescribed. Risk factor control has since evolved, with lower BP and LDL-
C targets, and new possibilities for lowering hs-CRP and triglycerides [84, 93, 122, 151]. There 
is walking impairment ascribed to intermittent claudication, which means a lifestyle 
intervention for PAD is distinct from uncomplicated diabetes. The clinical phenotype of PAD, 
as it relates to functional status, concomitant risk factors and medical comorbidities, can 
significantly vary from other high-risk conditions [1, 17, 136-139]. Therefore, the risks and 
benefits of intensively treating these patients differ, and this may, at least partly, explain the 
disappointingly low prescription of proven therapies that have been observed. 
There are other possible explanations for the high incidence of MACE in PAD, 
compared to CAD-only. The presence of concomitant PAD and CAD indicates a propensity 
for aggressive atherosclerotic disease. In a prior study, serial intravascular ultrasound imaging 
was used to compare coronary artery plaque burden and progression in 3,479 patients with and 
without PAD. The patients with concomitant PAD had more extensive and calcified coronary 
atherosclerosis and disease progression during serial follow-up [152]. High atherosclerotic 
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plaque burden on coronary intravascular ultrasound has been correlated with elevated rates of 
MACE [153]. 
The PAD cohort in ACCELERATE might have been negatively impacted by physical 
inactivity, given they are hallmarks of intermittent claudication; although this was not assessed 
[18]. A prior study of 15,486 patients with stable CAD found that moderate or high-intensity 
physical activity was associated with lower mortality (including cardiovascular-related 
mortality), compared with physical inactivity. The relationship between sedentary lifestyle and 
mortality was stronger in people classified as high-risk, which included PAD [154]. Another 
study assessed activity levels of 1,288 participants that underwent an elective coronary 
angiography. The individuals who self-reported regular and vigorous activity were less likely 
to have concomitant PAD, and this was associated with lower mortality during follow-up [41]. 
Inflammatory control could be a new strategy for improving cardiovascular outcomes 
in PAD. Lipid-lowering therapies have been shown to have pleiotropic benefits relating to hs-
CRP reduction [120, 155]. More recently, CANTOS was a clinical trial that tested the efficacy 
of a monoclonal antibody targeting interleukin-1b. A total of 10,061 participants with previous 
myocardial infarction and elevated hs-CRP (> 2mg/L) were randomised to placebo or 
canakinumab (50 mg, 150 mg or 300 mg) three-monthly subcutaneous injection. 
Canakinumab-treated individuals who achieved a hs-CRP <2 mg/L after an initial dose, had a 
25% relative risk reduction in MACE, compared to on-treatment participants with persistently 
elevated hs-CRP (≥ 2mg/L). These findings demonstrated how directly targeting elevated 
inflammation can improve cardiovascular outcomes [122]. 
While anti-inflammatory medications appear promising, their incorporation into 
clinical practice will require consideration for long-term safety and cost-effectiveness. 
Lifestyle modification, including exercise and weight loss in obesity, is often emphasised in 
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PAD [147], and this can theoretically reduce inflammation [156-158]. The AHA recommends 
supervised exercise training in symptomatic PAD, consisting of 30 to 45-minute sessions, 
performed at least three times per week for at least twelve weeks [19]. Studies that have 
associated exercise with a lesser risk of MACE and mortality were observational. There are 
difficulties with powering a clinical study to test the impact of lifestyle modification on 
cardiovascular outcomes. One alternative is to evaluate inflammatory marker reduction as a 
surrogate endpoint. Some PAD research has examined the effect of supervised exercise therapy 
on hs-CRP, although results have been inconsistent [156, 159]. These studies were limited by 
size, and duration of treatment or follow-up, and they did not target individuals with suboptimal 
inflammatory control. More research is needed into long-term training strategies that might 
lead to continued reduction in the markers of inflammation. 
In ACCELERATE, a BMI<25 was not associated with less MACE in PAD. Obesity 
has been previously associated with increased MACE [160]. Despite this link, weight loss in 
obesity might not always be advisable [115]. Weight loss in overweight and obese people is 
recommended for the general population and is associated with improved blood pressure, lipid, 
and glycaemic control [161]. However, PAD patients may have a higher degree of medical 
complexity, and an obesity paradox has been described, whereby a low or normal BMI is 
detrimental [162]. Other comorbidities, where elevated BMI is protective, such as chronic 
respiratory conditions, need to be considered. 
The risk factor targets in this analysis were not specific to PAD. Most substantial 
evidence for intensive blood pressure lowering in secondary prevention extends from SPRINT. 
However, many groups, such as diabetes, cerebrovascular disease, and age greater than 75 
years of age, were not examined in that trial [84]. Intensive glycaemic control in patients with 
established atherosclerotic cardiovascular disease was not shown to improve cardiovascular 
outcomes in randomised clinical trials [147, 163]. A post hoc analysis of diabetics in the 
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EUCLID trial did find that every 1% increase in HbA1c, was associated with a 14.2% increased 
relative risk for MACE [100]. While LDL-C <70 mg/dL is a conventional target, with the 
advent of new lipid-lowering therapies, more intensive LDL-C treatment could become the 
norm. PCSK9 inhibitors are associated with a reduction of MACE in PAD, and this correlation 
is evident even with very low LDL-C levels (< 10 mg/dL) [93]. High-dose omega-3 fatty acid 
supplementation reduced incidence of MACE in high-risk patients, including PAD, with a 
baseline triglyceride level of 135-499 mg/dL (1.52-5.63 mmol/L) and LDL-C of 41-100 mg/dl 
(1.06-2.59 mmol/L) [151]. Most participants in ACCELERATE were taking antiplatelet 
monotherapy, but this standard of care is also being challenged. In the PAD subset of 
COMPASS, combined rivaroxaban and aspirin was associated with a 31% relative risk 
reduction in MACE, compared with aspirin-alone [63]. The landscape of preventative therapy 
is changing, and new strategies need to be incorporated into PAD management. 
Some caveats should be noted. ACCELERATE was a clinical trial with a specified 
inclusion and exclusion criteria. Differences in patient complexity need to be considered when 
extrapolating these findings to other clinical settings. In many prior PAD studies, proven 
therapies, including statins, antiplatelets, ACEI or ARB, were less frequently used [10, 89]. 
ACCELERATE allowed for the evaluation of intensive multiple risk factor control when these 
guideline-recommended medications were commonly prescribed. This analysis reported 
MACE and mortality outcomes according to risk factor control, but the potential unmeasured 
benefit of reducing major adverse limb events would be an additional impetus for treating PAD 
patients. Major adverse limb events are a cause of permanent disability, and this can be 
modified by medical therapies [31]. Approximately half of the PAD participants had a history 
of non-coronary revascularisation or lower extremity amputation, which indicates they were at 
high risk of future major adverse limb events [28]. ACCELERATE was a phase 3 trial designed 
to investigate the effects of evacetrapib, which is a cholesteryl ester transfer protein inhibitor. 
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In this analysis, 3-month risk factor control was used, as that was the time that the LDL-C-
lowering effect of evacetrapib treatment plateaued. A decreased LDL-C level from evacetrapib 
did not correlate with a reduction in MACE [148], which is at odds with larger epidemiological 
studies [88]. Therefore, the relationship between lipid control (and other risk factors) and 
cardiovascular events could have been influenced by confounding. There was potential for 
significant heterogeneity in the duration of risk factor control, such as blood pressure. It can be 
expected that some participants achieved optimal control of hypertension for longer than 
others, dating before the commencement of the study. Prior diabetes studies have demonstrated 
a legacy effect, whereby cardiovascular benefits of risk factor control are seen years after 
medical prevention [132, 134]. The median study follow-up was 28 months and may have been 
too short to appreciate these effects. Some risk factors were not evenly distributed among the 
participants. For instance, there was a high proportion of non-smokers. Therefore, the power 
of the study to assess the effect of individual risk factor control could have been limited by the 
sample size. Despite these potential limitations, there was sufficient data to detect significant 
discrepancies between PAD and CAD-only patients. 
 
2.5.  Conclusions 
The presence of PAD in patients with or without CAD was associated with an elevated 
cardiovascular risk, despite intensive risk factor modification. This indicates a need for 














CHAPTER 3: RISK FACTOR CONTROL AND CORONARY ARTERY 





Background: Concomitant PAD in people with coronary artery disease (CAD) correlates with 
higher rates of major adverse cardiovascular events, even in the setting of intensive risk factor 
modification. One explanation is that PAD patients have high-risk coronary artery plaque that 
is more critical, diffuse and prone to thrombotic occlusion, although this has not been 
definitively proven. Intravascular ultrasound (IVUS) can be used to assess coronary artery 
atherosclerotic burden and progression, as it relates to risk factor control. 
Methods: This post hoc analysis compared a PAD (n =48) and a non-PAD (n =240) cohort 
that was matched for age and gender. Data were derived from three clinical trials where 
coronary artery disease of moderate severity was monitored with serial IVUS. Images of 
matched arterial segments were taken at baseline and the end of the clinical trials and compared. 
Measurements performed included vessel size (lumen and external elastic membrane [EEM] 
volumes, mm3), calcium (percent of images), and atherosclerotic plaque (percent atheroma 
volume [PAV, %] and total atheroma volume [TAV, mm3]), with values expressed as mean ± 
standard deviation. The annualised change in atheroma was quantified while adjusting for 
baseline plaque features. Baseline plaque burden and disease progression were compared 
between PAD and non-PAD patients, according to risk factor control. The plaque progression 
in PAD patients that achieved individual and combined risk factor control was compared with 
those that did not. 
Results: At baseline, PAD patients had a smaller EEM volume (253.5 ± 72.1 mm3 vs 307.4 ± 
103.7 mm3, p=0.001), lumen volume (408.1 ± 111.6 mm3 vs 486.9 ± 159.7 mm3, p=0.001), 
lower TAV (154.6 ± 62.2 mm3 vs 179.6 ± 74.1 mm3, p=0.03), but comparable PAV (37.5 ± 
8.2% vs 36.5 ± 8.7%, p=0.45) and calcium (33.1 ± 22.8% vs 26.7 ± 21.9%, p=0.06). There was 
no significant difference in the annualised change in PAV (-0.08 ± 0.31% vs -0.29 ± 0.24%, 
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p=0.40), and TAV (-1.83 ± 1.78 mm3 vs -3.50 ± 1.37 mm3, p=0.24), or the number of PAV 
progressors (14.6% vs 19.6%, p=0.42) and regressors (25.0% vs 35.4%, p=0.16) for PAD and 
non-PAD patients, respectively. The non-PAD group had a significant regression in the mean 
annualised TAV (mean change -3.50 mm3, 95% CI, -6.19 and -0.80, p=0.01), but the PAD 
patients did not (mean change -1.83 mm3, 95% CI, -5.33 to 1.66, p=0.30). More optimal risk 
factor control (mean difference -3.89, 95% CI, -7.35 to -0.42, p=0.03) and optimal triglycerides 
(mean difference -3.69, 95% CI, -7.04 to -0.34, p=0.03) was associated with more TAV 
regression in non-PAD than PAD patients, accordingly. In PAD patients achieving individual 
or combined risk factor control, there was no significant difference in PAV or TAV change, 
compared with PAD individuals that did not. 
Conclusions: Contrary to previous research, people with concomitant PAD did not have higher 
coronary artery atherosclerotic burden or progression. Also, there was no observed effect of 
individual and multiple risk factor control on plaque progression, suggesting resilience to 
medical treatments. These findings are consistent with chapter two, where multiple risk factor 
control was not associated with a significant reduction in major adverse cardiovascular events 





Peripheral artery disease (PAD) has been associated with a higher incidence of major adverse 
cardiovascular events (MACE), compared to other manifestations of atherosclerosis [53, 93]. 
In prior observational studies, PAD patients were not usually prescribed proven medical 
therapies, and risk factor control was largely inadequate [10, 12]. Therefore, an under-
prescription of guideline-recommended treatments might, at least partly, explain the elevated 
rates of MACE that have been described [10, 11, 150]. In chapter 2, we examined a relatively 
well-managed PAD cohort, and still observed higher rates of MACE, compared with coronary 
artery disease-only. There was no evidence that multiple risk factor control was associated with 
more favourable cardiovascular outcomes. Here the mechanistic basis for these findings is 
explored. 
A popular hypothesis is that PAD patients have high-risk coronary artery plaque 
properties that are more critical, diffuse and prone to thrombotic occlusion [164, 165]. Most 
studies that have attempted to prove this theory have been limited, as they were cross-sectional, 
used simple imaging modalities or were performed in an era before the widespread use of 
statins and other therapies [166-168]. The introductory chapter outlined the evidence for 
medical therapies in PAD, as they relate to hypertension, dyslipidaemia, hyperglycaemia and 
smoking. It is known from diabetes studies that control of multiple risk factors can have a more 
complex interaction, whereby the sum of the parts does not equal the whole [134, 169]. 
Although multiple risk factor control is recommended [147], little is known regarding the effect 
on the natural history of coronary artery atherosclerosis in PAD. 
Intravascular ultrasound imaging (IVUS) can be used to calculate the atherosclerotic 
plaque burden. Many clinical trials have incorporated serial IVUS imaging to assess the impact 
of medical therapies on coronary artery atheroma over time [170]. There is a correlation 
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between atheroma burden and progression evaluated with IVUS and the incidence of 
subsequent MACE [153]. IVUS imaging can provide insight into the cardiovascular issues 
affecting people with PAD. One prior study that utilised serial IVUS imaging showed that 
concomitant PAD was associated with more extensive coronary atherosclerosis and accelerated 
disease progression [152]. However, the comparisons made with non-PAD patients did not 
account for demographic differences or risk factor control. To our knowledge, there have been 
no previous studies that have assessed how risk factor control (blood pressure, low-density 
lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, high-sensitivity C-
reactive protein, and smoking) alone and in combination can be associated with coronary 
atheroma progression in PAD. This analysis utilised a pool of results from clinical trials, where 
the participants underwent serial IVUS imaging. We examine how atherosclerotic burden and 
progression in the coronary circulation might differ, in the setting of multiple risk factor 
control, between patients with concomitant PAD and in those without.  
 
3.2. Methods 
3.2.1.  Study population 
This post hoc analysis examined PAD (n = 48) and non-PAD (n = 240) participants from three 
clinical trials. The non-PAD group was age and gender-matched with the PAD group. Serial 
IVUS imaging was used to investigate the impact of lipid-lowering medications on coronary 
atherosclerosis in all studies. Details of study design, objectives, methods, and primary 
endpoints have been published previously [171-173]. The three included trials were GLAGOV 
(global assessment of plaque regression with a PCSK9 antibody as measured by intravascular 
ultrasound trial) [173], SATURN (the study of coronary atheroma by intravascular ultrasound: 
effect of rosuvastatin vs atorvastatin) [171], and ASTEROID (a study to evaluate the effect of 
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rosuvastatin on intravascular ultrasound-derived coronary atheroma burden) [172]. In 
GLAGOV, PAD was an inclusion criterion defined as either: current intermittent claudication 
of presumed atherosclerotic origin with an ankle-brachial index ≤0.9; or history of intermittent 
claudication with prior lower extremity revascularisation or related amputation within the last 
two years. The SATURN and ASTEROID trials identified PAD patients based on a 
documented history. Broadly, participants were eligible if they had bystander coronary artery 
disease with luminal stenosis >20% in at least one major coronary artery, which was confirmed 
by angiography in a clinically indicated setting. All trials complied with the Declaration of 
Helsinki and were approved by institutional boards at participating sites. 
 
3.2.2.  Study aims 
The aims of this analysis were to (1) compare baseline and serial measurements of coronary 
artery atherosclerotic plaque in PAD and non-PAD patients, (2) compare plaque progression 
in PAD and non-PAD patients, according to individual and combined risk factor control, (3) 
compare plaque progression in PAD patients that achieved risk factor control with those that 
did not. 
  
3.2.3.  IVUS imaging 
Comprehensive details of the methods for IVUS imaging acquisition and analysis have been 
published [171-173]. In brief, images were acquired from an arterial segment of at least 30 mm 
in length and with luminal stenosis of 20 to 50%. This coronary artery was required to be a 
non-culprit vessel and not require treatment with coronary angioplasty. A high-frequency 
ultrasound transducer (30-40 MHz) was inserted distal to the stenosis. An automated pullback 
of the catheter was performed at a constant rate of 0.5 mm/s, while continuous ultrasound 
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images were obtained. IVUS was performed of the same arterial segment at baseline and study 
end. The follow-up duration varied between 20 and 26 months across the three studies. 
IVUS images were digitised, and measurements were performed within a matched 
arterial segment (Figure 3.1). Cross-sectional images spaced precisely 1 mm apart were 
selected for analysis. The leading edges of the lumen (mm3) and external elastic membrane 
(EEM, mm3) were traced by manual planimetry. Areas between these leading edges were 
recognised as atherosclerotic plaque. Percent atheroma volume (PAV) was the proportion of 
the vessel wall that was occupied by plaque, as calculated using the following accepted 
equation [153]: 
 
PAV (%) = [∑ (EEMarea - LUMENarea)/ ∑ EEMarea] × 100 
A normalised total atheroma volume (TAV), was the summation of plaque area in each 
measured image calculated the following equation: 
 
TAVnormalised (mm3) = [∑ (EEMarea - LUMENarea)/ Number of slices in pullback] × Median 
number of images in cohort 
 
These volumes were normalised to adjust for differences in segment length between subjects. 
Progression and regression were a >5% relative increase or decrease in PAV, respectively. The 
proportion of images where calcium was observed in at least one quadrant was quantified. All 




Figure 3.1: Schematic for serial IVUS imaging measurements 
 
This diagram shows a relatively normal area (reference) and the site of disease (lesion). 
Hartmann M, Huisman J, Serial intravascular ultrasound assessment of changes in coronary 
atherosclerotic plaque dimensions and composition: an update, European Heart Journal – 
Cardiovascular Imaging. 2011 12(4):313-21 [170] Reproduced with permission from Oxford 
University Press, License number 4751150852242, License date Jan 17, 2020. 
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3.2.4.  Stratification of risk factor control 
The baseline and average follow-up risk factors were evaluated. A total of seven risk factors 
were quantified and the targets were as followed: systolic blood pressure (SBP) <130 mmHg, 
diastolic blood pressure (DBP) <80 mmHg, low-density lipoprotein cholesterol (LDL-C) <70 
mg/dL (1.80 mmol/L), high-density lipoprotein cholesterol (HDL-C) >40 mg/dL (1.03 
mmol/L), triglycerides <150 mg/dL (1.70 mmol/L), high-sensitivity C-reactive protein (hs-
CRP) <2.0 mg/L, and smoking abstinence. Individuals that achieved 4 to 7 targets were 
categorised as having “more optimal” control. Otherwise, people meeting 0 to 3 risk factors 
targets were classified as having “less optimal” control. 
 
3.2.5.  Statistical analysis 
Results are presented as percentages for categorical variables and mean ± SD for continuous 
variables. Clinical and plaque characteristics were compared by the Student t-test or analysis 
of variance for continuous variables as appropriate. For categorical variables, the chi-square 
test or Fisher’s exact test was used. Changes in measures of risk factors, atheroma burden, and 
vascular dimensions were compared by analysis of covariance, after controlling for baseline 
values, and expressed as least squared mean ± SE. A two-sided p-value <0.05 was considered 
statistically significant. All statistical analyses were performed with SAS version 9.1 (SAS 





3.3.1.  Patient characteristics, medication use and risk factor control 
The baseline characteristics and medication use of PAD and non-PAD patients are outlined in 
Table 3.1. The groups were matched for age and gender. The PAD patients had a greater history 
of hypertension (91.7% vs 77.5%, p=0.03), and were more likely to smoke (48.6% vs 24.6%, 
p=0.003). Otherwise, both groups had a comparable body mass index, history of diabetes, 
hyperlipidaemia, heart failure, myocardial infarction, and stroke. The baseline and concomitant 
medication use of statins, beta-blockers, aspirin, and angiotensin-converting enzyme (ACE) 
inhibitors were similar. Regarding the GLAGOV cohort, there were comparable numbers of 
PAD and non-PAD patients receiving placebo and evolocumab lipid-lowering therapy. The 
risk factor control at baseline and during study follow-up are summarised in Table 3.2. There 
was a lower baseline DBP (73.8 ± 13.3 mmHg vs 77.2 ± 10.2 mmHg, p=0.05), average follow-
up DBP (73.6 ± 11.6 mmHg vs 77.3 ± 9.6 mmHg, p=0.02), and higher median follow-up hs-
CRP (2.4 mg/L [1.5, 5.3] vs 1.4 mg/L [0.7, 2.9], p=0.005) in PAD compared to non-PAD 








(N = 240, 83.3%) 
PAD 
(N = 48, 16.7%) p value 
Age, mean ± SD 60.1 ± 9.5 60.1 ± 9.6  
Female 70 (29.2) 14 (29.2) 1.00 
Caucasian 232 (96.7) 46 (95.8) 0.68 
Current Smoker 49 (24.6) 18 (48.6) 0.003 
BMI, mean ± SD 28.7 ± 4.8 29.7 ± 5.7 0.21 
    
History    
    Hypertension 186 (77.5) 44 (91.7) 0.03 
    Diabetes 35 (14.6) 9 (18.8) 0.46 
    Hyperlipidaemia 190 (79.2) 35 (72.9) 0.34 
    Heart failure 10 (4.2) 2 (4.2) 1.00 
    Myocardial infarction 65 (27.1) 13 (27.1) 1.00 
    Stroke 3 (1.3) 0 (0.0) 1.00 
    
Baseline medication use    
    Statin 178 (74.2) 34 (70.8) 0.63 
    Beta blockers 180 (75.0) 33 (68.8) 0.37 
    Aspirin 217 (90.4) 41 (85.4) 0.30 
    ACE inhibitors 130 (54.2) 19 (39.6) 0.07 
    
Concomitant medication use    
    Statin 239 (99.6) 48 (100.0) 1.00 
    Beta blockers 184 (76.7) 36 (75.0) 0.80 
    Aspirin 218 (90.8) 42 (87.5) 0.43 
    ACE Inhibitors 129 (53.8) 22 (45.8) 0.32 
    
Treatment Group for GLAGOV 
(N = 110) 
  0.55 
    Placebo 48/ 92 (52.2) 8 /18 (44.4)  
    Evolocumab 44/ 92 (47.8) 10 /18 (55.6)  
 
Age and body mass index expressed as mean ± standard deviation. Other values are expressed 
as N (%). ACE, angiotensin-converting enzyme; BMI, body mass index; GLAGOV, Global 
assessment of plaque regression with a PCSK9 antibody as measured by intravascular 
ultrasound trial; PAD, peripheral artery disease 
90 
 
Table 3.2: Risk factor control 
Parameter Non-PAD (N = 240) 
PAD 
(N = 48) p value 
LDL-C    
    Baseline, mg/dL 112.3 ± 33.0 104.7 ± 26.4 0.14 
    Follow-up, mg/dL 64.4 ± 28.6 60.7 ± 24.3 0.41 
    Percent change -39.8 ± 29.4 -39.0 ± 27.7 0.87 
    
HDL-C    
    Baseline, mg/dL 45.5 ± 12.1 43.5 ± 10.5 0.29 
    Follow-up, mg/dL 50.1 ± 12.8 48.1 ± 11.2 0.33 
    Percent change 11.2 ± 17.0 12.2 ± 18.8 0.72 
    
Triglycerides    
    Baseline, mg/dL 145.6 ± 73.5 148.1 ± 73.7 0.90 
    Follow-up, mg/dL 129.4 ± 54.0 131.9 ± 56.3 0.70 
    Percent change -1.6 ± 38.2 -2.8 ± 32.2 0.79 
    
Hs-CRP    
    Baseline, mg/L 1.7 (0.8, 3.3) 2.8 (1.2, 4.2) 0.11 
    Follow-up, mg/L 1.4 (0.7, 2.9) 2.4 (1.5, 5.3) 0.005 
    Percent change 60.0 ± 355.7 61.3 ± 175.1 0.09 
    
Systolic blood pressure    
    Baseline, mmHg 130.6 ± 17.3 131.1 ± 20.1 0.86 
    Follow-up, mmHg 131.5 ± 16.9 133.9 ± 18.7 0.40 
    Percent change 1.8 ± 14.3 3.6 ± 16.8 0.43 
    
Diastolic blood pressure    
    Baseline, mmHg 77.2 ± 10.2 73.8 ± 13.3 0.05 
    Follow-up, mmHg 77.3 ± 9.6 73.6 ± 11.6 0.02 
    Percent change 1.2 ± 14.5 1.4 ± 17.4 0.93 
 
Values expressed as mean ± standard deviation or median (interquartile range) 
LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; Hs-




3.3.2.  Baseline atherosclerotic plaque features and progression 
The baseline atherosclerotic plaque volume and vessel wall measurements are described in 
Table 3.3. The PAD patients had smaller vessel (EEM) (253.5 ± 72.1 mm3 vs 307.4 ± 103.7 
mm3, p=0.001) and lumen volumes (408.1 ± 111.6 mm3 vs 486.9 ± 159.7 mm3, p=0.001). 
People with PAD had lower TAV (154.6 ± 62.2 mm3 vs 179.6 ± 74.1 mm3, p=0.03) but had 
similar PAV (37.5 ± 8.2% vs 36.5 ± 8.7%, p=0.45) and calcium (33.1 ± 22.8% vs 26.7 ± 21.9%, 
p=0.06), compared with the non-PAD group. The annualised change in atheroma was 
calculated after adjusting for baseline plaque (see Table 3.4). There was no significant 
difference in the annualised change in EEM volume, lumen volume, PAV, and TAV between 
groups. The annualised change in PAV did not regress or progress (mean change -0.08%, 95% 
CI, -0.69 to 0.53, p=0.79; mean change -0.29%, 95% CI, -0.76 to 0.18, p=0.23) for PAD and 
non-PAD patients. There was significant regression in annualised TAV in non-PAD (mean 
change -3.50 mm3, 95% CI, -6.19 and -0.80, p=0.01), but not in PAD (mean change -1.83 mm3, 
95% CI, -5.33 to 1.66, p=0.30). The proportion of people that had PAV progression (14.6% vs 
19.6%, p=0.42) and regression (25.0% vs 35.4%, p=0.16) were similar for PAD and non-PAD 
patients, respectively (see Table 3.5). Calcification did not significantly differ during follow-




Table 3.3: Baseline atherosclerotic plaque and vessel wall measurements 
Risk factor Non-PAD (N = 240) 
PAD 
(N = 48) p value 
EEM volume, mm3 307.4 ± 103.7 253.5 ± 72.1 0.001 
Lumen volume, mm3 486.9 ± 159.7 408.1 ± 111.6 0.001 
PAV, % 36.5 ± 8.7 37.5 ± 8.2 0.45 
TAV, mm3 179.6 ± 74.1 154.6 ± 62.2 0.03 
Calcium, % 26.7 ± 21.9 33.1 ± 22.8 0.06 
 
Values expressed as mean ± standard deviation. EEM, external elastic membrane; PAV, 
percent atheroma volume; TAV, total atheroma volume 
 
Table 3.4: Annualised change in atheroma burden in PAD and non-PAD patients after 
adjusting for baseline plaque measurements 
Parameter Non-PAD (N = 240) PAD (N = 48)  
 Mean ± SD  95% CI 
p value 







EEM, mm3 -4.40 ± 2.28 (-2.92, 1.93) 0.06 -2.33 ± 3.67 (-5.64, 5.00) 0.53 0.56 
Lumen, mm3 -0.49 ± 1.23 (-8.89, 0.09) 0.69 -0.32 ± 2.70 (-9.55, 4.90) 0.91 0.95 
PAV, % -0.29 ± 0.24 (-0.76, 0.18) 0.23 -0.08 ± 0.31 (-0.69, 0.53) 0.79 0.40 
TAV, mm3 -3.50 ± 1.37 (-6.19, -0.80) 0.01 -1.83 ± 1.78 (-5.33, 1.66) 0.30 0.24 
 
Abbreviations as per Table 3.3. Lumen and EEM parameters were measured volumes. 
 
Table 3.5: PAV progression, regression and change in calcium 
Parameters Non-PAD (N = 240) 
PAD 
(N = 48) p value 
Progression 47 (19.6) 7 (14.6) 0.42 
Regression 85 (35.4) 12 (25.0) 0.16 
Calcium, % 29.4 ± 22.9 35.7 ± 24.8 0.06 
 
Calcium is expressed as mean percentage ± standard deviation. The other values are expressed 
as N (%). 
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3.3.3.  Plaque progression in PAD and non-PAD according to risk factor control 
Annualised changes in PAV and TAV according to risk factor control are summarised in Table 
3.6 and 3.7. The average change in PAV was comparable for PAD and non-PAD patients, when 
they achieved optimal LDL-C, HDL-C, triglycerides, SBP, DBP, hs-CRP, smoking abstinence, 
and more optimal risk factor control. More optimal risk factor control (mean difference -3.89, 
95% CI, -7.35 to -0.42, p=0.03) and optimal triglycerides (mean difference -3.69, 95% CI, -
7.04 to -0.34, p=0.03) was associated with more TAV regression in non-PAD than PAD 
patients, respectively. There were no significant differences in TAV change for control of LDL-
C, HDL-C, SBP, DBP, hs-CRP, and smoking abstinence. 
 The PAD patients achieving LDL-C, HDL-C, triglycerides, SBP, DBP, hs-CRP, 
smoking abstinence or more optimal risk factor control, had a similar annualised change in 




Table 3.6: Change in annualised percent atheroma volume after adjusting for baseline 
plaque measurements and according to risk factor control 
 Non-PAD PAD  
Risk factor PAV change, % [mean ± S.E.] 
PAV change, % 









LDL-C      
   <70 mg/dL -0.43 ± 0.25 -0.18 ± 0.35 -0.26 (-0.86, 0.35) 0.41 0.87 
   ≥70 mg/dL -0.03 ± 0.27 0.14 ± 0.43 -0.17 (-0.97, 0.63) 0.68  
      
HDL-C      
   >40 mg/dL -0.21 ± 0.25 0.04 ± 0.35 -0.25 (-0.82, 0.32) 0.39 0.99 
   ≤40 mg/dL -0.55 ± 0.31 -0.31 ± 0.48 -0.24 (-1.18, 0.70) 0.61  
      
Triglycerides      
   <150 mg/dL -0.35 ± 0.25 0.02 ± 0.35 -0.37 (-0.95, 0.22) 0.22 0.40 
   ≥150 mg/dL -0.14 ± 0.29 -0.22 ± 0.45 0.08 (-0.78, 0.95) 0.85  
      
SBP      
   <130 mmHg -0.42 ± 0.26 -0.15 ± 0.40 -0.27 (-0.99, 0.45) 0.46 0.88 
   ≥130 mmHg -0.18 ± 0.25 0.02 ± 0.37 -0.19 (-0.86, 0.47) 0.56  
      
DBP      
   <80 mmHg -0.25 ± 0.26 0.05 ± 0.34 -0.30 (-0.87, 0.27) 0.31 0.59 
   ≥80 mmHg -0.34 ± 0.28 -0.35 ± 0.49 0.00 (-0.93, 0.94) 0.99  
      
Hs-CRP      
   <2 mg/L -0.31 ± 0.42 0.33 ± 0.53 -0.64 (-1.39, 0.12) 0.10 0.14 
   ≥2 mg/L -0.32 ± 0.43 -0.51 ± 0.54 0.19 (-0.61, 1.00) 0.64  
      
Smoking      
   No -0.36 ± 0.38 0.10 ± 0.52 -0.46 (-1.23, 0.31) 0.24 0.29 
   Yes -0.19 ± 0.42 -0.33 ± 0.51 0.14 (-0.67, 0.95) 0.73  
      
RF Control      
   More optimal -0.35 ± 0.27 0.20 ± 0.37 -0.55 (-1.16, 0.06) 0.08 0.04 
   Less optimal -0.08 ± 0.33 -0.78 ± 0.51 0.70 (-0.28, 1.69) 0.16  
Measurements adjusted for baseline percent atheroma volume. More optimal risk factor control was 4 or more 
specified risk factor targets achieved. Less optimal risk factor control was 3 or less risk factor targets achieved. 
DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein 
cholesterol; Hs-CRP, high-sensitivity C-reactive protein; PAV, percent atheroma volume; RF, risk factor; SBP, 
systolic blood pressure 
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Table 3.7: Change in annualised total atheroma volume according to risk factor control 
after adjusting for baseline plaque measurements 
 Non-PAD PAD  
Risk factor 
TAV change,  
mm3 
[mean ± S.E.] 
TAV change, 
mm3 









LDL-C      
   <70 mg/dL -4.23 ± 1.37 -1.60 ± 1.98 -2.63 (-6.12, 0.86) 0.14 0.36 
   ≥70 mg/dL -2.26 ± 1.50 -2.31 ± 2.45 0.05 (-4.57, 4.67) 0.98  
      
HDL-C      
   >40 mg/dL -3.37 ± 1.41 -1.81 ± 1.97 -1.57 (-4.83, 1.69) 0.35 0.87 
   ≤40 mg/dL -3.95 ± 1.74 -1.83 ± 2.73 -2.11 (-7.51, 3.28) 0.44  
      
Triglycerides      
   <150 mg/dL -4.15 ± 1.39 -0.46 ± 1.97 -3.69 (-7.04, -0.34) 0.03 0.03 
   ≥150 mg/dL -1.87 ± 1.61 -4.61 ± 2.54 2.74 (-2.15, 7.62) 0.27  
      
SBP      
   <130 mmHg -4.33 ± 1.54 -1.11 ± 2.34 -3.22 (-7.39, 0.94) 0.13 0.32 
   ≥130 mmHg -2.79 ± 1.50 -2.41 ± 2.14 -0.38 (-4.14, 3.38) 0.84  
      
DBP      
   <80 mmHg -4.13 ± 1.46 -1.24 ± 1.98 -2.90 (-6.20, 0.41) 0.09 0.22 
   ≥80 mmHg -2.39 ± 1.58 -3.33 ± 2.77 0.94 (-4.28, 6.16) 0.72  
      
Hs-CRP      
   <2 mg/L -2.25 ± 1.94 1.20 ± 2.72 -3.46 (-7.80, 0.89) 0.12 0.26 
   ≥2 mg/L -2.76 ± 2.03 -2.87 ± 2.72 0.11 (-4.46, 4.68) 0.96  
      
Smoking      
   No -2.29 ± 1.67 1.23 ± 2.56 -3.53 (-7.87, 0.81) 0.11 0.29 
   Yes -3.05 ± 1.94 -2.93 ± 2.53 -0.12 (-4.75, 4.51) 0.96  
      
RF Control      
   More optimal -3.95 ± 1.28 -0.07 ± 1.95 -3.89 (-7.35, -0.42) 0.03 0.03 
   Less optimal -0.32 ± 1.67 -3.56 ± 2.73 3.24 (-2.29, 8.77) 0.25  
 




This study investigated the basis for the high rates of MACE in PAD that were described in 
chapter two. A conventional explanation is that coronary artery disease with concomitant PAD 
reflects a high-risk vascular phenotype as this relates to plaque. The PAD participants in this 
study appeared to have early atherosclerosis with negative remodelling. On most IVUS 
measures, these patients had comparable plaque burden and progression to individuals without 
PAD. There was some evidence that non-PAD patients benefitted more from multiple risk 
factor control than in PAD, consistent with the clinical observations of the ACCELERATE 
cohort. There was no significant association between risk factor control and coronary artery 
plaque progression in PAD. These findings do not negate the importance of risk factor 
modification, although, they do underscore the resilience of coronary artery disease to standard 
medical treatments.  
The PAD patients were more likely to receive guideline-recommended therapies and 
achieve risk factor control than the populations that have been previously researched [10, 12, 
150]. The follow-up LDL-C, HDL-C, triglycerides and diastolic blood pressures were optimal 
when evaluated as a cumulative average. Aspirin and a statin were frequently prescribed. In 
contrast, an audit of PAD clinic visits in the United States found the uses of an antiplatelet, 
statin, and ACE inhibitor (or angiotensin 2 receptor blockers) were 36%, 33%, and 28%, 
accordingly [12]. In chapter two, we proposed that hs-CRP control would be a necessary 
strategy for reducing MACE. Here, hs-CRP and smoking were the least well-controlled risk 
factors. In general, this data provided an opportunity to study another well-managed PAD 
group, compared to other observational studies. 
The PAD patients had a smaller EEM and lumen volume, but similar PAV to the non-
PAD group. These findings may indicate constrictive (negative) remodelling. Atherosclerosis 
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is a dynamic pathophysiological process, where the arterial wall can expand or contract. 
Constrictive remodelling is characterised by early luminal stenosis and ischaemia. Prior studies 
of coronary artery disease have described an association between constrictive remodelling and 
stable angina presentations. Alternatively, expansive (positive) remodelling is a mechanism, 
whereby, the luminal area remains relatively preserved. Expansive remodelling has been linked 
with acute plaque rupture in the coronary circulation [174]. However, few studies have 
evaluated remodelling in lower extremity arteries. PAD is typically manifested by intermittent 
claudication and critical limb ischaemia. We postulate that these patients have a predilection 
for constrictive remodelling in the peripheries, as was evident here in the coronary circulation.  
Prior studies that have investigated coronary artery plaque in PAD have been limited. 
The more substantial part of this research was cross-sectional and did not account for 
contemporary risk factor control [166-168]. Hussein et al. showed that PAD-affected 
individuals had greater coronary atherosclerotic burden and progression than non-PAD patients 
[152]. However, this was a univariate comparative analysis. Questions remain as to whether 
differences in demographics and risk factor control could explain these observations. Central 
to this issue is the relationship between risk factors and PAD, compared to other atherosclerotic 
conditions. Smoking has a more substantial role in the development of PAD, whereas 
hypertension and elevated LDL-C have a modest association when contrasted with coronary 
artery disease [1, 15-17]. If we reconcile previous studies with our analysis, PAD patients have 
more comorbidities that are associated with high-risk coronary artery plaque. We propose that 
PAD is occurring in more complex patients, as this relates to an older age, elevated 
inflammation, smoking and poorly controlled diabetes. 
Several caveats should be noted regarding this exploratory analysis. There were 
limitations in the sample size, thereby making it difficult to make any definite conclusions. A 
single specified arterial segment was examined, where other arteries could have different 
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atherosclerotic morphologies. Serial IVUS imaging was used to assess the volume of plaque, 
calcium, and vessel size, although other plaque features that relate to inflammatory 
composition and arterial remodelling were not assessed. While the PAD and non-PAD groups 
were comparable across various baseline characteristics, there were some differences in 
smoking, hypertension, and inflammatory control. As this analysis was observational, the 
potential for unmeasured confounders cannot be excluded. This data was derived from three 
prior clinical trials of intensive lipid-lowering, whereas other risk factor interventions were not 
explicitly implemented. The duration of risk factor control preceding the commencement of 
study could vary between participants. In investigating the effects of multiple risk factor 
control, a more extended follow-up could be worthwhile. Long-term studies of multiple risk 
factor control in diabetes, suggest that the observable impact on MACE can be delayed [134]. 
Nevertheless, this study provided a unique longitudinal examination of coronary artery 
atherosclerosis in a setting where risk factors were assessed comprehensively. Participants 
were not routinely screened for PAD, and they underwent coronary angiography for a clinically 
indicated reason. Therefore, these findings do not necessarily reflect other situations of 
bystander PAD or coronary artery disease, that is more clinically quiescent. Despite these 
limitations, there are few analyses of this kind in PAD, partly due to the challenges of 
performing multiple invasive procedures on people in a clinical trial.  
 
3.5. Conclusions 
Patients with concomitant PAD did not exhibit more significant coronary artery disease burden 
or progression, as is commonly accepted. There was no observed impact of individual and 
multiple risk factor control on plaque progression, suggesting resilience to current treatments. 
More research is needed into the interaction with coronary artery atherosclerosis in PAD 
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patients, to understand better why they experience such high rates of MACE. Studies that use 














CHAPTER 4: GENDER DIFFERENCES IN LONG-TERM MORTALITY AND 





Background and aims: Individual studies in peripheral artery disease (PAD) indicate that 
there are gender discrepancies in symptoms, functional status, and treatment utilisation. It 
remains uncertain whether this translates to different long-term outcomes. We examine 
potential gender differences in mortality and major adverse cardiovascular events (MACE) in 
PAD. 
Methods: PubMed and Embase databases were searched for studies between 2000 until 
January 2019. After a review of 13,582 citations, fourteen articles were analysed. The reported 
age-adjusted hazard ratios (HR) for gender differences in mortality and MACE were included 
for meta-analysis. 
Results: Male gender was associated with a greater risk of all-cause mortality (HR 1.13, 95% 
CI 1.10 to 1.16, p<0.001) and MACE (HR 1.10, 95% CI 1.06 to 1.14, p<0.001). In a sensitivity 
analysis, male gender was associated with higher mortality risk for patients presenting with 
either critical limb ischaemia (HR 1.08, 95% CI 1.05 to 1.10, p<0.001) or mixed clinical 
presentations (HR 1.16, 95% CI 1.11 to 1.21, p<0.001), but not for those with intermittent 
claudication (HR 1.13, 95% CI 0.98 to 1.30, p=0.09). Elevated mortality risk was evident 
following revascularisation (HR 1.11, 95% CI 1.04 to 1.19, p=0.003), hospitalisation (HR 1.15, 
95% CI 1.08 to 1.22, p<0.001), and amputation (HR 1.09, 95% CI 1.08 to 1.10, p<0.001), 
although not in outpatient clinics (HR 1.13, 95% CI 0.97 to 1.32, p=0.13), in males compared 
with females. 
Conclusions: Greater mortality and MACE rates in men with PAD occurred despite other 
accepted gender disparities. The mechanism underlying these gender differences in outcomes 






Peripheral artery disease (PAD) is associated with substantial morbidity and mortality. While 
coronary artery disease and cerebrovascular disease are the most common causes of death (40-
60% and 10-20%, respectively) in PAD patients, 20-30% of patients are likely to die from non-
cardiovascular causes [6]. PAD has been traditionally studied as a disease affecting males. 
However, the true gender-specific prevalence is unclear, as many cases are clinically silent. It 
has been observed that PAD in females is less frequent than in age-matched males, but the total 
burden, in terms of the number of affected individuals is higher [140, 175, 176]. Studies have 
demonstrated gender discrepancies in clinical symptoms, functional status, and quality of life 
for patients with PAD [140-142]. Females are more likely to be asymptomatic or have atypical 
symptoms, further challenging clinical diagnosis [175, 176]. PAD is associated with more 
walking impairment and progressive functional decline in women [141]. Research into gender 
differences in the prescription of medical and lifestyle therapies for PAD is lacking. However, 
there is broad evidence in the cardiovascular setting that females are treated less intensively to 
achieve cardiovascular risk factor targets [177]. With gender disparities in clinical features and 
practices, there is potential for a vast divergence in long-term outcomes for PAD. 
 While adjustment for age has been found to abate the reported long-term gender 
differences in mortality after myocardial infarction [178], PAD has been less well studied. 
Scientific statements have increasingly promoted the need for increased awareness and further 
research into gender-specific concerns in PAD. Women are consistently under-represented in 
clinical trials in this space [140], and accordingly, it is difficult to draw too many conclusions 
from individual studies. This study examined the impact of gender on all-cause mortality and 




4.2.1.  Search strategy 
A digital search was conducted on PubMed and Embase databases for studies in the English 
language between the 1st January 2000 and 10th January 2019. Articles before the 1st January 
2000 were not included, to reflect modern clinical trends, such as the emerging use of statins 
and other advances in risk factor control. The following terms were searched in the titles and 
abstracts of articles: (“peripheral arterial disease” or “peripheral artery disease” or “peripheral 
vascular disease” or “peripheral arterial occlusive” or “claudication” or “claudicant” or “ankle 
brachial ind” or “critical limb” or “amputation” or “lower limb” or “lower extremity”) and 
(“mortality” or “death” or “survival” or “cardiovascular event” or “myocardial infarction” or 
“acute coronary syndrome” or “stroke” or “cerebrovascular event” or “CVA”). This broad 
approach was not restricted by gender-related terms, to find all relevant studies, even those not 
primarily focused on gender. That process was the basis for finding all the included studies. 
For completion, a manual search of abstracts was made for PAD studies that contained gender 
terms, such as “gender” and “women”. The study protocol was prospectively registered with 
the PROSPERO international register (CRD42018110144) and fully adhered to the PRISMA 
statement (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). An 
example search strategy is presented in the supplemental material.  
 
4.2.2.  Eligibility criteria 
Only studies of symptomatic PAD were included, and this was characterised as any one of the 
following: intermittent claudication or a diagnosis of symptomatic PAD, critical limb 
ischaemia, a PAD revascularisation procedure, a lower limb amputation for PAD, or 
hospitalisation for PAD. Thus, randomised clinical trials of symptomatic PAD, as well as 
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observational analyses of PAD interventions and hospitalisations were eligible, while 
population studies of ankle-brachial index screening were not. For inclusion, these studies also 
had to: (1) report a hazard ratio (HR) with 95% confidence interval (95% CI) for gender-
specific all-cause mortality or major adverse cardiovascular events (3-point composite of 
myocardial infarction, stroke and mortality); (2) have a follow-up duration of 12 months or 
more. 
Studies were excluded if the: (1) reported hazard ratio did not adjust for age as a 
covariate; (2) PAD was not distinguished from other conditions such as diabetic foot syndrome, 
coronary artery disease or abdominal aortic aneurysm; (3) article was published before 1st 
January 2000; (4) cohort was followed from before 1st January 1990; (5) sample size was less 
than 1000. Only all-cause mortality and a 3-point MACE composite endpoint were considered. 
Where multiple studies described the same population, the study with the most comprehensive 
gender analysis was included. If a study provided a range of follow-up periods, analysis of the 
longest duration was used. Individual definitions of endpoints were included in the 
supplemental material. 
 
4.2.3.  Data extraction and quality assessment 
Data extraction and quality assessment were conducted by two independent authors using the 
predefined eligibility criteria. Where there were any differences, a third reviewer was 
consulted. Information was transcribed into a spreadsheet. Details recorded were the: study 
design; length of follow-up; baseline demographics and risk factors; definition of PAD; a 
history of lower limb revascularisation; type of statistical analyses and covariate adjustment; 
hazard ratio; and 95% confidence intervals. Outcomes were defined in terms of long-term 
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MACE and all-cause mortality. The study quality was assessed using the Newcastle Ottawa 
Scale [179]. 
 
4.2.4.  Study aims 
The primary endpoint was an examination of gender differences in long-term mortality using 
the multivariate-adjusted hazard ratio. The combined results were expressed as a hazard ratio 
for male versus a female reference group. A sensitivity analysis was performed to consider 
clinical presentation (intermittent claudication and critical limb ischaemia) and follow-up 
context (outpatient encounter, hospitalisation, revascularisation, and amputation). The 
secondary endpoint was a gender-specific multivariate-adjusted hazard ratio for MACE. 
 
4.2.5.  Statistical analysis 
Statistical analysis was performed using Stata 14.1 and the metan suite of commands. Hazard 
ratios were examined on the log scale and transformed for graphical presentation, with 95% CI 
reported. Random effects modelling was used with the method of DerSimonian and Laird. 
Statistical heterogeneity was evaluated by the I2 statistic and quantified as low (<25%), 
moderate (25-75%), or high (>75%). Sensitivity analysis was performed by clinical setting and 
patient diagnosis. Publication bias was assessed visually by funnel plots and statistically by the 
Egger and Begg test. The Duval and Tweedie’s trim and fill method were also used to 





4.3.1.  Search results 
This search identified a total of 13,582 citations. There was a removal of 13,454 articles 
following the screening of titles and abstracts. A further 79 studies were excluded after full-
length review. The remaining 49 articles reported a statistical comparison between gender 
groups. Fourteen studies were included for meta-analysis [30, 180-192]. The reasons for study 
exclusion are summarised in Figure 4.1. More information about the excluded studies with a 





Figure 4.1: PRISMA diagram 
 
 
The search process for studies included in the meta-analysis. 





4.3.2.  Study quality and bias assessment 
There was significant heterogeneity in study inclusion, study design, treatment, follow-up 
duration, and statistical analysis. The study quality was assessed using the Newcastle-Ottawa 
scale (Table 4.1). Of the fourteen studies included in this review, six articles had a specific 
focus on gender differences in PAD [182, 184-187, 190]. Eight studies used an administrative 
dataset [30, 181, 183, 185, 187, 188, 191, 192], five examined a hospital or community cohort 
[180, 182, 184, 186, 190], and one used a randomised controlled trial [189]. A summary of 
study inclusion, primary endpoints, MACE definition, study characteristics and funnel plot 
analysis is in the supplemental material. No significant statistical bias was demonstrated on the 
Egger and Begg test for small-study effects (p=0.18). Duval and Tweedie’s trim and fill method 
did not alter overall summary point estimates. 
 
4.3.3.  Study characteristics and event rates 
The study characteristics and events rates are summarised in Table 4.1. The studies were 
published between 2003 and 2018. The sample size range was between 1,404 and 218,858 total 
subjects. Females represented 47.4% of the studied population. The mean follow-up for all 
studies was 46 ± 21 months, expressed as a mean ± standard deviation. The range of follow-up 
periods was between 12 and 77 months. Where each study was equally weighted, the incidence 
of mortality during follow-up was 50% or an annual event rate of 13%. Five studies examined 
MACE [180, 182, 183, 187, 190], and the average total incidence of MACE during follow-up 
was 45%. Two studies began following a vascular clinic review and not specifically relating to 
a PAD intervention or hospitalisation [183, 187]. Five articles provided details of baseline 
characteristics and treatment in men and women. The females had a higher mean age than 
males (71 ± 2 and 68 ± 4, respectively). There was a higher prevalence of smoking and coronary 
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artery disease in men, whereas hypertension was more common in women. Intermittent 
claudication was a more frequent clinical presentation in males. 
 
Table 4.1: Characteristics of included studies 
AUTHOR YEAR DX DATES LOCATION DATABASE TYPE CONTEXT NOS 
ABTAN [180] 2017 IC, CLI 2003-2008 INTERNATIONAL REACH PROSP HOSPIT 8 
AL-OMRAN [181] 2003 IC, CLI 1991-1998 CANADA CANADIAN 
INSTITUTE OF 
HEALTH INFO 
RETRO REVASC 8 
BUDTZ-LILLY 
[182] 
2015 IC, CLI 2000-2007 DENMARK DANISH VASCULAR 
REGISTRY 
RETRO REVASC 8 
CEA SORIANO 
[183] 
2017 IC 2000-2010 UK THE HEALTH 
IMPROVEMENT 
NETWORK 
RETRO OPD 9 
DUFFY [184] 2014 IC, CLI 2003-2010 UK VASCULAR STUDY 
GROUP OF ENGLAND 
PROSP REVASC 9 
FREISINGER [185] 2018 IC, CLI 2009-2013 GERMANY BARMER GEK RETRO HOSPIT 8 
GROOTENBOER 
[186] 
2011 IC, CLI 1993-2006 NETHERLANDS ERASMUS CENTER PROSP REVASC 8 
HUSSAIN [187] 2016 IC 2004-2007 CANADA ONTARIO 
ADMINISTRATIVE 
DATASET 
RETRO OPD 9 
JONES [30] 2013 CLI 2000-2008 US CENTER FOR 
MEDICARE AND 
MEDICAIDE SERVICES 
RETRO AMPUT 8 
MUSTAPHA [188] 2018 CLI 2010-2015 US CENTER FOR 
MEDICARE AND 
MEDICAIDE SERVICES 
RETRO HOSPIT 9 
SCHANZER [189] 2008 CLI 2001-2003 US/ CANADA PREVENT III - RCT PROSP REVASC 9 
SIGVANT [190] 2017 IC, CLI 2006-2013 SWEDEN SWEDISH NATIONAL 
PATIENT REGISTER 
RETRO HOSPIT 8 
TURLEY [191] 2017 IC, CLI 2010-2012 US CENTER FOR 
MEDICARE AND 
MEDICAIDE SERVICES 
RETRO REVASC 9 





RETRO HOSPIT 8 
CLI, critical limb ischaemia; DX, diagnosis; HOSPIT, hospitalisation; IC, intermittent claudication; NOS, 




4.3.4.  All-cause mortality 
For the primary endpoint of all-cause mortality, thirteen studies incorporating 668,690 patients 
were evaluated (Figure 4.2 and Table 4.2). There was an increased risk of all-cause mortality 
for males (HR 1.13, 95% CI 1.10 to 1.16, p<0.001, I2 88%). In nine studies, male gender was 
significantly associated with all-cause mortality, with a hazard ratio ranging between 1.06 
(95% CI 1.04 to 1.08) and 1.36 (95% CI 1.21 to 1.53). For the remaining four studies, there 
was no statistically significant gender difference in all-cause mortality. 
A sensitivity analysis was performed based on the clinical presentation and follow-up 
context of the observed cohort (Figure 4.3). Male gender was associated with increased all-
cause mortality for patients with critical limb ischaemia (HR 1.08, 95% CI 1.05 to 1.10, p< 
0.001, I2 68%) and mixed clinical presentations (HR 1.16, 95% CI 1.11 to 1.21, p<0.001, I2 
83%), but not for those with intermittent claudication (HR 1.13, 95% CI 0.98 to 1.30, p=0.09, 
I2 88%). All-cause mortality was higher in males for studies following revascularisation (HR 
1.11, 95% CI 1.04 to 1.19, p=0.003, I2 76%), hospitalisation (HR 1.15, 95% CI 1.08 to 1.22, 
p<0.001, I2 93%) and amputation (HR 1.09, 95% CI 1.08 to 1.10, p<0.001), compared with 
females. There was no significant gender difference in all-cause mortality for studies following 
an outpatient encounter (HR 1.13, 95% CI 0.97 to 1.32, p=0.13, I2 94%). 
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Figure 4.2: Relative risk estimates of all-cause mortality 
Forest plot reporting the hazard ratios (HR) with 95% confidence interval of all-cause mortality 
in patients, with females as the reference group. Note that Duffy 2014 examined intermittent 



























37.2 - 9874 4342 9732 12% 1.26 1.19 1.33 
BUDTZ-
LILLY, 2015 




76.8 0% 17053 11431 16147 9% 1.22 1.18 1.27 
DUFFY (IC), 
2014 
48 0% 515 197 - - 1.12 0.76 1.67 
DUFFY 
(CLI), 2014 
48 100% 1233 631 - - 1.06 0.92 1.23 
FREISINGER
, 2018 
48 49% 23282 18591 - - 1.16 1.11 1.21 
GROOTENB
OER, 2011 
76.8 - 753 293 610 9% 1.02 0.85 1.23 
HUSSAIN, 
2016 
64.8 0% 4454 2461 4120 11% 1.04 0.97 1.11 
JONES,  
2013 
22.7 100% 89627 96711 132114 24% 1.09 1.08 1.09 
MUSTAPHA, 
2018 
48 100% 37681 34518 38987 27% 1.06 1.04 1.08 
SCHANZER, 
2008 
12 100% 897 507 234 17% 0.92 0.68 1.23 
SIGVANT, 
2017 
33.6 - 34587 31602 39104 21% 1.14 1.11 1.16 
TURLEY, 
2017 
12 22% 115170 103688 29702 14% 1.08 1.05 1.12 
VAARTJES, 
2009 
60 - 2539 1619 1229 6% 1.36 1.21 1.53 
Abbreviations: 95% CI, 95% confidence interval; CLI, critical limb ischaemia; FU, follow-up 




Figure 4.3: Relative risk estimates of all-cause mortality based on situation 
(A) clinical presentations, and (B) follow-up context. Forest plot reporting the hazard ratios 
(HR) with 95% confidence interval of all-cause mortality in patients, according to clinical 




4.3.5.  Major adverse cardiovascular events 
Five included studies reported a multivariate-adjusted hazard ratio for MACE (Figure 4.4 and 
Table 4.3). There was a significant association for male gender and MACE (HR 1.10, 95% CI 
1.06 to 1.14, p<0.001, I2 53%). Male gender was significantly associated with increased MACE 
in three studies. In the two remaining studies, there was no significant gender discrepancy in 
MACE. 
 
Figure 4.4: Relative risk estimates of major adverse cardiovascular events 
Forest plot reporting the hazard ratios (HR) with 95% confidence interval of major adverse 






Table 4.3: Multivariate-adjusted hazard ratio for major adverse cardiovascular events 
















ABTAN, 2017 48 - 4156 1849 1057 4% 1.14 0.77 1.22 
BUDTZ-LILLY, 2015 63.6 65% 6289 4945 7195 12% 1.10 1.05 1.16 
CEA SORIANO, 2017 76.8 0% 17053 11431 5460 4% 1.15 1.09 1.22 
HUSSAIN, 2016 64.8 0% 4454 2461 4504 12% 0.99 0.92 1.05 
SIGVANT, 2017 33.6 - 34587 31602 30765 17% 1.10 1.07 1.13 
 
95% CI, 95% confidence interval; CLI, critical limb ischaemia; F, female; FU, follow-up 





From a pooled result of thirteen studies, male gender was independently associated with a 13% 
relative increase in all-cause mortality in patients with PAD. With sensitivity analysis, this 
trend was consistent across different domains, where the clinical presentation and follow-up 
context was determined. The follow-up of patients ranged between 12 and 77 months. The 
incidence of mortality was high for both men and women and estimated at 13% each year when 
studies were equally weighted. Additionally, from a combination of five studies, the male 
gender was associated with a 10% increase in MACE. This secondary analysis suggested that 
the increased mortality in men may be at least partly attributable to cardiovascular-related 
events. These findings establish gender differences in long-term mortality and MACE among 
patients with symptomatic PAD and differ from coronary artery disease patients, in which age 
plays an important role in gender-related differences in clinical outcomes [178]. 
In order to understand why male gender correlated with increased mortality, the 
potential for unmeasured confounders should be considered. The multivariate regression 
analyses did not account for disease severity, psychosocial factors, some medical 
comorbidities, effects of medical and lifestyle therapies, and complications from lower 
extremity revascularisation, and these could explain the outcome differences [10, 28, 41, 63, 
89, 193, 194]. Women had a higher mean age than men, and this was likely to correspond with 
variations in functional status and psychosocial factors. Social circumstances can impact 
patient compliance, and this is particularly important in PAD, where there is an emphasis on 
lifestyle modification [147]. While many studies adjusted for multiple cardiovascular risk 
factors and comorbidities, for others, the list was less comprehensive. Diabetes in females is 
more strongly associated with intermittent claudication and fatal coronary artery disease 
compared with males [177]. Therefore, differences in the prevalence of comorbidities, 
including diabetes, might explain the outcome discrepancies to a certain extent. In this 
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systematic review, a few studies reported a higher incidence of hypertension [182, 184-186] in 
women, whereas coronary artery disease [182, 184-186], diabetes [182, 185] and smoking 
[182, 184-186] were more common in men. Still, for those studies, their hazard ratios adjusted 
for these distinctions. The optimal control of these conditions might vary according to gender. 
In general, there continues to be less awareness and recognition of cardiovascular risk in 
women. Females receive less intensive treatment of hypertension and dyslipidaemia [195]. It 
could be that the diagnosis of PAD is a catalyst or “wake-up call” for change, although there 
is a paucity of substantiating evidence. The REACH registry was a prospective international 
study that followed 8,322 people with symptomatic PAD for up to four years. In that study, 
male gender was independently associated with optimal risk factor control, when compared 
with females (odds ratio 1.9) [10]. More observational research is needed to define how men 
and women with PAD are medically managed. 
This meta-analysis evaluated MACE as a secondary outcome, as this is the leading 
cause of death for PAD patients [6]. Male gender was associated with higher age-adjusted 
mortality in PAD, unlike coronary artery disease [178], and this might point to a non-cardiac 
aetiology. Major adverse limb events commonly occur following lower extremity 
revascularisation [28] and could affect men and women discordantly. These outcomes, which 
can include acute or chronic limb-threatening ischaemia and lower limb amputation, are 
associated with a 3-fold increase in the 1-year mortality [31]. Some studies have shown how 
major adverse limb events contributed to higher mortality in men. Freisinger et al. examined 
an administrative dataset of 41,873 people undergoing lower extremity revascularisation. The 
authors performed propensity score matching to assess the effect of gender on in-hospital and 
long-term (4-year) outcomes. Despite comparable rates of many perioperative adverse events, 
male gender remained an independent risk factor for in-hospital and long-term incidence of 
amputation (HR 1.28, p<0.001) [185]. Similarly, Hess et al. investigated 1-year outcomes 
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following lower extremity revascularisation in 381,415 patients. Female gender was associated 
with less major adverse limb events [28]. These findings suggest that there are technical factors 
related to lower extremity revascularisation that may contribute to excess mortality in males. 
Patients with conservatively-treated intermittent claudication are unlikely to die from major 
adverse limb events [25]. This meta-analysis featured three studies of more stable PAD groups; 
and in these, there was still a trend for increased mortality in men [180, 183, 187]. So, while 
this meta-analysis focused on mortality and MACE, an investigation into potential gender 
differences in major adverse limb events would be of interest in future analyses. 
The assessment of mortality according to the presentation and follow-up context gives 
further insight into the existing discrepancies and may adjust for significant group differences. 
Two studies in this meta-analysis reported more women with CLI than men [184, 185], which 
is meaningful, given the difference in prognosis between CLI and intermittent claudication [7]. 
PAD patients that undergo intervention or require hospitalisation are generally at higher risk 
than those seen in the clinic setting [28]. Here, the gender divergence in mortality was possibly 
greater in more advanced disease and after revascularisation. Prior research has suggested that 
men and women are selected differently for lower extremity revascularisation [140]. The 
sensitivity analysis of post-revascularisation studies found male gender to be associated with 
an 11% higher mortality risk, thereby accounting for differences in the use of these 
interventions. 
From 1980 through 2000, there was a significant reduction in cardiovascular-related 
deaths, which was attributable to emerging medical therapies and advances in risk factor 
control [196]. During this era, gender disparities in heart disease gained increasing attention. 
Professional bodies have introduced initiatives to promote the awareness of cardiovascular 
disease in women. Over the subsequent decade, there was a notable improvement in clinical 
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outcomes [197]. In this meta-analysis, a focus was made on modern literature after the 
incorporation of health campaigns and medical therapies such as statins. 
Most of the included studies were retrospective and used administrative datasets. In the 
examination of gender and mortality, the use of large administrative datasets is, in many ways, 
preferable to prospective clinical trials. It is expected that data regarding gender and mortality 
were reliably coded. Real-world datasets allow the evaluation of large numbers of individuals, 
which is better suited to review current practice than the confines of a clinical trial. Prospective 
clinical studies can be limited by enrolment bias, which is especially relevant, given that 
women are usually under-represented [140]. 
Several caveats should be noted. Gender was not the primary focal point of many 
included studies. The regression analysis in these articles might not have adequately adjusted 
for gender-related confounders. These studies did not assess disease severity, psychosocial 
factors, some medical comorbidities, effects of medical and lifestyle therapies, and 
complications from lower extremity revascularisation. Furthermore, there was significant 
heterogeneity across studies regarding disease severity, follow-up, treatment, and endpoint. 
There were differences in the covariates used in the regression model. However, sensitivity 
analysis discerned between the clinical presentations and types of follow-up and found a 
minimal impact on the pooled hazard ratio and 95% confidence interval. The descriptions of 
follow-up were characterised by how data was initially captured, although this had limitations. 
Studies following PAD hospitalisation did not differentiate between the interventions received. 
Also, over time, PAD patients will naturally crossover between revascularisation, amputation, 
hospitalisation, and clinic review. Nevertheless, a focus on the study context delineated 
between higher and lower-risk patients and accounted for group differences in revascularisation 
use. The initial search identified articles that featured more than 100 patients, but smaller 
studies (n=100-1,000) were subsequently excluded [99, 142, 198-210]. Those study findings, 
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as well as an overview of their quality, are summarised in the supplemental materials. The main 
reason for removing them was to avoid analysis bias. A vast body of research has evaluated 
mortality outcomes in PAD, but a considerable portion of smaller studies do not test for gender 
differences. The lack of gender comparisons in clinical trials is common and has been described 
[140, 211]. Less sizeable studies are possibly underreporting gender analysis because few 
events occur, and their findings are not significant. Their inclusion for meta-analysis has the 
potential to favour positive data. Hence, larger studies were chosen because gender-analysis 
was more consistently performed. There was no publication bias detected visually with funnel 
plot or statistically with the Begg and Egger testing. Of note, if these smaller studies had been 
added, they would have a modest weighting in the random-effects model of statistical analysis. 
 
4.5. Conclusions 
Male gender was associated with long-term MACE and mortality in symptomatic PAD. The 
gender discrepancies in mortality were evident across different clinical domains. This 
divergence was potentially greater in advanced disease, where there is critical limb ischaemia 
or a need for a lower extremity procedure. It remains to be seen whether this reflects clinical 
factors that are negatively affecting males or if this more relates to females that have benefitted 
from treatment. Notwithstanding, there were exceptionally high rates of MACE and mortality 
for both men and women, indicating an urgent need for new strategies. An evaluation of the 
attitudes and behaviours of clinicians and their patients with a gender-specific lens is required. 
Consideration for the effect of clinical variables on men and women could lead to more 
effective health initiatives that are attentive to both gender groups. There may be a role for 
PAD care delivery models that focus separately on men and women, as has been introduced in 
other aspects of cardiovascular medicine [212]. The increased mortality in men does not 
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minimise the importance of PAD in women. There are many female-predominant issues in 
PAD, including challenges with the clinical diagnosis; a lack of public and clinician awareness; 
under-representation of women in clinical trials; and possibly an under-utilisation of 
treatments, such as lower extremity revascularisation [140]. The association between male 
gender and mortality occurred despite these other disparities, and this paradox should be 




4.6.  Supplemental material 
Table 4.4: Example search strategy (PubMed) 
# SEARCHES RESULTS 
1 Peripheral Arterial Disease [MH] 6263 
2 Peripheral Arterial Disease* [TI]  3689 
3 Peripheral Vascular Diseases [MH:NOEXP] 12406 
4 Peripheral Vascular Disease* [TI] 2351 
5 Peripheral arterial occlusive* [TI] 898 
6 Intermittent Claudication [MH] 7711 
7 Claudication* [TI] 2888 
8 Claudicant* [TI] 112 
9 Ankle Brachial Ind* [TI] 921 
10 Critical limb* [TI] 1613 
11 Amputation* [TI] 10430 
12 Lower limb* [TI] 12289 
13 Lower extremity* [TI] 9622 
14 1 or 2 or 3 or 4 or 5 20891 
15 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 40491 
16 14 or 15 57338 
17 Mortality [MH] OR Mortality [TW] OR Death* [TW] OR 
Survival [TW] 
2379199 
18 Cardiovascular Event [TW] OR Myocardial Infarction 
[TW] 
234348 
19 Stroke [MH] OR Stroke [TW] OR Cerebrovascular Event 
[TW] OR CVA [TW] 
287473 




Table 4.5: Adjusted variables in hazard ratios reported for all-cause mortality 
AUTHOR ADJUSTMENT FACTORS 




Age, risk factors (BMI, diabetes, hypertension, tobacco use), comorbidities (creatinine, 
pulmonary disease, prior MI, prior CVA, prophylactic medication) 
CEA SORIANO, 
2017 
Age, risk factors (BMI, smoking, hypertension, dyslipidaemia, DM), comorbidities 
(MI, IHD, CCF, AF, CVA, COPD, medication use), Townsend deprivation score 
DUFFY, 2014 Age, race, smoking, comorbidities (CAD), risk factors (hypertension, statin use), 
operative factors (operation indication, pre-op ambulation, graft origin and recipient, 
conduit type), length of follow-up 
FREISINGER, 
2018 
Propensity score matching: Age, risk factors (hypertension, smoking, obesity, 
dyslipidaemia), comorbidities (CAD, CCF, CKD, malignancies) 
GROOTENBOER, 
2011 
Age, risk factors (hypertension, dyslipidaemia, diabetes, smoking), comorbidities 
(IHD, previous PCI/CABG, CCF, COPD, renal impairment), medication use (statin, 
beta blocker, aspirin) 
HUSSAIN, 2016 Age, income level, comorbidities, medication use, use of healthcare services 
JONES, 2013 Age, risk factors, comorbidities 
MUSTAPHA, 2018 Age, race, geography, risk factors (hypertension, diabetes, coronary artery disease, 
chronic kidney disease, hyperlipidaemia, smoking), clinical presentation 
SCHANZER, 2008 Age, race, institutional setting, risk factors, comorbidities, CLI, medication use, 
surgical 
SIGVANT, 2017 Age, risk factors, comorbidities 
TURLEY, 2017 Age, comorbidities (cancer, COPD, diabetes mellitus, dementia, heart failure, 
hypertension, ischemic heart disease, prior myocardial infarction, renal disease, 
stroke), location, type of intervention, clinical presentation 
VAARTJES, 2009 Age, comorbidities 
 
AF, atrial fibrillation; BMI, body mass index; CABG, coronary artery bypass graft; CCF, 
congestive cardiac failure; CKD, chronic kidney disease; CLI, critical limb ischaemia; COPD, 
chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DM, diabetes 




Table 4.6: Study inclusions and endpoints 
AUTHOR DATABASE AND STUDY INCLUSION OUTCOME DATA 
ABTAN, 2017 International Reduction of Atherothrombosis for 
Continued Health Registry 
Prospectively collected data from 7 geographical regions 
Inclusion: Age³ 45, documented PAD with 1 or more of 
the following: active intermittent claudication with 
ankle-brachial index <0.9; history of intermittent 
claudication with previous peripheral vascular 
intervention including amputation 
No history of stroke/ transient ischemic attack 
Primary outcome: MACE at 4 years 
MACE definition: composite of 




Canadian Institute of Health Information and Ontario 
Health Insurance Plan 
Database recorded discharges from all acute care 
hospitals in Ontario, including day surgeries. 
Inclusion: Arterial bypass surgery or percutaneous 
transluminal angioplasty for peripheral arterial occlusive 
disease 
ICD-9 code primary diagnosis and treatment codes were 
based on the Canadian Classification of Diagnostic, 
Therapeutic and Surgical Procedures. 
Comparison of revascularisation procedures 
Primary outcome: Cumulative survival rate 




National Danish Vascular Registry 
Database of all patients undergoing surgery for PAD in 
Danish hospitals. All operations were primary 
revascularisation procedures. All data were entered 
prospectively. Patients were stratified according to the 
PAD surgical procedure performed. Indications included 
stable claudication and critical limb ischaemia. 
Gender comparison 
Primary outcome: First incidence of 
myocardial infarction, stroke or death, each as 
an individual endpoint 
MACE definition: myocardial infarction, 




United Kingdom observational cohort 
Database enrolment initiated via primary care physician. 
Requirement was for the patient to be known for at least 
2 years, with at least 1 clinic visit during that time. 
Inclusion: Age 50-89 years and symptomatic PAD 
Automated database search using Read codes indicative 
of symptomatic PAD diagnosis and/or related surgical 
procedures. 
Comparison between symptomatic PAD and a 
matched cohort without PAD 
Primary outcome: Incidence of MACE 
MACE definition: myocardial infarction, 
ischemic stroke or cardiovascular-related 
death  
DUFFY, 2014 Vascular Study Group of New England 
Prospectively collected data following infrainguinal 
lower extremity bypass operation 
Gender comparison 
Primary outcome: ambulatory status and 
living status at discharge and 1-year follow-up 
FREISINGER
, 2018 
Public German health insurance database 
Inclusion: Index hospitalisation with ICD-10 codes 
170.20-170.24 as primary diagnoses or secondary 
diagnosis combined with at least one of the following 
main diagnoses: diabetes with vascular complications, 
other peripheral vessel diseases, arterial embolism and 
thrombosis, or ulcers. 
Gender comparison with propensity score 
matching 
Primary outcome: In-hospital and long-term 




Diagnostic, endovascular and surgical procedures were 
coded using German procedure classification 
GROOTENB
OER, 2011 
Prospectively collected data of all patients undergoing 
non-cardiac open vascular surgery at the Erasmus MC, 
Rotterdam, the Netherlands 
Participants that were included underwent non-cardiac 
vascular surgery, such as peripheral arterial occlusive 
disease  
Gender comparison 




Ontario administrative dataset 
Billing code algorithm and ICD-9/ ICD-10 codes for 
peripheral artery disease 
Inclusion: Age³ 40, diagnosis of PAD within 3 years 
before a visit to Vascular Surgeon in Ontario 
Gender comparison 
Primary outcome: MACE 
MACE definition: composite of death or 
hospital admission for stroke or myocardial 
infarction 
JONES, 2013 US Centers for Medicare and Medicaid Services 
Medicare administrative claims for PAD-related 
hospitalisation. 
Inclusion: ICD-9-CM diagnosis code or procedure code 
for lower extremity peripheral artery disease. 
Comparison between PAD cohort with lower 
extremity amputation and those without 
Primary outcome: All-cause mortality 
MUSTAPHA, 
2018 
US Medicare administrative claims for critical limb 
ischaemia hospitalisations 
Inclusion: Critical limb ischaemia primary diagnosis 
(ICD-9 codes 440.22-440.24) or critical-limb ischaemia-
related procedure code (endovascular revascularisation, 
surgical revascularisation, above or below ankle 
amputation) 
Propensity score matching comparing 
endovascular revascularisation, surgical 
revascularisation and major amputation 
Primary outcome: Survival and major 
amputation through 4-year follow-up 
SCHANZER, 
2008 
The Project of Ex-Vivo vein graft Engineering via 
Transfection III (PREVENT III) cohort 
Multicentre, randomised prospective trial testing the 
efficacy of edifoligide for prevention of graft failure 
Inclusion: Critical limb ischaemia undergoing lower 
extremity bypass grafting 
Propensity score matching examining the 
effect of statins, beta-blockers and antiplatelet 
agents 
Primary outcome: MACE £30 days, vein graft 
patency and 1-year survival 
Definition of MACE: composite of 
myocardial infarction, stroke or death 
SIGVANT, 
2017 
Swedish National Registry for Vascular Surgery 
Prospectively collected data for vascular procedures in 
Sweden 
Inclusion: Age> 50 years. Underwent lower limb 
revascularisation for chronic PAD 
Examined effects of secondary preventive 
drug treatment 
Primary outcome: MACE 
MACE definition: nonfatal myocardial 




US Centers for Medicare and Medicaid Services 
Medicare beneficiaries with a diagnosis of PAD 
identified by ICD-9-CM codes. Peripheral 
revascularisation procedures were identified using CPT 
codes. 
Inclusion: Age ³ 65, undergoing lower extremity 
revascularisation procedure 
Comparison of inpatient and outpatient 
clinical care settings  
Primary outcome: 30-day and 1-year rate of 
all-cause mortality, major lower extremity 
amputation, repeat revascularisation, and all-






National Hospital Discharge Registry and the Dutch 
Population Registry. Nationwide database of hospital 
admissions 
First hospital admission for PAD (defined by ICD-9 
codes). Those with a previous admission for PAD were 
excluded 
Gender comparison 




Table 4.7: Study quality analysis 
STUDY CHARACTERISTIC REFERENCE 
Study design 
Administrative dataset Al-Omran, Cea Soriano, Freisinger, Hussain, Jones, Mustapha, Turley, 
Vaartjes 
Hospital or community cohort Abtan, Budtz-Lilly, Duffy, Grootenboer, Sigvant 
Randomised clinical trials Schanzer 




    Arterial bypass surgery Abtan, Al-Omran, Budtz-Lilly, Duffy, Freisinger, Grootenboer, Jones, 
Mustapha, Schanzer, Sigvant, Turley 
    Endovascular surgery Abtan, Al-Omran, Budtz-Lilly, Freisinger, Jones, Mustapha, Sigvant, 
Turley 
    Amputation Abtan, Budtz-Lilly, Jones, Mustapha 
Non-procedural diagnosis Abtan, Cea Soriano, Hussain, Vaartjes 
Age-criteria Abtan, Cea Soriano, Hussain, Sigvant, Turley 
  
Follow-up point 
Admission Al-Omran (Arterial bypass surgery), Freisinger, Vaartjes 
Post-procedure Al-Omran (Endovascular), Budtz-Lilly, Grootenboer, Jones, Mustapha, 
Sigvant, Turley 
Discharge Duffy 
After randomisation/ enrolment Abtan, Schanzer 
Multiple starting points Cea Soriano, Hussain 
  
Follow-up duration 
12 months Schanzer, Turley 
1-4 years Al-Omran, Duffy, Freisinger, Jones, Mustapha, Sigvant 





Table 4.8: Gender characteristics 
CHARACTERISTIC Higher Percentage in 
Women 
No Difference Between 
Genders 
Higher Percentage in 
Men 
Comorbidities 
Hypertension Freisinger, Budtz-Lilly, 
Duffy, Grootenboer 
  
Diabetes Mellitus  Hussain, Duffy, 
Grootenboer 
Freisinger, Budtz-Lilly 
Smoking   Freisinger, Budtz-Lilly, 
Duffy, Grootenboer 
Obesity   Freisinger 
CAD/ MI  Hussain Freisinger, Budtz-Lilly, 
Duffy, Grootenboer 
CVD  Hussain Budtz-Lilly 
CKD  Duffy, Grootenboer Hussain 
CHF Freisinger Duffy Hussain 
COPD/ Lung disease Budtz-Lilly Hussain, Duffy, 
Grootenboer 
 
Non- ambulatory Duffy   
Clinical Presentation 
CLI Freisinger, Duffy   
IC   Freisinger, Budtz-Lilly, 
Duffy 
Medications 
Statin  Hussain, Budtz-Lilly, 
Grootenboer 
Duffy 
Antithrombotic Budtz-Lilly Duffy Hussain 
Antihypertensive Hussain   
Procedures 
Any revascularisation  Freisinger  
Surgery   Freisinger 
Endovascular Freisinger   
 
Five studies included that performed a gender comparison. Vaartjes was not included as it 
performed an adjusted analysis. Abbreviations: CAD, coronary artery disease; CHF, chronic 
heart failure; CKD, chronic kidney disease; CLI, critical limb ischaemia; COPD, chronic 
obstructive pulmonary disease; CVD, cerebrovascular disease; IC, intermittent claudication; 











95% CI 95% CI NOS 
AQUARIUS  2009 184 2.30 0.60 8.60 8 
BUNTE 2016 258 1.47 1.02 2.10 8 
DREYER 2014 816 1.16 0.75 1.82 RCT 
GARDNER 2008 434 1.97 0.96 4.07 9 
GENOVESE  2016 411 0.67 0.46 0.96 9 
HOWARD 2015 93 (ALI) 2.04 0.62 6.69 8 
  202 (CLI) 0.78 0.38 1.63  
JEON-
SLAUGHTER  
2017 898 4.55 0.98 20.00 8 
KLAPHAKE 2018 181 1.25 1.02 1.54 9 
LEJAY 2015 584 0.67 0.49 0.93 8 
OHMINE 2015 153 1.39 0.63 3.21 8 
SENDA  2017 441 1.14 0.68 1.89 8 
SHIRAKI 2014 459 0.89 0.60 1.44 8 
SPRENGERS 2009 800 1.0 0.7 1.6 8 
TAKAHARA  2010 278 1.38 0.78 2.41 9 
TAKEJI 2018 643 1.17 0.89 1.58 8 
 
Reported hazard ratios (HR) with 95% confidence interval of all-cause mortality in patients, 
with females as the reference group. Abbreviations: 95% CI, 95% confidence interval; ALI, 






Table 4.10: Studies removed due to duplicate dataset 





Assessed the impact of diabetes on critical limb ischaemia 
Freisinger performed propensity score matched gender analysis with 





Assessed the association of chronic kidney disease with morbidity and 
















Assessed the association of atrial fibrillation or flutter on outcomes of patients 
hospitalised for PAD 
SI, 2018[217] REACH Assessed the prevalence and outcomes of undiagnosed peripheral among high-
risk patients in Australia 
Abtan studied the largest PAD cohort from REACH [180] 
WINKEL, 
2010[218] 
REACH Assessed  the prognosis of atrial fibrillation in patients with PAD 
SUCKOW, 
2015[219] 
VSGNE Assessed the impact of statin therapy after infrainguinal bypass surgery for 
critical limb ischaemia 
Duffy performed gender-specific comparison [184] 
GOODNEY, 
2010[220] 





Table 4.11: Funnel plot analysis 
 
Egger’s test for small-study effects: p=0.18 















CHAPTER 5: GENDER DIFFERENCES IN LONG-TERM OUTCOMES IN PAD – 





Introduction: There are several recognised gender disparities in peripheral artery disease 
(PAD). Previous studies have found male gender to be associated with increased major adverse 
cardiovascular events (MACE) and mortality. However, there is a lack of high-quality 
comparative analyses to explain the observed differences in long-term outcomes.   
Methods: ACCELERATE was a randomised trial of evacetrapib and placebo, which studied 
626 females and 1,729 males with PAD. This analysis compared MACE and all-cause mortality 
rates according to gender. 
Results: The rates of MACE in females and males were comparable (16.0% vs 17.4%, p=0.32, 
respectively). There was no significant difference in cardiovascular mortality (3.8% vs 5.8%, 
p=0.08), non-fatal myocardial infarction (6.1% vs 6.2%, p=0.98), non-fatal stroke (2.4% vs 
2.8%, p=0.53), hospitalisation for unstable angina (2.2% vs 3.1%, p=0.11), and coronary 
revascularisation (8.2% vs 8.4%, p=0.52), in women compared with men. Females were 
significantly less likely to die from any cause than males (5.6% vs 9.2%, p=0.01). In the 
patients that achieved less optimal risk factor control, the incidence of all-cause mortality (4.7% 
vs 6.9%, p=0.36) was comparable for females and males, respectively. Female PAD patients 
that achieved more optimal risk factor control had significantly lower all-cause mortality than 
their male counterparts (4.0% vs 8.6%, p=0.004). Male gender was independently associated 
with all-cause mortality (adjusted hazard ratio [HR] 1.62, 95% CI, 1.11 to 2.38, p=0.01). 
Conclusions: Male gender was associated with higher rates of mortality, and this was not 
attributable to gender differences in age, comorbidities, or non-fatal MACE. Women that 
achieved multiple risk factor control were significantly less likely to die than men, suggesting 
they might benefit more from intensive treatment. If the mechanisms contributing to this 
disparity were better understood, they could lead to better strategies in PAD treatment for both 




Peripheral artery disease (PAD) is associated with a high incidence of major adverse 
cardiovascular events (MACE) and mortality [24]. A scientific statement from the American 
Heart Association highlighted many gender disparities in PAD that weigh against women 
[140]. Females with PAD are less likely to experience intermittent claudication but are more 
afflicted with functional impairment and reduced quality of life [140-142]. The absence of 
typical symptoms and low clinical awareness of PAD could lead to more under-diagnosis and 
under-treatment in women [221]. Females are usually under-represented in clinical trials of 
medical and lifestyle therapies [140]. There could be differences in the utilisation of treatments, 
as some studies have found women to undergo lower extremity revascularisation less 
frequently than men [140, 222]. 
Despite these accepted gender disparities, chapter 4 showed that men had higher rates 
of MACE and mortality in long-term studies of symptomatic PAD. These differences in 
mortality were apparent across different clinical situations, although the divergence was 
potentially more significant with advanced disease requiring hospitalisation or a lower limb 
procedure. However, most of these studies did not focus on gender, and the potential for 
unmeasured confounders relating to risk factor control and treatment utilisation could not be 
excluded. It remains to be seen whether this discrepancy is due to clinical factors that negatively 
affect males, or if this is from females that have benefitted from treatment. Therefore, the 
mechanisms for the observed gender differences in MACE and mortality remain poorly 
understood. 
ACCELERATE (Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein 
Inhibition with Evacetrapib in Patients at High Risk for Vascular Outcomes) was a randomised 
controlled trial of evacetrapib [148], which featured 626 females and 1,729 males with PAD. 
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In chapter 2, PAD patients in ACCELERATE experienced disproportionately high MACE 
rates, compared with coronary artery disease-only, even in the setting of multiple risk factor 
control [223]. In this chapter, we assessed the long-term outcomes in PAD patients according 
to gender, to determine whether previously described disparities were evident after adjusting 
for medical management and other covariates. 
 
5.2. Methods 
5.2.1.  Trial design and population 
This study was an exploratory analysis of a randomised controlled trial. ACCELERATE was 
a multicentre study, which compared the effects of evacetrapib and placebo in 12,092 statin-
treated patients with atherosclerotic cardiovascular disease. Evacetrapib is a cholesteryl ester 
transfer protein inhibitor, which raises high-density lipoprotein cholesterol (HDL-C), reduces 
low-density lipoprotein cholesterol (LDL-C), and enhances cholesterol efflux capacity. Details 
of the study design, objectives, methods, and endpoints have previously been published [148]. 
The trial was sponsored by Eli Lilly and was coordinated by the Cleveland Clinic Coordinating 
Center for Clinical Research (C5Research) and Covance (Princeton, NJ). 
For inclusion into ACCELERATE, participants had at least one of the following 
conditions: an acute coronary syndrome within the previous 30 to 365 days, atherosclerotic 
cerebrovascular disease, PAD, or diabetes with coronary artery disease. The PAD criterion was 
defined as current intermittent claudication or resting limb ischaemia and either an ankle-
brachial index ≤0.90 or history of atherosclerotic limb ischaemia leading to previous non-
coronary revascularisation or amputation. Some people with known PAD were not included on 
this basis, but an alternative diagnosis. All participants were required to take a maximally 
tolerated dose of statin and to meet specific lipid levels. 
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5.2.2.  Study aims 
ACCELERATE study outcomes have been previously detailed [148]. The primary outcome 
was a composite of MACE endpoints defined as either cardiovascular-related mortality, non-
fatal myocardial infarction, non-fatal stroke, coronary revascularisation, or hospitalisation for 
unstable angina. There was no significant difference in the primary outcome between patients 
receiving evacetrapib and placebo, and the study was ceased after a mean follow-up of 28 
months. 
The aims of this analysis were to (1) compare the incidence of MACE and mortality in 
male and female patients with PAD, (2) evaluate these outcomes, according to multiple risk 
factor control, and (3) use logistic regression to identify clinical factors associated with MACE 
and mortality in PAD. 
 
5.2.3.  Stratification of optimal risk factor control 
Risk factor control was evaluated at three months after randomisation. The targets were as 
followed: glycated haemoglobin (HbA1c) <7.0%, systolic blood pressure <130 mmHg, body 
mass index (BMI) ≤25, diastolic blood pressure <80 mmHg, LDL-C <70 mg/dL (1.80 
mmol/L), triglycerides <150 mg/dL (1.70 mmol/L), high-sensitivity C-reactive protein (hs-
CRP) <2.0 mg/L, and smoking abstinence. The patients were categorised as having “more 





5.2.4.  Statistical analysis 
Baseline clinical characteristics of male and female patients were compared using the 
Wilcoxon test for continuous variables and chi-square test for categorical variables. The Cox 
proportional hazard regression model was used to assess for the effect of gender on mortality 
and MACE. The associations were reported as hazard ratios (HR) with a 95% confidence 
interval, where p <0.05 was considered significant. Kaplan-Meier curves were created for the 
rate of the first occurrence of MACE and all-cause mortality in men and women. All analyses 
used STATA 15.1 (StataCorp, College Station, TX). 
 
5.3. Results 
5.3.1.  Baseline characteristics 
There was a total of 2,355 participants with PAD, inclusive of 626 (26.6%) females and 1,729 
males. The baseline characteristics stratified by gender are outlined in Table 5.1. The groups 
were of similar age. Females had a higher mean body mass index (30.2 vs 29.4, p=0.001), and 
had less history of coronary artery disease (57.2% vs. 72.0%, p<0.001), acute coronary 
syndrome (27.6% vs 39.8%, p<0.001), coronary artery bypass graft surgery (33.4% vs 46.4%, 
p<0.001) and lower limb revascularisation (39.1% vs 46.3%, p=0.002), compared with males. 
There were less women taking statins (93.5% vs 96.3%, p=0.003) and ACE-inhibitor or ARB 





Table 5.1: Baseline characteristics 
Characteristic Female 
(N = 626) 
Male 
(N = 1,729) 
p value 
Age (years)  66.3 ± 9.3 66.5 ± 8.6 0.56 
White race (N, %) 501 (80.0) 1,546 (89.4) <0.001 
Body mass index 30.2 ± 6.4 29.4 ± 5.0 0.001 
PAD history (N, %)    
      PAD inclusion criteria* 449 (71.7) 1,225 (70.9) 0.68 
      Ankle brachial index ≤0.9 376 (85.1) 994 (84.4) 0.73 
      Limb revascularisation 245 (39.1) 801 (46.3) 0.002 
      Amputation 25 (4.0) 91 (5.3) 0.73 
Coronary artery disease history (N, %) 358 (57.2) 1,245 (72.0) <0.001 
      Acute coronary syndrome 173 (27.6) 688 (39.8) <0.001 
      PCI 224 (62.6) 770 (61.8) 0.80 
      CABG 120 (33.4) 578 (46.4) <0.001 
Cerebrovascular disease (N, %) 223 (35.6) 634 (36.7) 0.64 
Current smoking (N, %) 155 (24.8) 452 (26.1) 0.50 
Diabetes (N, %) 384 (61.3) 988 (57.1) 0.07 
Baseline medication use (N, %)    
Statin 585 (93.5) 1,665 (96.3) 0.003 
ACE inhibitor/ ARB 449 (71.7) 1,340 (77.5) 0.004 
Aspirin 456 (72.8) 1,292 (74.7) 0.36 
Diabetes medication 348 (55.6) 901 (52.1) 0.14 
Antihypertensive  561 (89.6) 1,547 (89.5) 0.92 
 
Age and BMI expressed as mean ± standard deviation. *Participants that were included into 
ACCELERATE based on PAD eligibility criteria. Abbreviations: ACE, angiotensin-converting 
enzyme; ARB, angiotensin 2 receptor blocker; CABG, coronary artery bypass graft; PAD, 
peripheral artery disease; PCI, percutaneous coronary intervention 
 
5.3.2.  Incidence of MACE and all-cause mortality 
The rates of MACE in females and males were comparable (16.0% vs 17.4%, p=0.32, 
respectively) (Table 5.2 and Figure 5.1). There was a fewer number of cardiovascular-related 
deaths in females, although this was not significantly different (3.8% vs 5.8%, p=0.08). There 
were similar rates of non-fatal myocardial infarction (6.1% vs 6.2%, p=0.98), non-fatal stroke 
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(2.4% vs 2.8%, p=0.53), hospitalisation for unstable angina (2.2% vs 3.1%, p=0.11), and 
coronary revascularisation (8.2% vs 8.4%, p=0.52), in women compared with men. Females 
were significantly less likely to die from all-causes than males (5.6% vs 9.2%, p=0.01) (Figure 
5.2). For patients that achieved less optimal risk factor control, the incidence of MACE (20.0% 
vs 16.5%, p=0.79) and all-cause mortality (4.7% vs 6.9%, p=0.36) were comparable for 
females and males, respectively (Table 5.3). For PAD patients achieving more optimal risk 
factor control, females had lower rates of all-cause mortality (4.0% vs 8.6%, p=0.03), while 
differences in MACE did not meet statistical significance (13.2% vs 17.4%, p=0.07).  
 
Table 5.2: Incidence of events according to gender 
Events (N, %) Female 
(N = 626) 
Male 
(N = 1,729) 
p value 
MACE composite 87 (16.0) 268 (17.4) 0.32 
Cardiovascular mortality 22 (3.8) 90 (5.8) 0.08 
Non-fatal myocardial infarction 35 (6.1) 95 (6.2) 0.98 
Non-fatal stroke 12 (2.4) 40 (2.8) 0.53 
Hospitalisation for unstable angina 10 (2.2) 47 (3.1) 0.11 
Coronary revascularisation 43 (8.2) 131 (8.4) 0.52 
All-cause mortality 32 (5.6) 143 (9.2) 0.01 
 
Table 5.3: Risk factor control and outcomes according to gender 
Events, % Female Male p value 
MACE    
       Less optimal control 20.0 16.5 0.79 
       More optimal control 13.2 17.4 0.07 
    
All-cause mortality    
       Less optimal control 4.7 6.9 0.36 
       More optimal control 4.0 8.6 0.004 
 
Less optimal control defined as <4 of 8 risk factor targets achieved. More optimal control 
defined as ≥4 of 8 risk factor targets achieved. 
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Figure 5.1: Kaplan-Meier survival curve for the first occurrence of MACE  
 
Number at risk 
Males      1,729          1,646               1,573             1,500             1,302             341 





Figure 5.2: Kaplan-Meier survival curve for all-cause mortality 
 
Number at risk 
Males      1,729            1,701              1,669             1,624             1,439             389 
Females        626               616                 606                600                529              148 
 
 
5.3.3.  Factors associated with MACE and all-cause mortality 
Multivariate analysis found age, body mass index, lower limb amputation, limb 
revascularisation, cerebrovascular disease, coronary artery disease, acute coronary syndrome, 
diabetes mellitus and non-use of statins to be predictors of MACE (Table 5.4). Male gender 
was not associated with MACE (adjusted hazard ratio [HR], 1.00, 95% CI, 0.78 to 1.28, 
p=0.99). Logistic regression analysis identified older age, male gender, and history of lower 
limb revascularisation, cerebrovascular disease, and diabetes mellitus to be significantly 
associated with all-cause mortality (Table 5.5). Male gender was independently associated with 




Table 5.4: Multivariate analysis of MACE  
Characteristic MACE 
 HR 95% CI p value 
Demographics    
       Age (years) 1.02 1.01 – 1.03 0.001 
       Male gender 1.00 0.78 – 1.28 0.99 
       White 1.17 0.83 – 1.67 0.37 
PAD history    
       PAD inclusion criteria 0.97 0.76 – 1.23 0.79 
       ABI ≤0.9 0.74 0.54 – 1.01 0.06 
       Lower limb amputation 1.89 1.29 – 2.77 0.001 
       Limb revascularisation 1.37 1.11 – 1.70 0.003 
Comorbidities    
       Cerebrovascular disease 1.65 1.34 – 2.04 <0.001 
       Coronary artery disease 1.65 1.22 – 2.25 0.001 
       Acute coronary syndrome 1.34 1.06 – 1.69 0.01 
       Diabetes mellitus 1.48 1.17 – 1.87 0.001 
       Body mass index 1.02 1.00 – 1.04 0.03 
       Current smoker 1.03 0.79 – 1.33 0.84 
Medication use    
       Aspirin 1.06 0.83 – 1.36 0.65 
       Statin 0.63 0.42 – 0.95 0.03 
       ACE/ ARB 1.07 0.82 – 1.40 0.62 
       Diabetes medication 1.02 0.67 – 1.56 0.92 
       Antihypertensives 1.61 0.96 – 2.69 0.07 
 




Table 5.5: Multivariate analysis of all-cause mortality 
Characteristic All-cause mortality 
 HR 95% CI p value 
Demographics    
       Age (years) 1.04 1.02 – 1.06 <0.001 
       Male gender 1.62 1.11 – 2.38 0.01 
       White race 0.92 0.59 – 1.44 0.73 
PAD history    
       PAD inclusion criteria 1.23 0.90 – 1.78 0.17 
       ABI ≤0.9 0.83 0.51 – 1.35 0.46 
       Lower limb amputation 3.38 2.19 – 5.23 < 0.001 
       Limb revascularisation 1.32 0.98 – 1.79 0.07 
Comorbidities and history    
       Cerebrovascular disease 1.53 1.13 – 2.06 0.005 
       Coronary artery disease 1.25 0.87 – 1.77 0.23 
       PCI 0.74 0.53 – 1.04 0.09 
       Acute coronary syndrome 1.33 0.98 – 1.81 0.06 
       Diabetes mellitus 1.47 1.07 – 2.02 0.02 
       Body mass index 1.00 0.97 – 1.03 0.77 
       Current smoker 0.86 0.58 – 1.27 0.45 
Medication use    
       Aspirin 0.91 0.65 – 1.26 0.57 
       Statin 0.80 0.42 – 1.52 0.49 
       ACE-inhibitor/ ARB 0.86 0.60 – 1.23 0.42 
       Diabetes medication 1.08 0.58 – 1.99 0.82 
       Antihypertensives 1.32 0.71 – 2.46 0.38 
 





This study examined gender differences of a PAD cohort in a clinical trial setting. The 
incidence of MACE was comparable for men and women, and this was the predominant cause 
of death. Male PAD patients had considerably higher all-cause mortality than females, 
consistent with the findings of the meta-analysis in chapter 4. The gender difference in 
mortality was most evident for PAD patients that had more optimal risk factor control, which 
could be reflecting how women benefitted from intensive treatment. There was a disconnect 
between non-fatal MACE and all-cause mortality. In addition to the male gender, lower limb 
amputation appeared more predictive of all-cause mortality than MACE. This could be pointing 
to major adverse limb events, as the cause of gender differences in mortality, although these 
occurrences were not recorded in this study.  
 In chapter 2, PAD patients from ACCELERATE experienced higher MACE than 
coronary artery disease-only, even in the setting of multiple risk factor control [223]. There are 
many difficulties with reducing the risk of adverse events in these patients. Intermittent 
claudication and limb-threatening ischaemia correlate with considerable functional impairment 
and various medical comorbidities [18, 31, 204, 210, 224]. Lower extremity revascularisation 
carries a risk of major adverse limb events, including amputation, and acute limb ischaemia  
[27, 28, 225]. PAD patients are less likely to receive guideline-recommended therapies and 
optimal risk factor control, compared with coronary artery disease [10]. The theoretical 
incentive to treat PAD is higher, as these medications have potentially a dual benefit of 
reducing MACE and major adverse limb events [147]. Studies have found that the attitudes of 
clinicians and their patients are contributing to the under-treatment of PAD [13]. A higher 
medical complexity could be complicating clinical decisions to prescribe intensive treatments, 
such as antithrombotics, hypertension, diabetes, and dyslipidaemia. This problem underscores 
the importance of examining risk factor control and treatment utilisation in all PAD patients. 
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 The disconnect between the rates of non-fatal MACE and all-cause mortality was 
inverse to the ODYSSEY trial. That study compared 18,924 patients with a recent acute 
coronary syndrome, which were randomised to alirocumab (proprotein convertase 
subtilisin/kexin type 9 [PCSK9] inhibitor) or placebo [226]. Non-fatal cardiovascular events 
were proportional to a higher rate of cardiovascular and non-cardiovascular mortality. 
Alirocumab was associated with a relative risk reduction in all-cause mortality (HR 0.85; 95% 
CI, 0.73 to 0.98, p=0.03), including fewer non-cardiovascular causes. Steg et al. suggested 
many explanations for the beneficial effects of alirocumab on non-cardiovascular deaths. Non-
fatal MACE could be instrumental in the development of further disability, frailty, and 
susceptibility to non-cardiovascular illnesses [227]. The ODYSSEY trial investigated coronary 
artery disease patients, whereas this analysis was of PAD. Here, the link between non-fatal 
MACE and functional disability could be weaker, as these patients have overriding lower limb 
issues. Moreover, ACCELERATE was a shorter study and could be too narrow to observe a 
progression from non-fatal MACE to non-cardiovascular mortality. 
Female PAD patients that achieved more optimal risk factor control had a lower 
incidence of all-cause mortality than their male counterparts. Given the separation between 
non-fatal MACE and all-cause mortality, risk factor control may have disproportionately 
reduced major adverse limb events in women. The interaction between conventional risk 
factors and PAD, according to gender, are not as well understood as with coronary artery 
disease. In general, smoking has a more substantial role in PAD, whereas hypertension and 
elevated LDL-C, correlate less, than with coronary artery disease [1, 16, 17]. Diabetes, HDL-
C, and triglycerides have been associated with a higher risk of coronary artery disease in 
women, compared to men. Additionally, smoking and elevated hs-CRP appear to be more 
deleterious in female coronary artery disease patients than for males [177, 228, 229]. Diabetes 
has been more associated with intermittent claudication in women than in men [177]. Whether 
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risk factor control affects PAD differently in men and women needs clarification. While 
contemporary clinical trials have investigated the effects of medical treatment in preventing 
MALE, fewer women are usually enrolled [140]. This study raises the possibility that women 
with PAD benefit more from intensive risk factor control than men.  
The Kaplan-Meier survival curves for all-cause mortality visually separated at fifteen 
months after randomisation and were widest apart at study end. In chapter 4, we proposed that 
the gender disparities in all-cause mortality could be more significant with advanced disease 
requiring hospitalisation or lower extremity revascularisation. The ACCELERATE study 
randomised patients to evacetrapib or placebo, based on a history of high-risk atherosclerotic 
conditions, which included PAD. In clinical trials of this nature, participants are usually stable 
for inclusion and mostly followed in an outpatient setting. The number of lower extremity 
revascularisation procedures were not documented, but this procedure is an essential 
contributor to morbidity and mortality. If there were gender differences in the utilisation of 
lower extremity revascularisation, as has been observed in some previous studies [140], this 
could explain the divergence in the Kaplan-Meier survival curves during follow-up. The 
clinical decisions surrounding lower extremity revascularisation are highly individualised, and 
operator dependent [19, 230]. Further research is needed to understand these decisions, as they 
relate to gender. 
Some caveats should be noted. This study was an exploratory analysis of 
ACCELERATE, which investigated the efficacy of evacetrapib in high-risk cardiovascular 
conditions. Major adverse limb events and lower extremity revascularisation were not studied 
endpoints. These factors can have a profound impact on outcomes in PAD and are not 
necessarily related to MACE [231]. Defining the severity of lower extremity disease was not a 
primary focus, and we could not evaluate their role in the gender disparities. Psychosocial 
factors and functional status were also not assessed. However, the advantage of 
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ACCELERATE was the comprehensive information obtained regarding patient demographics 
and cardiovascular-related issues. These details were more extensive and more reliable than 
the administrative data in the studies that were reviewed in chapter 4. ACCELERATE 
examined participants that were eligible for inclusion into a cardiovascular outcome trial. This 
group would be more homogenous than people observed in hospital registry-based studies. 
Patients in ACCELERATE were less likely to be affected by unmeasured confounders 
concerning a PAD-related hospitalisation or procedure.  
An enrolment bias limits clinical trials. In ACCELERATE, 27% of PAD patients were 
female, whereas this would be near parity if it reflected the disease prevalence [175]. An under-
representation of women in clinical trials is typical for studies in this space [140]. There is an 
inherent rigidity that is associated with trial participation, which can limit the generalisability 
of findings to other clinical settings. These were well-managed PAD patients that had higher 
use of statins, antiplatelets, antihypertensives, and better risk factor control when compared 
with patients in other observational studies [10-12, 150]. Nevertheless, in chapter 4, we 
observed the association between male gender and increased rates of mortality in the non-trial 
setting. ACCELERATE provided an opportunity to evaluate the factors that could give rise to 
this disparity. The potential is there to review other cardiovascular outcome studies that feature 
PAD patients, to shed more light on this subject. 
 
5.5. Conclusions 
Male gender was associated with elevated all-cause mortality in PAD. Both men and women 
with this condition experienced high rates of MACE and mortality, and they require new 
approaches to management. Further research is needed to investigate if there are gender 
differences in long-term major adverse limb events and the responsible factors. The impact of 
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risk factor control on PAD outcomes in men and women need further evaluation. If this 















CHAPTER 6: MAJOR ADVERSE LIMB EVENTS AND MORTALITY 







Background: Major adverse limb events (MALE) cause permanent disability and contribute 
to the high rates of mortality in peripheral artery disease (PAD). Lower extremity 
revascularisation, either through endovascular or surgical means, can be complicated by MALE 
and other major adverse events, which require careful consideration. Persisting debate exists 
as to which approach has greater durability, and accordingly, lower risk of MALE in the longer 
term. Current evidence supporting the role of open vs endovascular revascularisation strategies 
are conflicting.  
Methods: Patients undergoing lower extremity revascularisation with a primary diagnosis of 
PAD between 2008 and 2015 in the Australian Admitted Patient Collection and New Zealand 
National Minimum Dataset were examined. We evaluated long-term outcomes (up to eight 
years) of endovascular and surgical revascularisation, in both unmatched groups (surgery, n = 
15,239; endovascular, n = 59,950) and with a propensity-score matched analysis (surgery, n = 
14,560; endovascular, n = 14,560). The primary endpoint was MALE, defined as a composite 
of acute limb ischaemia, urgent surgery or endovascular reintervention, or major amputation. 
Secondary endpoints included mortality, elective surgical or endovascular reintervention, 
minor amputation, major bleeding, and all-cause acute hospitalisation. A multivariate logistic 
regression analysis identified factors that predicted a composite of MALE or mortality. 
Results: In unmatched surgery and endovascular groups, the incidence of major adverse events 
was as followed: MALE (17.9% and 15.3%, p<0.0001), all-cause mortality (29.3% and 29.1%, 
p=0.89), MALE or all-cause mortality (40.4% and 38.3%, p<0.0001), major bleeding (9.6% 
and 8.2%, p<0.0001), all-cause acute hospitalisations (56.2% and 50.5%, p<0.0001), 
respectively. Predictors of MALE or mortality were age (years, hazard ratio [HR] 1.03, 95% 
CI, 1.02 to 1.03, p<0.0001), male gender (HR 1.08, 95% CI, 1.05 to 1.10, p<0.0001), critical 
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limb ischaemia (HR 1.53, 95% CI, 1.49 to 1.57, p<0.0001), vascular disease history (HR 1.14, 
95% CI, 1.11 to 1.17, p<0.0001), prior PAD intervention (HR 1.16, 95% CI, 1.11 to 1.22, 
p<0.0001), lower limb amputation (HR 1.12, 95% CI, 1.04 to 1.21, p=0.005), and renal failure 
(HR 1.26, 95% CI, 1.21 to 1.31, p<0.0001). With a propensity-matched comparison, 
endovascular repair had a higher rate of all-cause mortality (HR 1.14, 95% CI 1.10 to 1.19, 
p<0.001), composite of MALE or all-cause mortality (HR 1.12, 95% CI, 1.07 to 1.16, p<0.001), 
and composite of other limb events (HR 1.12, 95 % CI, 1.09 to 1.15, p<0.001), but similar rates 
of MALE (HR 1.02, 95%  CI, 0.96 to 1.07, p=0.58), major bleeding (HR 0.99, 95% CI, 0.92 
to 1.07, p=0.84), all-cause acute rehospitalisation (HR 1.00, 95% CI 0.97 to 1.03, p=0.77), 
compared to surgery.  
Conclusions: Enduring advantages of surgical revascularisation include lower all-cause 
mortality and endovascular reinterventions. The overall incidence of MALE or mortality was 
very high for both strategies, indicating patient comorbidities and potential limitation of 
treatment. Patients will benefit from multidisciplinary care and the ongoing advances in 






A focal point of this thesis has been to compare PAD and coronary artery disease patients. 
Major adverse limb events (MALE) cause permanent disability and increased mortality. These 
occurrences are a factor that distinguishes this condition from coronary artery disease. The 
introductory chapter described how MALE and other major adverse events could complicate 
lower extremity revascularisation. When a patient with intermittent claudication is treated 
conservatively, the likelihood of MALE is considered low [25, 26]. However, despite its risks, 
peripheral artery revascularisation is sometimes offered to ameliorate pain and walking 
impairment. At the other end of the spectrum, in managing critical limb ischaemia (CLI), there 
is a reliance on revascularisation to improve wound healing and limb salvage [19]. The 
incidence of MALE and other major adverse events after lower extremity revascularisation 
have not been well characterised in a local population or with an extended follow-up period. 
Traditionally, revascularisation was achieved with open surgical repair, where lower 
extremity atherosclerotic plaques are removed by endarterectomy or bypassed using an 
autogenous vein or prosthetic graft [232]. Endovascular repair, consisting of balloon 
angioplasty and stent insertion, has evolved with drug-coating and has rapidly gained 
dominance as the more commonly used approach to revascularisation [233]. 
The popularity of endovascular repair stems from the less-invasive nature of these 
procedures, shorter length of hospital stay, and a perceived reduction in perioperative 
complications compared to open surgery [234]. However, persisting debate exists as to whether 
surgical repair leads to more lasting revascularisation, and therefore is associated with less 
reintervention and a lower long-term risk of major adverse limb events (MALE) and mortality. 
Current evidence favouring either strategy is limited, with few randomised trials directly 
comparing endovascular or surgical repair [235]. Existing clinical trials have also been 
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restricted by small sample size, open-label, and non-comparative designs, limiting the strength 
of their conclusions [236]. So, despite the widespread use of revascularisation for PAD 
treatment, the optimal strategy for durable outcomes has not been determined. 
In this study, we evaluated long-term (up to eight-year) outcomes post revascularisation 
using national data from Australia and New Zealand. We examined the incidence of MALE 
(composite of acute limb ischaemia, urgent surgical or endovascular reintervention, or major 
lower limb amputation), mortality, and other adverse events. This study aimed to: (1) evaluate 
the incidence of MALE and other major adverse events after lower extremity revascularisation, 
(2) identify patient factors that were predictive of MALE or mortality, and (3) compare major 
adverse events following endovascular and surgical repair using propensity-score matching.  
 
6.2. Methods 
6.2.1.  Data source 
We used hospitalisation data from the Admitted Patient Collection from each Australia State 
and Territory and the equivalent New Zealand National Minimum Dataset (Hospital Events). 
These datasets record patient encounters for all in‐patient and day‐only admissions from all 
public and most private sector hospitals and day procedure centres. For each encounter, 
procedural data are collected using a standard set of variables including patient characteristics, 
primary and secondary diagnoses, all procedures performed and the patient status at discharge. 
In both Australia and New Zealand, diagnoses are coded as per the International Classification 
of Diseases, 10th Revision‐Australian Modification (ICD‐10‐AM) and all procedures are 
coded according to the Australian Classification of Health Interventions (ACHI). Prior studies 
of coding accuracy in the Australian setting have shown >85% accuracy for diagnoses and 
154 
 
procedure coding with cardiovascular diagnoses and procedures being particularly well coded 
[237]. 
In Australia, patient’s hospitalisation encounters were linked to subsequent 
hospitalisation and each individual’s registry of deaths. Linkages of all health records were 
performed using probabilistic matching techniques based on multiple patient identifiers by 
designated data‐linkage units within each region. In New Zealand, hospital encounters are 
linked nationally using a unique National Health Index number, and all deaths are recorded in 
the National Health Index sociodemographic profile. 
The Human Research Ethics Committees of the University of Adelaide and respective 
Australian states and territories provided ethical approval to undertake the study with a waiver 
of informed consent to use de-identified patient data. Data from New Zealand are obtained 
under a data user agreement with the New Zealand Ministry of Health. 
 
6.2.2.  Study population 
Figure 6.1 summarises the process of patient selection. We included patients ³ 18 years 
hospitalised with a primary diagnosis of PAD who had surgical or endovascular 
revascularisation during their admission. ICD-10-AM diagnoses and ACHI procedure codes 
were used to define the patient selection. For patients with multiple hospitalisations in the study 
period, the first hospitalisation was considered as the index encounter. We excluded other 
vascular conditions or procedures, such as aortic aneurysm, carotid and upper extremity 
disease, hybrid interventions (combined open surgery and endovascular intervention), 




6.2.3.  Study outcomes 
The primary outcome was the incidence of MALE, which was defined as any of the following: 
a primary diagnosis of acute limb ischaemia, urgent endovascular reintervention or 
embolectomy, urgent surgical reintervention, or major amputation (at or above the ankle). 
Secondary outcomes were individual MALE endpoints, all-cause mortality, all-cause 
unplanned readmissions, other limb events, and major bleeding. Other limb events included 
other presentations to hospital with a primary diagnosis of PAD, elective admissions for lower 
extremity reintervention, and minor amputation (below the ankle).  
 
6.2.4.  Statistical analysis 
Data are summarised as frequencies and percentages for categorical variables. Continuous 
variables are presented as mean and standard deviation or median and interquartile range. . The 
chi-square and student’s t-tests were used to compare endovascular and surgical intervention 
as appropriate. 
We used propensity matching to account for differences in baseline characteristics 
arising from the non-random assignment of surgical or endovascular intervention. We then 
developed a propensity score, indicating the conditional probability that any individual patient 
would undergo endovascular intervention using a logistic regression model. Variables included 
patient age, gender, geographic region, vascular and limb history, cardiovascular history, and 
other comorbidities. Cardiac history and comorbidities were derived from the secondary 
diagnosis and procedure codes from the index hospitalisation and the principal and secondary 
codes from all hospitalisations in the preceding 12 months using the Condition Categories 
classification. Patients undergoing endovascular intervention were then matched 1:1 without 
replacement to patients that underwent surgery based on the propensity score a using a calliper 
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width of 0.01 to derive a propensity score-matched cohort. Further details of propensity-
matching are outlined in the supplemental materials. 
Unadjusted event-free survival curves in the propensity score-matched cohort were 
generated using Kaplan-Meier estimates and compared using the log-rank test. Adjusted 
survival curves were estimated using a Cox Proportional Hazards Model. All time-to-event 
outcomes were reported as HRs and 95% CI with patients treated with surgery as the reference 
group. The significance levels were 2‐sided with a p<0.05, and the analyses were conducted 

























129,782 hospitalisations in patients aged 
≥18 between 2008-2015 in Australia and 
New Zealand with a procedure code for 
endovascular or surgical PAD intervention 
and a primary diagnosis consistent with 
PAD 
Study population 
75,189 patients meeting inclusion and 
exclusion criteria. 
Exclusions 
(not mutually exclusive) 
• Not the first hospitalisation in the 
study period (N = 48,503) 
• Discharged against medical advice 
(N = 581). 
• Surgical and endovascular (hybrid) 
intervention (N = 8,854) 
Surgical intervention 
N = 15,239 (20.3%) 
Endovascular intervention 
N = 59,950 (79.7%) 
1:1 Propensity-matched cohort 




6.3.1.  Baseline characteristics of unmatched groups 
75,189 patients were eligible, inclusive of 15,239 surgery and 59,950 endovascular cases. The 
baseline characteristics of unmatched groups are displayed in Table 6.1. Patients receiving 
surgery had lower mean age (70.8 vs 73.3, p<0.001), were more frequently men (73.5% vs 
62.1%, p<0.001), a greater history of vascular disease (46.4% vs 22.4%, p<0.001), prior 
vascular intervention (6.5% vs 5.2%, p<0.001), and lesser prior lower limb amputation (4.6% 
vs 5.0%, p=0.05), compared to the endovascular group, respectively. Surgery was more 
frequently performed in an elective setting (78.5% vs 76.8%, p<0.001), and less commonly in 
a private hospital (29.3% vs 40.8%, p<0.001). There were significant differences across various 
cardiovascular and non-cardiovascular comorbidities. Surgical group had less history of acute 
coronary syndrome (5.1% vs 4.7%, p=0.004), congestive heart failure (7.4% vs 8.3%, 
p<0.001), diabetes (27.1% vs 30.8%, p<0.001), renal failure (8.3% vs 11.0%, p<0.001), 






Table 6.1: Baseline characteristics of unmatched groups 
Baseline characteristics Overall Surgical Endovascular  
p value N = 75,189 N = 15,239 N = 59,950 
N % N % N % 
Demographics 
Age (mean ± SD), yrs. 72.8 ± 11.7 70.8 ± 11.6 73.3 ± 11.6 <0.001 
Age group        
      18-54  5,452 7.3 1,339 8.8 4,113 6.9 
<0.001 
      55-64 12,238 16.3 2,888 19.0 9,350 15.6 
      65-74 21,925 29.2 4,901 32.2 17,024 28.4 
      75-84 23,794 31.7 4,547 29.8 19,247 32.1 
      ≥85 11,780 15.7 1,564 10.3 10,216 17.0 
Male 48,456 64.5 11,206 73.5 37,250 62.1 <0.001 
Presenting characteristics 
Elective 58,002 77.1 11,959 78.5 46,043 76.8 <0.001 
CLI 21,856 29.1 4,394 28.8 17,462 29.1 0.48 
Private hospital 28,947 38.5 4,465 29.3 24,482 40.8 <0.001 
Presenting region 
NSW/ACT 23,923 31.8 3,437 22.6 20,486 34.2 
<0.001 
VIC 19,103 25.4 3,849 25.3 15,254 25.4 
QLD 10,331 13.7 3,319 21.8 7,012 11.7 
SA/NT 3,287 4.4 998 6.6 2,289 3.8 
TAS 694 0.9 145 1.0 549 0.9 
WA 8,621 11.5 829 5.4 7,792 13.0 
NZ 9,230 12.3 2,662 17.5 6,568 11.0 
Vascular and limb history 
Prior vascular disease 20,511 27.3 7,077 46.4 13,434 22.4 <0.001 
Prior vascular intervention  4,107 5.5 987 6.5 3,120 5.2 <0.001 
Prior limb amputation  3,671 4.9 698 4.6 2,973 5.0 0.05 
Cardiovascular history 
Prior coronary angiogram 4,914 6.5 1,089 7.2 3,825 6.4 0.001 
Prior PCI 1,777 2.4 309 2.0 1,468 2.5 0.002 
Prior CABG 928 1.2 224 1.5 704 1.2 0.003 
Acute coronary syndrome  3,837 5.1 708 4.7 3,129 5.2 0.004 
Ischaemic heart disease  7,738 10.3 1,801 11.8 5,937 9.9 <0.001 
Hypertension 23,290 31.0 5,215 34.2 18,075 30.2 <0.001 
Congestive heart failure  6,096 8.1 1,129 7.4 4,967 8.3 <0.001 
Valvular and rheumatic 
heart disease 
1,687 2.2 398 2.6 1,289 2.2 <0.001 
Arrythmia or conduction 
disorder 
6,357 8.5 1,149 7.5 5,208 8.7 <0.001 
Cerebrovascular diseases  2,384 3.2 504 3.3 1,880 3.1 0.28 
Other comorbidities 
Diabetes  22,592 30.1 4,125 27.1 18,467 30.8 <0.001 
Advanced or metastatic 
cancer  1,336 1.8 272 1.8 1,064 1.8 
 
0.93 
Other cancers and tumors  5,230 7.0 1020 6.7 4,210 7.0 0.15 




Table 6.1. Continued 
Baseline characteristics Overall Surgical Endovascular  
p value N = 75,189 N = 15,239 N = 59,950 
N % N % N % 
Other comorbidities 
Renal failure  7,874 10.5 1,267 8.3 6,607 11.0 <0.001 
Pneumonia 3,297 4.4 747 4.9 2,550 4.3 <0.001 
Haematological disorders  9,697 12.9 2,820 18.5 6,877 11.5 <0.001 
Chronic liver disease  325 0.4 75 0.5 250 0.4 0.21 
Dementia  1,825 2.4 302 2.0 1,523 2.5 <0.001 
Psychiatric disorders  1,862 2.5 473 3.1 1,389 2.3 <0.001 
Paralysis or functional 
disability 5,255 7.0 992 6.5 4,263 7.1 0.009 
Parkinson and Huntington’s 
disease 199 0.3 36 0.2 163 0.3 
 
0.44 
Seizure  343 0.5 68 0.5 275 0.5 0.84 
Malnutrition 2,839 3.8 644 4.2 2,195 3.7 0.001 
Other significant endocrine 
and metabolic disorder 1,695 2.3 381 2.5 1,314 2.2 
 
0.02 
Disorder of fluid and 
electrolytes 6,207 8.3 1,100 7.2 5,107 8.5 <0.001 
HIV 76 0.1 20 0.1 56 0.1 0.19 
Other significant endocrine/ 
metabolic disorder 8,919 11.9 2,211 14.5 6,708 11.2 <0.001 
Inflammatory bowel disease 115 0.2 26 0.2 89 0.2 0.53 
Bone, joint or muscle 
infection/ necrosis  2,728 3.6 439 2.9 2,289 3.8 <0.001 
RA or inflammatory CTD 813 1.1 137 0.9 676 1.1 0.02 
Spinal disorder 1,022 1.4 183 1.2 839 1.4 0.06 
Hip or knee osteoarthritis 921 1.2 151 1.0 770 1.3 0.003 
Artificial openings for 




Statistical comparison between unmatched surgical (n = 15,239) and endovascular (n = 
59,950) groups. Age is expressed in mean ± standard deviation, years. Abbreviations: CABG, 
coronary artery bypass grafting; CLI, critical limb ischaemia; CTD, connective tissue disease; 





6.3.2.  Major adverse events in unmatched groups 
During the period of observation following lower extremity revascularisation, the incidence of 
major adverse events for all patients (n = 75,189) was as follows: MALE (15.8%), all-cause 
mortality (29.1%), MALE or all-cause mortality (38.7%), other limb events (36.5%), major 
bleeding (8.5%), all-cause acute hospitalisation (51.6%) (see Table 6.2). In unmatched surgery 
(n = 15,239) and endovascular (n = 59,950) groups, the incidence of major adverse events was 
as follows: MALE (17.9% and 15.3%, p<0.0001), all-cause mortality (29.3% and 29.1%, 
p=0.89), MALE or all-cause mortality (40.4% and 38.3%, p<0.0001), major bleeding (9.6% 
and 8.2%, p<0.0001), all-cause acute hospitalisations (56.2% and 50.5%, p<0.0001), 
respectively. 
 
6.3.3.  Factors predictive of major adverse limb events or mortality 
The predictors of a composite of MALE or mortality were identified using logistic regression 
model (Table 6.3). Significant factors included age (years, HR 1.03, 95% CI, 1.02 to 1.03, 
p<0.0001), male gender (HR 1.08, 95% CI, 1.05 to 1.10, p<0.0001), CLI (HR 1.53, 95% CI, 
1.49 to 1.57, p<0.0001), vascular disease history (HR 1.14, 95% CI, 1.11 to 1.17, p<0.0001), 
prior PAD intervention (HR 1.16, 95% CI, 1.11 to 1.22, p<0.0001), prior lower limb 
amputation (HR 1.12, 95% CI, 1.04 to 1.21, p=0.005), acute coronary syndrome (HR 1.12, 
95% CI, 1.06 to 1.19, p<0.0001), diabetes (HR 1.04, 95% CI, 1.01 to 1.07, p=0.01), renal 
failure (HR 1.26, 95% CI, 1.21 to 1.31, p<0.0001), advanced or metastatic cancer (HR 2.11, 
95% CI 1.98 to 2.26, p<0.0001), and dementia (HR 1.38, 95% CI, 1.31 to 1.46, p<0.0001). 
Some cardiovascular history appeared protective, including cerebrovascular disease (HR 0.91, 
95% CI 0.86 to 0.97, p=0.005), prior coronary angiogram (HR 0.70, 95% CI, 0.65 to 0.76, 
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p<0.0001), prior percutaneous coronary intervention (HR 0.89, 95% CI, 0.81 to 0.98, p=0.02), 
and prior coronary artery bypass graft operation (HR 0.73, 95% CI, 0.65 to 0.82, p<0.0001). 
 
Table 6.2: Major adverse events in unmatched groups 
Outcomes Overall cohort 
(N = 75,189) 
Surgical 
(N = 15,239) 
Endovascular 














































































































Table 6.3: Multivariate analysis of major adverse limb events or mortality in all 
unmatched patients 





     
Demographics     
Age (years) 1.03 1.02 1.03 <0.0001 
Male gender 1.08 1.05 1.10 <0.0001 
     
Presenting characteristics     
CLI 1.53 1.49 1.57 <0.0001 
Elective procedure 0.60 0.59 0.62 <0.0001 
Private hospital 0.89 0.86 0.91 <0.0001 
     
Presenting region 
    
 NSW/ACT 1.07 1.03 1.12 <0.0001 
 NZ 1.18 1.13 1.24  
 QLD 1.01 0.96 1.06  
 SA/NT 1.11 1.04 1.18  
 TAS 1.24 1.11 1.40  
 VIC 0.92 0.88 0.96  
     
Vascular and limb history     
Vascular disease 1.14 1.11 1.17 <0.0001 
Prior PAD intervention 1.16 1.11 1.22 <0.0001 
Lower limb amputation 1.12 1.04 1.21 0.005 
     
Cardiovascular history     
Prior coronary angiogram 0.70 0.65 0.76 <0.0001 
Prior PCI 0.89 0.81 0.98 0.02 
Prior CABG 0.73 0.65 0.82 <0.0001 
Acute coronary syndrome 1.12 1.06 1.19 <0.0001 
Ischaemic heart disease 1.17 1.11 1.22 <0.0001 
Hypertension 1.23 1.19 1.26 <0.0001 
Arrythmia or conduction disorder  1.06 1.02 1.10 0.003 
Cerebrovascular diseases 0.91 0.86 0.97 0.005 
     
Other Comorbidities     
Diabetes 1.04 1.01 1.07 0.01 
Advanced or metastatic Cancer 2.11 1.98 2.26 <0.0001 
Chronic lung disease 1.38 1.31 1.44 <0.0001 
Pneumonia 1.19 1.13 1.25 <0.0001 
Renal failure 1.26 1.21 1.31 <0.0001 
Hematological disorders 1.14 1.10 1.18 <0.0001 
Chronic liver disease 1.74 1.53 1.99 <0.0001 
Dementia 1.38 1.31 1.46 <0.0001 
Psychiatric Disorders 1.18 1.11 1.25 <0.0001 
Paralysis or functional disability 1.14 1.06 1.22 0.0003 
Seizures 1.21 1.06 1.40 0.007 
Other significant endocrine and 
metabolic disorders 
1.10 1.03 1.17 0.006 
Disorders of fluid and electrolytes 0.93 0.90 0.97 0.001 
HIV 1.66 1.16 2.37 0.006 
Other endocrine/metabolic/nutritional 
disorders 
1.17 1.13 1.21 <0.0001 
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Table 6.3. Continued 





Inflammatory bowel disease 1.35 1.04 1.75 0.02 
Bone, joint, or muscle infection/ 
necrosis 
0.90 0.85 0.95 <0.0001 
RA or inflammatory CTD 1.48 1.35 1.61 <0.0001 
Spinal disorder 0.88 0.81 0.97 0.01 
Organ transplant status 1.19 1.14 1.25 <0.0001 
Incontinence, UTI and other urinary 
tract disorders 
1.16 1.12 1.21 <0.0001 
Chronic ulcers 1.17 1.13 1.22 <0.0001 
Artificial openings for feeding or 
elimination 
1.28 1.13 1.44 <0.0001 
 
 
CABG, coronary artery bypass graft; CL, confidence limit; CTD, connective tissue disorder; 
HIV, human immunodeficiency virus; PCI, percutaneous coronary intervention; RA, 




6.3.4.  Propensity-matched comparisons of surgery and endovascular revascularisation 
outcomes 
A defined comparison was made between patients undergoing endovascular intervention (n = 
14,560) and surgical intervention (n = 14,560). When comparing the endovascular group to 
open surgery there were similar rates of MALE (HR 1.02, 95%  CI, 0.96 to 1.07, p=0.58), 
major bleeding (HR 0.99, 95% CI, 0.92 to 1.07, p=0.84) and all-cause acute rehospitalisations 
(HR 1.00, 95% CI 0.97 to 1.03, p=0.77) (see Table 6.4). The endovascular group had a higher 
rate of all-cause mortality (HR 1.14, 95% CI 1.10 to 1.19, p<0.001), a composite of MALE or 
all-cause mortality (HR 1.12, 95% CI, 1.07 to 1.16, p<0.001), and a composite of other limb 
events (HR 1.12, 95 % CI, 1.09 to 1.15, p<0.001). Figure 6.2 and Figure 6.3 are Kaplan-Meier 
curves for the first occurrence of MALE, and the composite of MALE and mortality, according 
to revascularisation strategy. These curves illustrate the similarities in the rates of MALE and 
the lower likelihood of MALE or mortality for the surgery group. 
Of the MALE subcategories, endovascular patients were less likely to require urgent 
surgical reintervention (HR 0.70, 95% CI, 0.63 to 0.78, p<0.001), or experience arterial 
embolus/ thrombus (HR 0.83, 95% CI, 0.76 to 0.91, p<0.001), but at the expense of higher 
urgent endovascular reintervention (HR 1.18, 95 % CI, 1.09 to 1.28, p<0.001). Examining other 
limb events that were not categorised as MALE, the endovascular patients had a higher elective 
endovascular intervention (HR 1.49, 95% CI, 1.42 to 1.56, p<0.001), and minor amputation 
(HR 1.35, 95% CI, 1.24 to 1.47, p<0.001), but fewer elective surgical reintervention (HR 0.65, 





Table 6.4: Major adverse events in propensity-matched groups  
Outcomes Overall cohort 
(N = 29,120) 
Surgical 
(N = 14,560) 
Endovascular 
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0.58 
Secondary endpoints  
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0.77 
MALE subcategories  
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(0.60 – 0.69) 
<0.001 









(1.42 – 1.56) 
<0.001 







(1.24 – 1.47) 
<0.001 
-PAD-related 
readmission not meeting 












Hazard ratio expressed with surgical intervention as the reference group. 
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This study evaluated the long-term outcomes of lower extremity revascularisation in an 
Australia and New Zealand population. After propensity-matching, the patients undergoing 
endovascular repair had a 14% higher likelihood of all-cause mortality, 12% higher MALE or 
all-cause mortality, 35% higher minor amputation, and 49% greater elective endovascular 
reintervention, compared to surgery. These were some enduring advantages for open surgery, 
which has become less favoured as it is more invasive. There were no significant differences 
in MALE, major bleeding, or all-cause acute rehospitalisation. The overall rates of MALE were 
15.8%, all-cause mortality was 29.1%, and the composite of MALE or all-cause mortality was 
38.7% during an extended follow-up period, suggesting new strategies are required. There were 
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several associations between medical comorbidities and MALE or mortality, indicating the 
complex multidisciplinary needs of these PAD patients. 
Few randomised studies have compared endovascular and surgical revascularisation 
outcomes. The BASIL trial featured 452 patients presenting with CLI randomised to initial 
bypass surgery or balloon angioplasty. No significant differences in amputation-free survival 
were apparent during the first two years, although beyond that time, open surgery was 
associated with higher amputation-free survival [235, 238]. Our findings were consistent with 
the BASIL trial’s long-term outcomes, as here the matched surgery patients were at lower long-
term risk of mortality, as well as major and minor amputation. The BASIL trial had caveats 
that would limit generalisability to current practice. The study investigated a modest number 
of patients and only CLI presentations. Participant recruitment began twenty years ago, in an 
era before modern endovascular techniques, such as stenting. A high proportion (25%) of 
surgical patients received a prosthetic graft, which is less durable than the saphenous vein graft 
[19, 232]. In our cohort, encounters from 2008 onwards were chosen to reflect current vascular 
practice, thus incorporating more advanced endovascular interventions and progress in surgical 
planning. The endovascular approach was preferred, as evidenced by an approximate 4:1 ratio 
of endovascular to surgery cases in the unmatched groups, consistent with other recent 
observational studies [239, 240]. It can also be argued that the results of earlier studies have 
become less applicable, with the evolution of medical therapy, public health messages 
regarding smoking, clinical guidelines, and the familiarity that specialists have with newer 
procedures [10, 28, 87, 241]. These trends necessitate a comparative analysis in a more 
contemporary setting than with the BASIL study. 
Our findings expand insights into PAD beyond the United States and other well-
researched populations. The outcomes of lower extremity revascularisation are operator 
dependent and can differ across specialists [28, 242]. In Australia and New Zealand, vascular 
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surgeons and interventional radiologists primarily perform these procedures. The rates of 
MALE and mortality varied significantly between regions, which again, shows the value in 
studying multiple geographies. Also, PAD revascularisation performed in the private hospital 
setting appeared to have more favourable outcomes, compared to public hospitals. These 
findings could relate to differences in patient selection, operator experience, medical treatment 
and follow-up. Postprocedural surveillance is a potential driver of reintervention, and this 
might differ across healthcare systems. The current consensus is that patients should undergo 
serial imaging to evaluate vessel patency after lower extremity revascularisation [243]. The 
rationale for postprocedural surveillance is to detect arterial restenosis early, as this could be 
treated electively and with a less complicated procedure, than if this were to advance. The 
efficacy of these programs has not been demonstrated in a randomised clinical trial, and it is 
unclear how these influence the rates of MALE and other limb events [244]. 
Amputation-free survival is a common primary endpoint for studies of lower extremity 
revascularisation. We examined a broad MALE composite, which has been previously 
described [245]. Major amputation, acute limb ischaemia, and urgent reintervention are clinical 
endpoints that are likely indicative of an unsuccessful procedure. The introductory chapter 
highlighted the dangers of MALE and the importance of prevention. Modern clinical trials of 
medical therapies are increasingly incorporating MALE as an endpoint [31, 93, 246, 247]. With 
PAD being integrated with other areas of cardiovascular medicine, the examination of MALE 
consistently across the literature would be prudent. 
Endovascular revascularisation is often preferred in sicker patients considered high risk 
for open surgery [19]. In this study, the unmatched surgery group were younger, and more 
likely elective, compared with the endovascular group. They had less history of acute coronary 
syndrome, congestive heart failure, diabetes, and renal failure, however other cardiorespiratory 
comorbidities were overrepresented. A traditional school of thought is that open surgery 
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achieves superior long-term arterial patency than endovascular repair when performed in less 
complicated patients [232]. Of the limb outcomes assessed, elective endovascular 
reintervention was the most frequent occurrence, affecting 20% of surgery, and 30% of the 
endovascular unmatched groups. This finding supports the idea that surgery can achieve better 
long-term outcomes for some patients. Notwithstanding, the exceptionally high rates of 
mortality would need to be factored when adopting this more invasive approach.  
Most of the lower extremity revascularisations were performed in an elective and non-
CLI setting. This raises questions as to the clinical scope in deferring these procedures and 
adopting a conservative approach. In prior observational studies, conservative management of 
intermittent claudication has corresponded with a low likelihood of progression to MALE [25, 
26]. Supervised exercise therapy is the recommended initial treatment for stable symptomatic 
PAD [19]. The CLEVER study was a randomised controlled trial that demonstrated supervised 
exercise therapy to have comparable efficacy to stent revascularisation, in the setting of 
intermittent claudication due to aortoiliac disease. However, there are challenges with 
implementing a supervised exercise program, which would preclude most patients. In the 
CLEVER study, 999 patients were screened in order to find 119 eligible participants [44]. 
Some significant barriers to supervised exercise include a lack of availability, transport 
accessibility, and compliance. Many patients with intermittent claudication can have other 
comorbidities that impede training [147]. Peripheral artery revascularisation is sometimes the 
only possible option to resolve lifestyle-limiting claudication. In this setting, the long-term risk 
of mortality, MALE and other limb events need to be weighed against this potential benefit 
and discussed with the patient. 
Consistent with findings in chapter 4 and 5, male gender was independently associated 
with an 8% higher rate of MALE or mortality. In chapter 4, the meta-analysis showed that male 
gender was associated with a 13% adjusted increase in all-cause mortality. This divergence in 
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outcome was potentially more significant in advanced diseases, such as CLI or those treated 
with revascularisation. The secondary analysis implied that gender differences in mortality 
were at least partly attributable to cardiovascular-related events. However, this was at odds 
with coronary artery disease, where most observed gender differences in long-term mortality 
become attenuated when adjusting for age [178]. In ACCELERATE, male gender was 
significantly associated with higher adjusted mortality, but not major adverse cardiovascular 
events. These observations pointed to limb-related issues as an explanation. Prior 
epidemiological studies have found that there are more women with PAD than men in high-
income countries [2]. Our dataset drew from comprehensive hospital records across Australia 
and New Zealand, and significantly fewer females were treated than males, especially with 
open surgery. Therefore, the selection of patients for revascularisation appeared to differ, 
according to gender, and this could be benefitting women. To test this hypothesis, we would 
also need to evaluate the clinical outcomes of the men and women with PAD that were managed 
conservatively. Further research into revascularisation decisions, relating to gender, is required.  
Other predictors of MALE or mortality included older age, the presentation with CLI, 
a history of PAD or lower limb amputation, and medical comorbidities. Surprisingly, some 
cardiovascular history appeared to be protective, such as a prior percutaneous coronary 
intervention or coronary artery bypass graft operation. This thesis has described the robust 
relationship between PAD and coronary artery disease. The observations in this chapter could 
be revealing an advantage from completed coronary revascularisation, as it precedes a lower 
extremity intervention. A history of cerebrovascular disease also appeared to be beneficial. 
Patients with these other atherosclerotic conditions were potentially being treated more 
intensively with preventative treatments.  
Advanced cancer was associated with a more than 2-fold increased likelihood of MALE 
or mortality, although we did not delineate between these endpoints. Cancer is a prothrombotic 
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condition, but a connection with MALE has not been established [248]. The associations 
between several non-PAD comorbidities and MALE or mortality were substantial, indicating 
that there are likely to be multiple contributing mechanisms. These findings underscore the 
multidisciplinary needs of these patients, which continues well beyond revascularisation.  
Our study has some caveats worth noting. This was a retrospective evaluation of 
administrative data, which has the potential for coding and data entry inaccuracies. While 
propensity-score matching was performed, the possibility of unmeasured confounders cannot 
be excluded. Clinical information on lower limb disease related to anatomical and lesion 
characteristics, smoking, and medication use was unavailable. It is uncertain how these factors 
affected patient selection, where the endovascular approach was overwhelmingly preferred. 
Despite these limitations, there is evidence that broader details of demographics and medical 
comorbidities, can correlate with patterns of vascular disease [27, 249, 250]. This study 
compared revascularisation outcomes by focusing on MALE, mortality, and other less-severe 
adverse events. Some results, including quality of life, and walking impairment, were not 
captured. There are upcoming randomised clinical trials that will compare endovascular and 
surgical revascularisation by evaluating various clinical endpoints, and these will be less 
affected by confounding [121, 251]. Nevertheless, the strength of our data is in the 
heterogeneity of the study population, as this is likely to reflect current real-world practice 
better than clinical trials where participation is subject to recruitment and eligibility. 
 
6.5. Conclusions 
Endovascular lower extremity revascularisation was associated with a 14% higher likelihood 
of all-cause mortality, 49% greater urgent endovascular reintervention, and comparable rates 
of MALE to open surgery. The incidence of MALE or mortality for the overall cohort was very 
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high, which indicate the limitations of both strategies and the importance of ongoing 
multidisciplinary care. Personalised clinical decisions should dictate management, including 
consideration for conservative options. New procedures and medications are required to alter 
the clinical course of PAD in these advanced stages. 
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6.7. Supplemental material 
Table 6.5: Clinical characteristics of propensity-matched groups 
Baseline characteristics Overall Surgical Endovascular Standardised 
difference of 
the mean (%) 
/variance ratio 
N = 29,120 N = 14,560 N = 14,560 
N % N % N % 
Age (mean ± SD), y 71.0 ±11.8 71.0 ±11.5 71.0 ±12.2 1.11* 
18-54  2,736 9.4 1,231 8.5 1,505 10.3 
0.5 
55-64 5,392 18.5 2,720 18.7 2,672 18.4 
65-74 9,033 31.0 4,699 32.3 4,334 29.8 
75-84 8,628 29.6 4,384 30.1 4,244 29.2 
85+ 3,331 11.4 1,526 10.5 1,805 12.4 
Male 21,152 72.6 10,599 72.8 10,553 72.5 0.7 
Presenting characteristics 
Elective 22,287 76.5 11,385 78.2 10,902 74.9 8.0 
CLI 8,738 30.0 4,171 28.7 4,567 31.4 6.0 
Private hospital 8,189 28.1 4,368 30.0 3,821 26.2 7.9 
Presenting region 
-NSW/ACT 7,312 25.1 3,413 23.4 3,899 26.8 Reference 
-VIC 7,069 24.3 3,739 25.7 3,330 22.9 6.5 
-QLD 5,728 19.7 3,010 20.7 2,718 18.7 5.4 
-SA/NT 1,873 6.4 917 6.3 956 6.6 1.2 
-TAS 285 1.0 143 1.0 142 1.0 0.1 
-WA 1,513 5.20 824 5.66 689 4.7 3.2 
-NZ 5,340 18.3 2,514 17.27 2,826 19.4 6.2 
Vascular history 
Vascular disease  13,473 46.3 6,428 44.2 7,045 48.39 9.2 
Prior intervention  2,048 7.0 953 6.6 1,095 7.5 4.2 
Lower limb amputation  1,494 5.1 675 4.6 819 5.6 4.6 
Other cardiovascular history 
Acute coronary syndrome  1,478 5.1 680 4.7 798 5.5 3.7 
Ischemic heart disease 3,572 12.3 1,683 11.6 1,889 13.0 4.5 
Hypertension  10,312 35.4 4,921 33.8 5,391 37.0 6.9 
Congestive heart failure 2,313 8.0 1,079 7.4 1,234 8.5 4.0 
Valvular and rheumatic 
heart disease 
797 2.7 373 2.56 424 2.9 2.3 
Arrythmia or conduction 
system disorder  
2,351 8.1 1,126 7.7 1,225 8.4 2.5 
Stroke and cerebrovascular 
diseases  
1,035 3.6 482 3.3 553 3.8 2.8 
Coronary angiogram 2,211 7.6 1,030 7.1 1,181 8.1 4.1 
PCI 634 2.2 299 2.1 335 2.3 1.7 
CABG  455 1.6 207 1.4 248 1.7 2.5 
Other comorbidities 
Diabetes  8,415 28.9 4,000 27.5 4,415 30.3 6.3 
Major and metastatic 
cancer  545 1.9 262 1.8 283 1.9 1.1 
Other cancers and tumours  2,087 7.2 977 6.7 1,110 6.6 3.6 
Chronic lung disease 1,709 5.9 812 5.6 897 6.2 2.7 
Pneumonia  1,466 5.0 701 4.8 765 5.3 2.1 
Renal failure  2,666 9.2 1,252 8.6 1,414 9.7 3.8 
Anemias and blood disease  5,408 18.6 2,534 17.4 2,874 19.7 6.6 
Chronic liver disease 147 0.5 72 0.5 75 0.5 0.3 
Dementia  610 2.1 293 2.0 317 2.2 1.1 
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Psychiatric disorders  936 3.2 423 2.9 513 3.5 3.8 
Paralysis and functional 
disorders 2,067 7.1 957 6.6 1,110 7.6 4.2 
Malnutrition  1,294 4.4 604 4.2 690 4.7 3.0 
HIV/AIDS 36 0.1 19 0.1 17 0.1 0.4 
Other significant endocrine 
and metabolic disorder  748 2.6 347 2.4 401 2.8 2.5 
Disorder of fluid and 
electrolytes  2,236 7.7 1,061 7.3 1,175 8.1 2.9 
Other endocrine/metabolic 
disorder  4,383 15.1 2,054 14.1 2,329 16.0 5.7 
Inflammatory bowel 
disease  61 0.2 24 0.2 37 0.3 2.2 
Bone/ joint muscle 
infection/ necrosis  932 3.2 427 2.9 505 3.5 3.0 
Rheumatoid arthritis and 
inflammatory connective 
tissue disease  294 1.0 133 0.9 161 1.1 
1.9 
Disorder of the vertebrae 
and spinal disc  367 1.3 176 1.2 191 1.3 0.9 
Osteoarthritis of hip or 
knee  313 1.1 147 1.0 166 1.1 1.2 
Parkinson and 
Huntington’s disease  70 0.2 34 0.2 36 0.3 0.3 
Seizure and convulsion  134 0.5 64 0.4 70 0.5 0.6 
Artificial openings for 
feeding for elimination  207 0.7 95 0.7 112 0.8 1.5 
 
CABG, coronary artery bypass grafting; CLI, critical limb ischaemia; CTD, connective tissue 




















CHAPTER 7: HDL-MEDIATED CHOLESTEROL EFFLUX CAPACITY AND PAD 





Background: There is a high prevalence of low high-density lipoprotein (HDL) cholesterol 
and cardiovascular disease in Indigenous Australians. A previous study found qualitative 
abnormalities of HDL in this population when they were compared with other non-Indigenous 
Australians. While dysfunctional HDL is an emerging risk factor for major adverse 
cardiovascular events (MACE), whether this translates to peripheral artery disease (PAD) has 
not been elucidated. 
Methods: Heart of the Heart (HotH) was a cross-sectional study of Indigenous populations in 
Central Australia. A total of 185 participants underwent an extensive clinical assessment, 
which included an ankle-brachial index (ABI) and a blood test. An ABI ≤0.9 or >1.40 was 
abnormal, and 0.9 <ABI <1.0 was considered borderline. Comparisons were made between 
normal and abnormal ABI because this clearly distinguished between PAD-affected people. 
Lipid studies [total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C, and triglyceride], apolipoprotein A-I (apoA-I), apolipoprotein 
B (apoB) and HDL-mediated cholesterol efflux capacity (HDL CEC) [total HDL, ATP-binding 
cassette transporter A1 (ABCA1), and non-ATP-binding cassette transporter A1 (non-
ABCA1)] were measured. The demographics, comorbidities, risk factor control, medication 
use and laboratory parameters of people with normal and abnormal ABI were compared.  
Results: Of 185 participants, 107 had a normal ABI, 51 had an abnormal ABI, and 27 had 
borderline ABI. People with abnormal ABI were more likely to have metabolic syndrome (47% 
vs 31%, p=0.047), but were less likely to smoke (26% vs 42%, p=0.04), compared to those 
with normal ABI. Otherwise, both groups had comparable demographics, body mass index, 
medical comorbidities, and medication use. The lipid profile, including HDL-C levels, and 
apoA-I did not differ. Despite these similarities, the people with abnormal ABI had a lower 
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median total HDL CEC (30.6% [27.3, 34.2] and 31.1% [29.5, 34.2], p=0.02). There was a 
significantly lower adjusted total HDL CEC (adjusted difference -1.40%, 95% CI, -2.46 to -
0.24, p=0.02) and ABCA-1 CEC (adjusted difference -1.20%, 95% CI, -2.11 to -0.19, p=0.02), 
when comparing abnormal with normal ABI. The difference in non-ABCA1 CEC was not 
statistically significant (adjusted difference -0.20%, 95% CI, -0.41 to 0.00, p=0.06).  
Conclusions: HotH participants with early evidence of PAD demonstrated lower HDL CEC. 
These qualitative differences in HDL were observed, despite no difference in HDL-C levels. 
This has potential mechanistic implications underscoring a role for dysfunctional HDL in the 
pathogenesis of PAD. Further research is needed to determine whether this association has any 






There is a far higher incidence of cardiovascular disease in Indigenous Australians when 
compared with other Australians [252]. Major adverse cardiovascular events (MACE) account 
for approximately one-third of an almost 20-year gap in life expectancy that has been reported 
[253]. These health disparities are not well understood or easily explained by differences in the 
prevalence of conventional risk factors, such as hypertension, dyslipidaemia, or obesity [145].  
Peripheral artery disease (PAD) is increasingly recognised as a high-risk condition with 
a clinical course that differs from other manifestations of atherosclerotic cardiovascular disease 
[93]. The presence of PAD is associated with disproportionately high event rates compared 
with other vascular groups [223], and this has become a focal point for studies of new medical 
therapies [147].  
Low high-density lipoprotein cholesterol (HDL-C) levels have an established 
association with the development of symptomatic PAD [15, 124, 125]. A high prevalence of 
low HDL-C has also been observed in Indigenous populations [254, 255]. Despite a compelling 
link between low HDL-C and cardiovascular disease [256], medical therapies that increase 
HDL-C levels have not been demonstrated to improve clinical outcomes [257]. Attention has 
shifted to measures of HDL function, including HDL-mediated cholesterol efflux capacity 
(HDL CEC), among other functions [257, 258]. In one observational study, HDL CEC was an 
independent predictor of MACE, whereas HDL-C levels corresponded with other conventional 
risk factors. People with the highest quartile HDL CEC had a 67% lesser incidence of MACE, 
compared with those in the lowest quartile [259]. While dysfunctional HDL is an emerging 
risk factor for MACE, whether this translates to PAD has not been elucidated. 
Heart of the Heart (HotH) was a cross-sectional study of Indigenous populations in 
Central Australia. Participants underwent extensive clinical assessment, which included an 
182 
 
ankle-brachial index (ABI) and a blood test for many laboratory parameters. It was previously 
shown that HDL CEC was reduced in Indigenous Australians from HotH when they were 
compared with a matched group of other Australians [260]. Here we compared the Indigenous 
Australians with early evidence of PAD to those without, to see whether there were qualitative 
differences in HDL. 
 
7.2. Methods 
7.2.1.  Study design 
HotH was a cross-sectional study of Indigenous populations within Central Australia, which 
was conducted between May 2008 and November 2009. The study design and data collection 
have been previously published [261, 262]. Participants were eligible if they were aged ³18 
years; self-reported as Indigenous residents of Central Australia; and were able to provide 
informed consent. In total, 436 volunteers underwent comprehensive clinical assessment, 
inclusive of 185 participants who had a screening ankle-brachial index and frozen blood 
samples. This study complied with the Declaration of Helsinki and was approved by the Central 
Australian Human Research Ethics Committee and the Monash University Standing 
Committee on Ethics in Research Involving Humans.  
 
7.2.2.  Data collection 
Participants underwent a structured interview. The details obtained included age; residence; 
socioeconomic status – income, education, employment; smoking status; alcohol intake; past 
medical history and current medications. Self-reported medical history was later corroborated 
with medical records. The participants underwent measurements of blood pressure, height, 
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weight, abdominal and hip circumference. Blood pressure was taken after the participant had 
been seated for 5 minutes. Participants completed a Rose angina questionnaire [263] and 
underwent electrocardiography (ECG). Non-fasting venous blood was taken, and 
plasma/serum was stored at -80°C after centrifugation until required. Laboratory tests included 
lipid studies, glycosylated haemoglobin (HbA1c), renal, thyroid and liver function, full blood 
count, high-sensitivity C-reactive protein (hs-CRP), asymmetric dimethylarginine (ADMA), 
and B-type natriuretic peptide (BNP). The total cholesterol, low-density lipoprotein cholesterol 
(LDL-C), HDL-C, triglycerides, apolipoprotein A-I (apoA-I), and apolipoprotein B (apoB) 
were analysed using a COBAS Integra 400 analyser (Roche Diagnostics, Basel, Switzerland). 
A spot urine sample was tested for urine albumin-creatinine ratio (ACR). 
 
7.2.3.  Study aims 
This analysis aimed to (1) compare demographics, clinical characteristics, and laboratory 
parameters of people with normal ABI and abnormal ABI, and (2) evaluate for differences 
HDL-mediated cholesterol efflux capacity, independent of other measured variables. 
 
7.2.4.  Definitions of comorbidities 
At-risk alcohol drinking was the consumption of more than two standard drinks per day [264]. 
Hypertension was defined by a measurement of systolic blood pressure (BP) >140 mmHg or 
diastolic BP >90 mmHg. Abnormal non-fasting lipid levels were characterised by a: total 
cholesterol ≥5.5 mmol/L, LDL-C ≥3.5 mmol/L, HDL-C <1.0 mmol/L for male and <1.3 
mmol/L for female, and triglycerides  ≥2.0 mmol/L. An HbA1c ≥6.5% was consistent with a 
diagnosis of diabetes mellitus. Obesity was recognised as a body mass index (BMI) ³ 30 kg/m2, 
or waist circumference >102 cm in males and >88cm in females. Metabolic syndrome was 
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defined based on the World Health Organisation criteria after adjusting TG levels for non-
fasting status [265]. Chronic kidney disease (CKD) was defined as estimated glomerular 
filtration rate (eGFR) <60 mL/min/1.73 m2 and/or urine ACR >2.5 mg/mmol for men and >3.5 
mg/mmol for women or a documented history of CKD [266]. Pre-existing coronary artery 
disease was definitive angina on the Rose angina questionnaire, prior acute coronary syndrome, 
positive coronary angiography, or evidence of Q-waves on ECG (reviewed by two independent 
investigators). Pre-existing cardiovascular disease was the presence of rheumatic heart disease, 
non-rheumatic valvular disease, atrial fibrillation, heart failure, coronary artery disease (as 
defined above), peripheral artery disease or cerebrovascular disease. 
 
7.2.5.  Measurement of the ankle-brachial index 
Certified technicians measured ankle and brachial systolic blood pressures with a handheld 
Doppler device. The ankle-brachial pressure index was calculated by dividing blood pressure 
in the ankle by the highest of two blood pressure readings in the arms. The index was recorded 
for each participant on both arms and the left leg. Assessments were performed using a portable 
Hadeco Bidirectional Smartdop 20 doppler ultrasound machine (Hayashi Denki Co., 
Kawasaki, Japan). An ABI ≤0.9 or >1.40 was abnormal, and 0.9 <ABI <1.0 was considered 
borderline [19]. 
 
7.2.6.  Measurement of HDL-mediated cholesterol efflux capacity 
Total HDL, ATP-binding cassette transporter A1 (ABCA1), and non-ABCA1-mediated CEC 
were measured using apolipoprotein B (apoB)-depleted serum samples. ApoB-containing 
lipoproteins were depleted with polyethylene glycol (Sigma, St. Louis, MO, USA) as has been 
previously described [267]. After labelling with BODIPY-cholesterol (Avanti Polar Lipids, 
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Alabaster, AL, USA) and upregulating ABCA1 expression by cAMP treatment, RAW 264.7 
macrophages were incubated with 1.4% apo B-depleted serum for 4h [268, 269]. The 
fluorescence intensity (FI) of the cell media and cell lysates was measured at Ex/Em 485/535 
nm using a Perkin Elmer Victor 3 plate reader (Perkin-Elmer, Wellesley, MA, USA). HDL- 
mediated CEC was determined as follows:  
CEC (%) =              Media FI at 4h             X 100 
      Media FI at 4h + Cell Lysate FI at 4h 
Total HDL/non-ABCA1-mediated CEC was defined as the CEC in cAMP treated/non-treated 
cells. In contrast, ABCA1-mediated CEC was calculated as the difference between the per cent 
efflux in cAMP treated cells and that of cAMP non-treated cells. All assays were performed in 
duplicate. 
 
7.2.7.  Statistical analysis 
Data were analysed for normal distribution using the Shapiro-Wilk test. Continuous parameters 
were expressed as median (interquartile range: IQR) and compared using unpaired t-test or 
Mann-Whitney U test if not normally distributed. Categorical variables were expressed as 
numbers and percentages and compared using the Chi-square test. Differences between ABI 
groups for continuous parameters were tested using the one-way analysis of variance 
(ANOVA) test. Significant differences between ABI groups were included for the adjustment 
by using analysis of covariance (ANCOVA), in order to compare HDL CEC. Multivariate 
linear regression analyses were performed to test the association between ABI and HDL CEC. 
This included demographics, medical history, medications, socioeconomic status, risk factor 
control, lipid parameters, and other laboratory parameters. Multicollinearity among variables 
was checked before a variable was included in the final model. A two-sided p value of less than 
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0.05 was considered significant. All statistical analyses were conducted using Stata 14.2 
version (StataCorp, College Station, TX, USA). 
 
7.3. Results 
7.3.1.  Participant characteristics according to ankle-brachial index 
Of 185 participants, there was 107 (58%) normal, 51 (28%) abnormal ABI, and 27 (15%) 
borderline ABI. The characteristics of people with normal ABI and abnormal ABI are 
summarised in Table 7.1. People with abnormal ABI were more likely to have metabolic 
syndrome (47% vs 31%, p=0.047), but were less likely to currently smoke (26% vs 42%, 
p=0.04), compared to those with normal ABI. Otherwise, both groups had comparable 
demographics, BMI, pre-existing medical comorbidities, and use of medications. 
 
7.3.2.  Laboratory parameters according to ankle-brachial index 
The laboratory parameters of people with normal and abnormal ABI are outlined in Table 7.2. 
The total cholesterol, LDL-C, apoA-I, HDL-C levels did not differ between normal and 
abnormal ABI groups. There were significant differences in the median total HDL-mediated 
CEC (31.1% [29.5, 34.2] and 30.6% [27.3, 32.7], p=0.02), ABCA1-mediated CEC (22.1% 
[20.7, 24.8] and 21.6% [18.6, 23.4], p=0.02), and non-ABCA1-mediated CEC (9.1% [8.7, 9.5] 
and 8.8% [8.4, 9.4], p=0.04), for normal and abnormal ABI, respectively. ADMA was 
significantly lower in normal ABI, compared with abnormal ABI (0.53 [0.47, 0.60] µmol/L 
and 0.57 [0.50, 0.64] µmol/L, p=0.04). Other non-lipid laboratory parameters, including hs-
CRP, HbA1c, and eGFR, were comparable between groups.  
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Table 7.1: Participant characteristics and comorbidities according to ABI 
Characteristic  Normal ABI 




Age, median (IQR) 46.0 (33.0, 54.0) 46.0 (30.0, 51.0) 0.43 
Male, N (%) 46 (43.0) 21 (41.2) 0.83 
BMI, kg/m2 (IQR) 28.0 (25.5, 31.0) 28.8 (25.8, 33.7) 0.09 
Obesity, N (%) 60 (56.1) 33 (64.7) 0.30 
SBP, mmHg (median, IQR) 126.0 (116.0, 141.0) 132.0 (119.0, 142.5) 0.17 
DBP, mmHg (median, IQR) 80.0 (73.5, 88.5) 83.5 (72.5, 88.5) 0.79 
    
History, N (%)    
  Hypertension 56 (52.3) 30 (58.8) 0.44 
  Diabetes 36 (33.6) 25 (49.0) 0.06 
  Dyslipidaemia 98 (91.6) 49 (96.1) 0.30 
  CKD 42 (39.3) 20 (39.2) 1.00 
  Metabolic syndrome 33 (30.8) 24 (47.1) 0.04 
  Current smoker 45 (42.1) 13 (25.5) 0.04 
  At-risk alcohol drinking 54 (50.5) 25 (49.0) 0.86 
  Depression 20 (18.7) 5 (10.0) 0.17 
  Pre-existing CAD 11 (10.3) 6 (11.8) 0.78 
  Pre-existing CVD 22 (20.6) 8 (15.7) 0.47 
    
Medications, N (%)    
  Antihypertensive 30 (28.0) 16 (31.4) 0.67 
  Lipid-lowering 30 (28.0) 15 (29.4) 0.86 
  Diabetes 21 (19.6) 14 (27.5) 0.27 
  Insulin 22 (20.6) 15 (29.4) 0.22 
  Antidepressant 6 (5.6) 4 (7.8) 0.59 
    
Education status    
 Education Attainment 8 (7.8) 2 (4.0) 0.61 
  Non-Advanced education 36 (35.0) 20 (40.0) 
  Advanced education 59 (57.3) 28 (56.0) 
    
Employment status    
  Unemployed 64 (62.7) 25 (50.0) 0.07 
  Part-time/ Casual 17 (16.7) 6 (12.0) 
  Full time 21 (20.6) 19 (38.0) 
    
Income (fortnightly)    
  $AU 0-199 8 (7.8) 4 (8.0) 0.19 
  $AU 200-399 42 (41.2) 21 (42.0) 
  $AU 400-599 24 (23.5) 5 (10.0) 
  $AU 600-799 8 (7.8) 10 (20.0) 
  $AU 800-999 5 (4.9) 2 (4.0) 
  $AU >1000 15 (14.7) 8 (16.0) 
 
Age, BMI, SBP and DBP expressed as median and interquartile range (IQR). ABI, ankle-
brachial index; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney 




Table 7.2: Laboratory parameters according to ABI 





Lipid Parameters (median)    
  Total cholesterol, mmol/L 4.60 (3.96, 5.51) 4.65 (3.70, 5.54) 0.85 
  LDL-C, mmol/L 2.62 (2.11, 3.51) 2.73 (1.94, 3.85) 0.60 
  HDL-C, mmol/L 0.92 (0.69, 1.11) 0.92 (0.77, 1.12) 0.87 
  TG, mmol/L 2.01 (1.38, 2.89) 1.85 (1.25, 2.77) 0.53 
  ApoA-I, mmol/L 1.31 (1.10, 1.55) 1.39 (1.18, 1.56) 0.34 
  ApoB, mmol/L 0.77 (0.63, 0.95) 0.75 (0.62, 1.02) 0.94 
  HDL-C/ApoA-I ratio 0.69 (0.61, 0.78) 0.67 (0.61, 0.79) 0.57 
    
  Total HDL CEC 31.1 (29.5, 34.2) 30.6 (27.3, 32.7) 0.02 
  ABCA1 CEC 22.1 (20.7, 24.8) 21.6 (18.6, 23.4) 0.02 
  Non-ABCA1 CEC 9.1 (8.7, 9.5) 8.8 (8.4, 9.4) 0.04 
    
Other Parameters (median)    
  Hs-CRP, mg/L 4.40 (2.00, 8.00) 3.40 (2.00, 8.20) 0.72 
  HbA1c, % 6.10 (5.70, 6.60) 6.35 (5.90, 8.10) 0.10 
  Urine ACR, mg/mmol 1.45 (0.60, 5.70) 1.90 (0.70, 12.60) 0.23 
  eGFR, mL/min/1.73m2 101.00 (86.80, 116.20) 97.30 (83.10, 110.70) 0.18 
  ADMA, µmol/L 0.53 (0.47, 0.60) 0.57 (0.50, 0.64) 0.04 
  BNP, pg/mL 7.60 (5.00, 15.60) 6.45 (5.00, 22.30) 0.99 
 
Values expressed as median and interquartile range (IQR). ABCA1 CEC, ATP-binding cassette 
transporter A1-mediated cholesterol efflux capacity; ACR, albumin-creatinine ratio; ADMA, 
asymmetric dimethylarginine; ApoA-I, apolipoprotein A-I, ApoB, apolipoprotein B; BNP, B-
type natriuretic peptide; eGFR, estimated glomerular filtration rate; HbA1c, glycated 
haemoglobin; HDL-C, high-density lipoprotein cholesterol; HDL CEC, high-density 
lipoprotein-mediated cholesterol efflux capacity; Hs-CRP, high sensitivity C-reactive protein; 




7.3.3.  HDL-mediated cholesterol efflux capacity according to ankle-brachial index 
Table 7.3 summarises the HDL-mediated CEC in people with normal and abnormal ABI. 
Adjusted analysis of HDL-mediated CEC was performed, which corrected for the group 
differences in metabolic syndrome, current smoker, and ADMA levels. When adjusting for 
these differences, there was a significantly lower total HDL-mediated CEC (adjusted 
difference, -1.40%, 95% CI, -2.46 to -0.24, p=0.02) and ABCA1-mediated CEC (adjusted 
difference, -1.20%, 95% CI, -2.11 to -0.19, p=0.02) in people with abnormal ABI, compared 
with normal ABI. The differences in non-ABCA1-mediated CEC were not statistically 
significant (adjusted difference, -0.20%, 95% CI, -0.41 to 0.00, p=0.06).  
 
Table 7.3: Comparison of HDL-mediated cholesterol efflux capacity between normal ABI 
and abnormal ABI group 
 Unadjusted Adjusted* 
Characteristic Normal ABI 
(N = 107) 
Abnormal ABI 
(N = 51) 





Total HDL CEC, % 31.1 (29.5, 34.2) 30.6 (27.3, 32.7) 0.02 -1.40 -2.46 -0.24 0.02 
ABCA1 CEC, % 22.1 (20.7, 24.8) 21.6 (18.6, 23.4) 0.02 -1.20 -2.11 -0.19 0.02 
Non-ABCA1 CEC, % 9.1 (8.7, 9.5) 8.8 (8.4, 9.4) 0.04 -0.20 -0.41 0.00 0.06 
 
* Differences between the groups: metabolic syndrome, current smoker, and ADMA levels 
were included for the adjustment using ANCOVA. †vs normal ABI group. Values are median 
(interquartile range). ABCA1 CEC = ATP-binding cassette transporter A1-mediated 
cholesterol efflux capacity, ANCOVA = analysis of covariance, non-ABCA1 CEC = non-ATP-
binding cassette transporter A1-mediated cholesterol efflux capacity, Total HDL CEC = total 





The HotH study sought to determine the prevalence of cardiovascular risk factors and evidence 
of manifest vascular disease in a well-phenotyped cohort of Indigenous Australians. This is 
particularly important given the documented premature cardiovascular risk that is reported in 
this population. We demonstrated that more than one-quarter of participants had an abnormal 
ABI, many of whom had an otherwise low prevalence of established cardiovascular risk 
factors. While many such risk factors did not associate with the presence of a low ABI, we did 
demonstrate that this group with early evidence of PAD demonstrated lower cholesterol efflux 
capacity. Prior studies have found HDL-C and apoA-I levels to correlate with cholesterol efflux 
capacity [270, 271]. Here, qualitative differences in HDL were observed, despite no difference 
in HDL-C or apoA-I levels. This has potential mechanistic implications underscoring a role for 
dysfunctional HDL in the pathogenesis of PAD. 
These findings extend reports of an association between lower cholesterol efflux 
capacity and cardiovascular risk to the setting of PAD. It remains to be determined whether 
this association reflects a mechanistic influence on the peripheral vasculature, has any 
prognostic significance or may be susceptible to therapeutic modification [272]. PAD has an 
accepted association with cardiovascular morbidity and mortality, for which new treatments 
are required [223]. LDL-C lowering through the use of statins and protein convertase 
subtilisin/kexin type 9 (PCSK9) inhibitors are effective in reducing MACE and major adverse 
limb events [86, 89, 93]. In the FOURIER study, a linear relationship was seen with LDL-C 
lowering through PCSK9 inhibition and the relative risk reduction in major adverse limb 
events, which continued even for LDL-C levels <10 mg/dL (0.26 mmol/L) [93]. With the 
combination of statins and PCSK9-inhibitors being potent LDL-C lowering agents, other 
approaches to lipid management are also being researched [135]. High cholesterol efflux 
capacity has been reported to associate with less mortality in patients six years following 
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myocardial infarction [129]. The infusion of reconstituted HDL mimetics in patients following 
myocardial infarction has been demonstrated to increase cholesterol efflux capacity [130], and 
the effects of this mimetic on cardiovascular events are now being investigated in a large 
clinical trial [131]. The proof-of-concept for treating PAD patients with reconstituted HDL 
mimetics was researched by an in vivo human study. A single infusion of HDL mimetic led to 
a visible reduction in the lipid and inflammatory composition of atherosclerosis, thereby 
appearing to stabilise the morphology of plaque in the peripheral artery [273]. Given these 
collective findings, a subgroup analysis of PAD in clinical trials of HDL mimetics would be of 
interest. 
The relationship between conventional risk factors and PAD is distinct from other 
atherosclerotic conditions [16]. Smoking appears to have a more substantial impact in PAD 
pathogenesis, whereas the effects of hypertension and elevated LDL-C, correlate less, than with 
coronary artery disease [1, 16, 17]. In an exploratory analysis of the Women’s Health Study, 
the lipid particle characteristics of 110 participants that developed symptomatic PAD during 
follow-up were compared with 27,778 unaffected women. Both groups had comparable total 
cholesterol and LDL-C levels. However, PAD-affected women had higher LDL and very-low-
density lipoprotein particle concentrations, raised triglyceride-rich lipoprotein levels, as well 
as lower HDL-C levels and HDL particle concentrations [15]. The constitution of their lipids 
was vastly different to patients with atherosclerosis of the coronary and cerebrovascular 
circulation, where apoB and LDL-C levels have a predominant role [15, 16]. Overall, the 
Women’s Health Study raised questions about the role of lipid abnormalities in the 
pathophysiology of PAD. We further these observations to a connection between lower 
cholesterol efflux capacity and early evidence of PAD.  
There are clinical differences between PAD and other manifestations of atherosclerotic 
cardiovascular disease, which have potential relevance to cholesterol efflux capacity. Walking 
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impairment is a prominent feature of PAD that can affect people even in the before the 
development of intermittent claudication [4, 5, 18]. In individuals without pre-existing 
cardiovascular disease, exercise has been related to increases in cholesterol efflux capacity 
[274]. One study of coronary artery disease patients that underwent exercise rehabilitation and 
lifestyle modification, there were observed increases in cholesterol efflux for those that 
accomplished the highest maximum workloads [270]. In PAD patients, there were no changes 
in HDL functionality seen after they performed a 24-week supervised exercise program. One 
hypothesis suggested by the authors of this study was that PAD limited exercise intensity to 
levels that could lead to appreciable improvements in HDL functionality [275]. The association 
between physical activity and cholesterol efflux could be significant in the PAD setting, 
although this has yet to be demonstrated. 
 Some limitations should be noted regarding this cross-sectional study. Although 
significant discrepancies in cholesterol efflux capacity were observed across patient groups, 
the absolute differences were relatively small. Multivariate logistic regression accounted for a 
wide range of clinical information; however, the potential for unmeasured confounders cannot 
be excluded. PAD was identified using an ABI. While this investigation has good sensitivity 
and specificity for PAD [276], more limb-specific details relating to signs and symptoms were 
not assessed. Only one lower limb was screened, thereby reducing sensitivity for overall 
disease detection. No conclusions can be drawn regarding the influence of cholesterol efflux 
capacity on peripheral vasculature without longitudinal data. The laboratory methods used to 
measure HDL function can differ, and currently, there is no consensus on what the gold 
standard should be [129, 267]. To better understand the relationship between cholesterol efflux 
capacity and PAD, cohort studies with limb-specific clinical information are needed. 
Nevertheless, the limitations of this study should be considered in light of the inherent 
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In the HotH study, there was a significant association between an abnormal ABI and reduced 
cholesterol efflux capacity. These qualitative differences in HDL were observed, despite no 
difference in HDL-C or apoA-I levels and many conventional cardiovascular risk factors. 
Previous studies have demonstrated an association between dysfunctional HDL and MACE, 
but this is the first to identify a link with PAD. Further research is needed to determine whether 
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CHAPTER 8: ANKLE-BRACHIAL INDEX SCREENING FOR INDIGENOUS 




Background: The early stages of peripheral artery disease (PAD) are frequently asymptomatic 
and under-diagnosed, which makes it difficult to approximate the actual prevalence in 
Australia. There are striking health disparities that affect young Indigenous people, and the 
estimation of cardiovascular risk is especially problematic. The usefulness of screening this 
population for early PAD with an ankle-brachial index (ABI) has not been evaluated. 
Methods: Heart of the Heart (HotH) was a cross-sectional study of Indigenous populations in 
Central Australia. A total of 185 participants underwent an extensive clinical assessment, 
which included an ABI and measurement of cardiovascular risk factors, inclusive of age, 
systolic blood pressure (BP), smoking status, total cholesterol, high-density lipoprotein 
cholesterol (HDL-C) and diabetes. The risk profile of people with normal ABI was compared 
to those with non-normal (borderline or abnormal) ABI. For those with non-normal ABI and 
no pre-existing cardiovascular disease, Framingham-based equations were applied to estimate 
the five-year risk of a major adverse event. These participants were classified as very low 
(<5%), low (5-9.9%), moderate (10-15%), and high risk (>15%). 
Results: Of 185 people, 58% had normal, 28% abnormal, and 15% borderline ABI. When 
comparing normal with non-normal ABI, both groups were of similar age, gender, history of 
hypertension, diabetes, and pre-existing coronary artery disease and cardiovascular disease. 
There was higher smoking in people with normal ABI. Otherwise, both groups had comparable 
risk factor control and the use of cardiovascular preventative therapies. When applying the 
National Vascular Disease Prevention Alliance algorithm to non-normal ABI, the proportion 




Conclusions: A considerable portion of Indigenous participants screened had evidence of 
PAD, and their cardiovascular risk was seemingly underestimated through conventional 
methods. These results raise the possibility that undiagnosed PAD is contributing to health 
disparities in Indigenous Australians. More extensive research is needed to confirm these 






The prevalence of PAD in Indigenous Australians and other Australians has not been well 
defined [252]. In other Western populations, approximately 3 to 10% of the non-Indigenous 
people are affected, and this increases to 20% of those above 70 years of age [7]. The 
difficulties arise in identifying early stages of PAD, which are frequently asymptomatic and 
under-diagnosed [4]. An ankle-brachial index (ABI) is a simple bedside test that has high 
sensitivity and specificity for PAD [19]. The introductory chapter described the natural history 
of patients found to have an abnormal or borderline ABI, compared to a normal ABI. Such 
evidence of PAD has significant implications regarding an individual’s future risk of major 
adverse cardiovascular events and mortality. A meta-analysis combined sixteen population 
studies and showed that an abnormal ABI (≤0.90 or >1.40) was connected with increased 
mortality independent to the Framingham risk equation [20]. Despite these associations, the 
use of ABI screening for PAD is not recommended in national guidelines [143, 144]. Problems 
with underestimating cardiovascular risk are especially relevant to the young Indigenous 
community [277]. There is a 10 to 20-fold increased mortality in young Indigenous Australians, 
compared with their non-Indigenous counterparts [145]. Cardiovascular disease accounts for 
approximately one-third of an almost 20-year gap in life expectancy that has been reported 
[253].  
In chapter 7, we demonstrated that more than one-quarter of Indigenous participants in 
the Heart of the Heart (HotH) study had an abnormal ABI, many of whom had an otherwise 
low prevalence of established cardiovascular risk factors. Here, the analysis is extended to all 
people with non-normal ABI (borderline or abnormal ABI). We applied accepted Framingham-
based equations to see whether a non-normal and abnormal ABI provided additional risk-
stratification. This chapter explores the potential implications of these findings concerning the 




8.2.1.  Study design and analysis 
Details of the study design, data collection and statistical analyses were described in chapter 7. 
In brief, HotH was a cross-sectional study conducted from May 2008 to November 2009, 
examining Indigenous populations within Central Australia. Participants were eligible if they 
were aged ³18 years; self-reported as Indigenous residents of Central Australia; and were able 
to provide informed consent. In total, 436 volunteers underwent comprehensive clinical 
assessment, inclusive of 185 participants who had a screening ABI and frozen blood samples. 
The participants were subject to an extensive clinical assessment with a structured interview 
and physical examination. Medical history and cardiovascular risk factors were confirmed by 
screening, as well as corroboration with medical documentation and medication history. 
 
8.2.2.  Study aims 
This analysis aimed to (1) compare demographics, clinical characteristics, and laboratory 
parameters of people with normal ABI and non-normal ABI, and (2) apply accepted 
cardiovascular risk algorithms to participants with abnormal and non-normal ABI. 
 
8.2.3.  Definition of comorbidities 
An ABI ≤0.9 or >1.40 was abnormal, and 0.9 <ABI < 1.0 was borderline. An ABI was 
considered non-normal if the result was abnormal or borderline. Hypertension was defined by 
a measurement of systolic blood pressure (BP) >140 mmHg or diastolic BP >90 mmHg. An 
HbA1c ≥6.5% was consistent with a diagnosis of diabetes mellitus. Pre-existing coronary 
artery disease was definitive angina on the Rose angina questionnaire, prior acute coronary 
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syndrome, positive coronary angiography, or evidence of Q-waves on ECG (reviewed by two 
independent investigators). Pre-existing cardiovascular disease was the presence of rheumatic 
heart disease, non-rheumatic valvular disease, atrial fibrillation, heart failure, coronary artery 
disease (as defined above), peripheral artery disease or cerebrovascular disease. 
 
8.2.4.  Risk calculation 
Framingham-based equations were applied to estimate the five-year risk of people with non-
normal or abnormal ABI that had no pre-existing cardiovascular disease. Two accepted 
equations were used. The National Vascular Disease Prevention Alliance (NVDPA) algorithm 
incorporates the following variables: gender, age (between 35 to 74), systolic blood pressure, 
smoking status, total cholesterol, HDL cholesterol, and diabetes [143]. In people with age 
outside the specified range, the closest qualifiable age was entered. An alternative Framingham 
equation [278] was applied, that utilised these same variables. This equation was validated for 
a cohort of 1,448 Indigenous Australians in Far North Queensland. Participants were classified 
as having a: very low (<5%), low (5-9.9%), moderate (10-15%), and high (>15%) five-year 
risk of an adverse cardiovascular event. 
 
8.3. Results 
8.3.1.  Characteristics of participants according to ABI 
Of 185 participants, there were 107 (58%) with normal and 78 with non-normal ABI. Non-
normal ABI comprised of 51 (28% of total) abnormal and 27 (15% of total) borderline 
measurements. The characteristics of the people with normal and non-normal ABI are 
summarised in Table 8.1. Both normal and non-normal ABI groups had comparable median 
age (46 and 44, p=0.45), proportion of females (57.0% and 65.4%, p=0.25), hypertension 
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(52.3% and 57.7%, p=0.47), diabetes (33.6% and 44.9%, p=0.12), pre-existing coronary artery 
disease (10.3% and 9.0%, p=0.77) and cardiovascular disease (20.6% and 17.9%, p=0.66), 
respectively. People with normal ABI were more likely to smoke than those with non-normal 
ABI (42.1% vs 25.6%, p=0.02). Otherwise, both groups had comparable risk factor control 
regarding systolic and diastolic blood pressure, low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, triglycerides, high sensitivity C-reactive protein, and glycated 
haemoglobin. There was a similar use of cardiovascular preventative therapies. 
 
8.3.2.  Absolute cardiovascular risk categories of people with abnormal ABI 
The estimated five-year risk of people with non-normal or abnormal ABI and no pre-existing 
cardiovascular disease is outlined in Table 8.2. When the NVDPA algorithm was applied to 
non-normal ABI, the proportion of people that were very low, low, moderate, and high-risk 
were 53%, 16%, 8%, and 23%, respectively. The alternative Framingham equation produced 
similar results, with the corresponding percentage of very low, low, moderate, and high-risk 
people as 50%, 14%, 13%, 23%. Applying the NVDPA algorithm to abnormal ABI, the 
proportion of people that were very low, low, moderate, and high-risk were 54%, 20%, 10%, 
and 22%, respectively. Using the alternative Framingham equation for abnormal ABI, the 





Table 8.1: Comparison of participants with normal and non-normal ABI 
Characteristic  Normal ABI 
(N = 107) 
Non-normal ABI 
(N = 78) 
p value 
Age, median (IQR) 46.0 (33.0, 54.0) 44.0 (30.0, 55.0) 0.45 
Male, N (%) 46 (43.0) 27 (34.6) 0.25 
BMI, kg/m2 (IQR) 28.0 (25.5, 31.0) 28.5 (25.5, 32.7) 0.35 
Obesity, N (%) 60 (56.1) 48 (61.5) 0.46 
SBP, mmHg 126.0 128.8 0.42 
DBP, mmHg 80.0 83.3 0.94 
    
History, N (%)    
  Hypertension 56 (52.3) 45 (57.7) 0.47 
  Diabetes 36 (33.6) 35 (44.9) 0.12 
  Dyslipidaemia 98 (91.6) 76 (97.4) 0.10 
  CKD 42 (39.3) 32 (41.0) 0.81 
  Metabolic syndrome 33 (30.8) 33 (42.3) 0.11 
  Current smoker 45 (42.1) 20 (25.6) 0.02 
  Pre-existing CAD 11 (10.3) 7 (9.0) 0.77 
  Pre-existing CVD 22 (20.6) 14 (17.9) 0.66 
    
Lipid Parameters (median)    
  Total cholesterol, mmol/L 4.60 4.78 0.82 
  LDL-C, mmol/L 2.62 2.75 0.59 
  HDL-C, mmol/L 0.92 0.92 0.71 
  Triglycerides, mmol/L 2.01 1.86 0.54 
    
Other Parameters (median)    
  Hs-CRP, mg/L 4.40 4.00 0.95 
  HbA1c, % 6.10 6.20 0.29 
  eGFR, mL/min/1.73m2 101.0 98.0 0.27 
    
Medications, N (%)    
  Antihypertensive 30 (28.0) 26 (33.3) 0.44 
  Lipid-lowering 30 (28.0) 25 (32.1) 0.56 
  Diabetes 21 (19.6) 21 (26.9) 0.24 
  Insulin 22 (20.6) 22 (28.2) 0.23 
 
ABI, ankle-brachial index; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney 
disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular 
filtration rate; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; hs-CRP, 
high sensitivity C-reactive protein; IQR, interquartile range; LDL-C, low-density lipoprotein 
cholesterol, SBP, systolic blood pressure.  
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Table 8.2: Estimated 5-year risk of people with non-normal or abnormal ABI and no pre-
existing cardiovascular disease 
 Non-normal ABI 
(N = 64) 
Abnormal ABI 
(N = 41) 
NVDPA algorithm*   
    Very low (<5% risk)  34 (53%) 22 (54%) 
    Low (5-9% risk) 10 (16%) 8 (20%) 
    Moderate (10-15% risk) 5 (8%) 4 (10%) 
    High (>15% risk) 15 (23%) 9 (22%) 
   
Framingham equation+   
    Very low (<5% risk)  32 (50%) 20 (49%) 
    Low (5-9% risk) 9 (14%) 6 (15%) 
    Moderate (10-15% risk) 8 (13%) 7 (17%) 
    High (>15% risk) 15 (23%) 10 (24%) 
 
* National Vascular Disease Prevention Alliance (NVDPA) algorithm [143] used to predict 5-year risk 
of cardiovascular disease. + Framingham equation calibrated for Indigenous Australians [278] used to 






Nearly half of HotH participants had a non-normal ABI, which is concerning given the young 
age and high proportion of females screened. This contrasts with conventional reports that PAD 
is more common in older subjects [10, 140]. The Framingham-based risk algorithms appeared 
to be inadequate in this study. These results suggest there is a high prevalence of undiagnosed 
PAD in young Indigenous Australians. ABI screening could be indicated for this population, 
although this is not currently recommended in the national guidelines [143, 144]. 
The usefulness of ABI screening is dependent on the likelihood of detecting 
asymptomatic disease, and the potential for treatment to change consequently. The prevalence 
of PAD in Australia has not been well characterised, although there are two other noteworthy 
studies in this space [217, 279]. The REACH Registry was an international observational study 
that examined people with established cardiovascular disease or a minimum of three risk 
factors. In a subset of 2,489 Australians that underwent PAD screening, 28% were found to 
have an abnormal ABI. These Australians were appreciably older than the HotH group (mean 
age of 73 and 44, respectively) [217]. The DRUID study tested for PAD and other 
complications of diabetes in 135 Indigenous people that resided in urban areas of Australia. In 
this setting, 12% of participants were diagnosed with PAD (ABI <0.90), and this was a 3-fold 
higher incidence compared with other Australians, after accounting for age and risk factors 
[279]. HotH differed from DRUID because, in addition to people with diabetes, it also featured 
non-diabetic and seemingly low-risk Indigenous Australians that lived in remote Central 
Australia. Also, while most PAD studies focus solely on a low ABI, in this analysis, an ABI 
>1.40 was classified as abnormal. An elevated ABI is suggestive of non-compressible lower 
extremity arteries [19] and strongly correlates with increased cardiovascular-related and all-
cause mortality [21, 140]. The HotH, REACH, and DRUID studies provide a snapshot of the 
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prevalence of PAD in different parts of Australia, but the problem needs to be better defined in 
larger populations [252]. 
PAD could be contributing to the lower life expectancy observed in Indigenous 
Australians. There were relatively fewer deaths and hospitalisations attributed to PAD for 
Indigenous Australians in 2007-2008, compared with other Australians [252]. However, the 
actual disease burden could be masked, as other causes of mortality might compete with PAD-
attributed events. One prospective study compared cardiovascular outcomes in Indigenous and 
non-Indigenous Australians after a clinic review for PAD. The Indigenous patients were 
younger but had a nearly five-fold increase (HR 4.72, 95% CI, 1.41 to 15.78, p=0.01) in major 
adverse cardiovascular events, compared with other Australians [280]. Of the HotH 
participants with a non-normal ABI, 82% had no history of cardiovascular disease. Both the 
NVDPA algorithm [143] and alternative Framingham equation [278] classified most of them 
as low risk. In chapter 1, we outlined the natural history of people that have an abnormal or 
borderline ABI, compared to those with normal ABI. Given the recognised association between 
PAD and major adverse cardiovascular events [20, 140], the risk model recommended in the 
national guidelines appear inaccurate. Here, the assertion is that non-normal ABI reclassifies 
people into a high-risk category, which warrants an intensive medical and lifestyle intervention 
[147]. 
ABI is a simple and non-invasive test with good sensitivity and specificity for detecting 
PAD [19]. The use of this test to diagnose asymptomatic PAD has not been endorsed in 
Australia [144, 252], whereas the American Heart Association recommends screening for 
specific populations and age groups [19]. People diagnosed with PAD can benefit from 
preventative treatments [19, 61, 147]. Nevertheless, the use of ABI to guide the prescription of 
therapies could lead to over-treatment in some cases where there is a false-positive screening 
for PAD.  
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This research complements some findings from Calabria et al. 2018 [277]. That study 
examined the absolute cardiovascular risk of 2,820 Indigenous Australians using the Australian 
NVDPA algorithm. In that analysis, 16% of participants aged 35 to 74 years of age were 
classified as a high primary five-year risk of a major adverse cardiovascular event. The author 
acknowledged that there is a deficiency in how younger Indigenous Australians are being risk-
stratified using these conventional models. One study examined the calibration and 
discrimination of the Framingham equation in 1,448 Indigenous people living in remote 
communities in Far North Queensland. The Framingham equation underestimated the five-year 
risk of cardiovascular disease by approximately one third [278]. The NVDPA algorithm does 
not apply to individuals below the age of 35, and therefore, it could miss people with premature 
atherosclerotic cardiovascular disease. Cardiovascular-related mortality affects Indigenous 
people of age 35 to 44 years by approximately 9 to 12 times more than non-Indigenous 
Australians [145, 281]. The national guidelines recommend a risk-stratified approach to 
hypertension and dyslipidaemia [143], and new strategies are imperative to identify and treat 
young Indigenous Australians. 
Several caveats should be noted regarding this retrospective and observational analysis. 
HotH was a community-based study with limited sample size. Therefore, it may not accurately 
reflect Indigenous populations living in urban and remote areas across Australia. Longitudinal 
data would be required to evaluate cardiovascular outcomes and to validate some clinical 
implications. An abnormal ABI differs from symptomatic PAD. Although PAD can be silent, 
an ABI should be interpreted with other clinical information, such as limb signs and symptoms, 
which were not documented. Some treatments for PAD, such as aspirin, do not have proven 
efficacy in the setting of asymptomatic disease [282]. ABI screening was performed on a 
random leg, thereby reducing sensitivity for the overall detection of PAD. Notwithstanding, 
206 
 
this study raises many questions that are relevant to the health disparities in Indigenous 
Australians, which are challenging to ascertain fully. 
 
8.5. Conclusions 
A considerable portion of Indigenous participants screened had evidence of PAD. Many 
conventional risk factors were not significantly associated with non-normal ABI. Framingham-
based risk algorithms appeared to underestimate the cardiovascular risk of these people. These 
results raise the possibility that undiagnosed PAD is contributing to health disparities in 
Indigenous Australians. If larger studies were to confirm these findings, the argument for 















CHAPTER 9: UTILITY OF CHADS2-BASED SCORES FOR PREDICTING 






Background: Prior studies have demonstrated a high incidence of major adverse 
cardiovascular events (MACE) in people with peripheral artery disease (PAD). The question 
remains whether all patients with PAD should be treated with the most intensive therapies, or 
if there is a role for a risk-stratified approach akin to atrial fibrillation management. 
Objectives: To evaluate several CHADS2-based scores (CHADS2, CHA2DS2-VASc, 
R2CHADS2) for predicting MACE in PAD following hospital presentations, compared with 
clinical manifestations of other vascular territories. 
Methods: Data were obtained from patient presentations to metropolitan Emergency 
Departments in South Australia, between June 2012 and July 2016. An analysis was performed 
on the period of observation following an acute presentation with PAD (n=2,371), coronary 
artery disease (CAD, n=25,253), and cerebrovascular accident (CVA, n=11,151), until a 
subsequent occurrence of MACE (composite of myocardial infarction, stroke, and mortality), 
or the end of the follow-up. CHADS2-based scores were calculated for these presentations, and 
discrimination of these risk prediction models was evaluated. 
Results: For presentations with a CHADS2 score of 0 and ³4, the incidence of subsequent 
MACE (per 100 person-years) increased from 27.1 to 120.1 for PAD, 14.2 to 73.4 for CVA, 
and 4.0 to 69.3 for CAD, respectively. The risk of MACE for every additional CHADS2 point 
was higher for CAD (hazard ratio [HR] 2.00, 95% CI, 1.95 to 2.05, p<0.01), compared with 
CVA (HR 1.53, 95% CI, 1.40 to 1.57, p<0.01) and PAD (HR 1.45, 95% CI, 1.38 to 1.53, 
p<0.01). When comparing the different models for PAD, there was higher hazard ratio for a 
unit change in the CHADS2 score (HR 1.45, 95% CI, 1.38 to 1.53, p<0.01), compared with 
CHA2DS2-VASc (HR 1.32, 95% CI, 1.27 to 1.38, p<0.01), and R2CHADS2 (HR 1.30, 95% CI, 
1.25 to 1.35, p<0.01). The C-statistic for the CHADS2 score predicting MACE was lower in 
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PAD, (C-statistic 0.53, 95% CI, 0.51 to 0.56, p=0.01), compared with CVA (C-statistic 0.59, 
95% CI, 0.58 to 0.60, p<0.01) and CAD (C-statistic 0.64, 95% CI, 0.63 to 0.65, p<0.01). The 
R2CHADS2 score was the best predictor of MACE in CAD (C-statistic 0.67, 95% CI, 0.66 to 
0.68, p<0.01). 
Conclusions: The incidence of subsequent MACE was markedly higher following a 
presentation with PAD, compared with CAD. The CHADS2 risk scores were more predictive 
of MACE in the CAD setting than for PAD. This highlights the exceptionally high clinical risk 





The prescription of any medical therapy requires an individualised consideration for the 
possible benefit and the risk of harm. For example, in atrial fibrillation (AF), oral 
anticoagulation significantly reduces the risk of ischemic stroke, while increasing the incidence 
of major bleeding [283]. The CHADS2 score (congestive heart failure, hypertension, diabetes 
mellitus, age ³75 years, prior stroke or transient ischemic attack) is a well-validated and 
straight-forward risk stratification tool used to guide anticoagulation in AF [284]. Newer scores 
have incorporated other risk factors, such as renal impairment (R2CHADS2) [285], and female 
sex, age 65-74, and history of vascular disease (CHA2DS2-VASc). Anticoagulation is 
recommended in AF patients that have a medium to high risk of stroke, as at this threshold, the 
net benefit largely outweighs the risk and harm of major bleeding [283]. The CHADS2 scores 
can also predict adverse outcomes in other cardiovascular conditions. In coronary artery disease 
(CAD), a higher CHADS2 score has been associated with more severe lesions [286], and an 
increased risk of major adverse cardiovascular events (MACE) [287, 288]. However, while 
these predictive models may discriminate between higher and lower-risk presentations, there 
is a point where the absolute number of events is too high for this to be clinically relevant [289].  
Peripheral artery disease (PAD) is increasingly recognised as a high-risk condition that 
is linked to MACE and mortality [10, 28, 147]. Many contemporary studies have investigated 
the efficacy of medical therapies in PAD [63, 107], with evidence of the potential for high 
modifiable risk reduction [93]. The implementation of more intensive antithrombotic, 
antihypertensives, anti-inflammatory, lipid-lowering, and glycemia-lowering medications all 
have a risk/reward trade-off [135, 147]. For instance, in the PAD subset of the COMPASS trial, 
combined rivaroxaban and aspirin was associated with a 31% relative risk reduction in MACE 
and 61% relative increase in major bleeding, in comparison with aspirin monotherapy. The 
benefit of combined rivaroxaban and aspirin was predominantly attributable to a 1% absolute 
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risk reduction in stroke (and in major adverse limb events), although this was comparable to 
the absolute increase in major bleeding [31, 63]. There is no consensus regarding the use of 
combined rivaroxaban and aspirin in PAD. Similarly, the incorporation of intensive targeting 
of blood pressure, lipid, glucose, and inflammation needs clarification [135, 147]. 
In people with AF, PAD is associated with a worse prognosis [290], and this would 
score an additional point when the CHA2DS2-VASc is applied [283]. The use of the CHADS2 
scores in PAD as a measure of vascular risk has not been determined. Hence, the question 
remains whether all patients with PAD should be treated with combined rivaroxaban and 
aspirin, and intensive blood pressure, lipid, glycemia, and inflammatory targets, or whether 
there is a role for a risk-stratified approach akin to AF management. There are more accurate 
predictors of mortality and MACE in acute coronary syndrome populations, such as the 
GRACE and TIMI scores [288, 291]. However, the CHADS2 score is well-known, easy to use, 
and widely applicable to heterogeneous patient groups. This study examined the predictive 
value of several CHADS2-based scores in PAD following hospital presentations and compared 
this with other atherosclerotic disease clinically manifest in other vascular territories.  
 
9.2. Methods 
9.2.1.  Data source and study populations 
The study population was drawn retrospectively from a state-wide clinical, administrative, and 
pathology reporting system assimilated dataset of all patient presentations to metropolitan 
Emergency Departments in South Australia, between June 2012 and July 2016. Each episode 
of care was linked to primary and secondary diagnostic codes based on the International 
Classification of Diseases, version 10, Australia Modified (ICD-10 AM). Patients aged ³18 
years with lower limb PAD (ICD-10 AM codes 170.20-170.24, 173.9, 174.3, 174.5), coronary 
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artery disease, and cerebrovascular accident as a primary diagnosis were included for analysis. 
The dataset comprised of patient demographics, diagnoses, medical comorbidities, renal 
function, troponin, and outcomes related to subsequent hospital presentations and mortality. 
The analysis was performed on the period of observation following an acute presentation with 
PAD (n = 2,371), coronary artery disease (n = 25,253), and cerebrovascular accident (n = 
11,151) until a subsequent representation with MACE or the end of the follow-up period. 
Presentations, where there was missing data during the initial encounter, were excluded from 
the study sample. The research proposal was approved by the Southern Adelaide Clinical 
Human Research Ethics Committee (EC00188). 
 
9.2.2.  Study aims 
The primary outcome of interest was hospital representation with MACE, defined as a 
composite of non-fatal myocardial infarction, non-fatal cerebrovascular accident, and 
cardiovascular-related mortality. The secondary outcome of interest was all-cause mortality. 
The period of observation was from the initial encounter until a representation with MACE, 
death, or the end of the follow-up period (July 2017). 
 This analysis aimed to (1) identify factors associated with MACE and mortality after 
different vascular presentations, and (2) evaluate the discrimination of CHADS2-based scores 
for MACE following different vascular presentations.  
 
9.2.3.  Calculation of scores 
The CHADS2 score was calculated by assigning 1 point for a history of heart failure, 
hypertension, age ³75 years, and diabetes mellitus; 2 points for a history of transient ischemic 
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attack or stroke. The R2CHADS2 score added 2 points for renal dysfunction (defined as an 
estimated glomerular filtration rate <60 mL/min/1.73 m2). The estimated glomerular filtration 
ratio was calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-
EPI) equation [292]. The CHA2DS2-VASc was calculated by adding 1 point for heart failure, 
hypertension, age 65-74, diabetes, and vascular disease history; 2 points for age ³75 years and 
history of transient ischemic attack or stroke. 
 
9.2.4.  Statistical analysis 
Cox proportional hazard regression models were used to identify the factors associated with 
the primary endpoint in the different vascular presentations. The associations were reported as 
hazard ratios (HR) with a 95% confidence interval, with p <0.05 considered as statistically 
significant. The Cox proportional hazard regression model was used to examine the relative 
increase in the hazard ratio of the primary outcome for each additional point of the CHADS2 
scores. The incidence rate per 100 patient-years of the primary outcome was calculated for 
different vascular presentations according to the CHADS2 score. The discriminatory ability of 
the CHADS2 scores was evaluated with the C-statistic, where a value of less than or equal to 
0.5 was considered ineffective and a value above 0.7, suggesting acceptable discrimination 
[293]. All analyses used STATA 15.1 (StataCorp, College Station, TX). 
 
9.3. Results 
9.3.1.  Factors associated with MACE 
The factors associated with MACE in all vascular presentations were age (years, hazard ratio 
[HR] 1.03, 95% CI 1.03 to 1.04, p<0.01), female sex (HR 1.06, 95% CI, 1.01 to 1.11, p=0.02), 
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CVA compared to CAD (HR 2.04, 95% CI, 1.94 to 2.15, p<0.01), PAD compared to CAD (HR 
3.05, 95% CI, 2.81 to 3.30, p<0.01), prior vascular disease of one territory (HR 1.69, 95% CI, 
1.59 to 1.79, p<0.01), two territories (HR 2.80, 95% CI 2.49 to 3.14, p<0.01) and three 
territories (HR 4.17, 95% CI, 2.47 to 7.07, p<0.01) (Table 9.1). 
For PAD presentations, cancer (HR 1.76, 95% CI, 1.10 to 2.82, p=0.02), hypertension 
(HR 1.75, 95% CI, 1.05 to 2.90, p=0.03), prior vascular disease in one territory (HR 3.11, 95% 
CI, 1.20 to 8.10, p=0.02), two territories (HR 7.72, 95% CI, 1.25 to 47.61, p=0.03), and three 
vascular territories (HR 13.94, 95% CI, 1.27 to 153.36, p=0.03), were predictive of MACE 
(Table 9.2). 
 
Table 9.1: Factors associated with MACE in all presentations 
Characteristic MACE 
 HR 95% CI 95% CI p value 
Age (years) 1.03 1.03 1.04 <0.01 
Gender (female) 1.06 1.01 1.11 0.02 
     
Vascular presentation     
    CAD presentation Ref.    
    CVA presentation 2.04 1.94 2.15 <0.01 
    PAD presentation 3.05 2.81 3.30 <0.01 
     
Renal impairment 0.99 0.99 0.99 <0.01 
     
Past history     
    1 vascular territory 1.69 1.59 1.79 <0.01 
    2 vascular territories 2.80 2.49 3.14 <0.01 
    3 vascular territories 4.17 2.47 7.07 <0.01 
 
95% CI, 95% confidence interval; CAD, coronary artery disease; CVA, cerebrovascular 




Table 9.2: Factors associated with MACE in PAD presentations 
Characteristic MACE 
 HR 95% CI 95% CI p value 
Age (years) 1.02 1.00 1.04 0.07 
Gender (female) 0.97 0.65 1.46 0.88 
     
Renal impairment 0.99 0.98 1.00 0.03 
Troponin rise 1.00 1.00 1.00 0.62 
     
Past history     
    1 vascular territory 3.11 1.20 8.10 0.02 
    2 vascular territories 7.72 1.25 47.61 0.03 
    3 vascular territories 13.94 1.27 153.36 0.03 
    Atrial fibrillation 1.00 0.60 1.67 0.99 
    Myocardial infarction 0.64 0.22 1.81 0.40 
    PAD 0.55 0.22 1.39 0.21 
    Chronic obstructive airways disease 0.70 0.15 3.31 0.65 
    Obesity 1.42 0.57 3.52 0.45 
    Cancer 1.76 1.10 2.82 0.02 
    Diabetes mellitus 1.29 0.78 2.13 0.33 
    Hypertension 1.75 1.05 2.90 0.03 
    Heart failure 1.18 0.75 1.85 0.47 
    Coronary artery bypass graft 0.75 0.35 1.61 0.47 
    Percutaneous coronary intervention 0.42 0.17 1.05 0.06 
 
9.3.2.  Factors associated with all-cause mortality 
The factors associated with all-cause mortality in all vascular presentations were age (years, 
HR 1.06, 95% CI 1.06 to 1.07, p<0.01), female sex (HR 1.13, 95% CI, 1.06 to 1.21, p<0.01), 
CVA compared to CAD (HR 3.07, 95% CI, 2.85 to 3.30, p<0.01), PAD compared to CAD (HR 
1.66, 95% CI, 1.42 to 1.94, p<0.01), prior vascular disease of one territory (HR 1.41, 95% CI, 
1.30 to 1.54, p<0.01), two territories (HR 2.13, 95% CI 1.77 to 2.56, p<0.01) and three 
territories (HR 3.04, 95% CI, 1.36 to 6.78, p=0.01) (Table 9.3). 
For PAD presentations, age (years, HR 1.03, 95% CI, 1.00 to 1.07, p=0.05), and cancer 
(HR 2.34, 95% CI, 1.21 to 4.52, p=0.01) were significantly predictive of all cause-mortality. 
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Renal impairment was marginally associated with less mortality (HR 0.98, 95% CI, 0.97 to 
0.99, p<0.01) (Table 9.4). 
 
Table 9.3: Factors associated with mortality in all presentations 
Characteristic Mortality 
 HR 95% CI 95% CI p value 
Age (years) 1.06 1.06 1.07 <0.01 
Gender (female) 1.13 1.06 1.21 <0.01 
     
Vascular group     
    CAD presentation Ref.    
    CVA presentation 3.07 2.85 3.30 <0.01 
    PAD presentation 1.66 1.42 1.94 <0.01 
     
Renal impairment 0.98 0.98 0.99 <0.01 
     
Past history     
    1 vascular territory 1.41 1.30 1.54 <0.01 
    2 vascular territories 2.13 1.77 2.56 <0.01 





Table 9.4: Factors associated with mortality in PAD presentations 
Characteristic Mortality 
 HR 95% CI 95% CI p value 
Age (years) 1.03 1.99 1.07 0.05 
Gender (female) 1.10 0.62 1.96 0.74 
     
Renal impairment 0.98 0.97 0.99 <0.01 
Troponin rise 1.00 1.00 1.00 0.90 
     
Past history     
    1 vascular territory 1.38 0.26 7.40 0.71 
    2 vascular territories 2.26 0.96 53.2 0.61 
    3 vascular territories 9.19 0.23 363.4 0.24 
    Atrial fibrillation 1.07 0.52 2.18 0.86 
    Myocardial infarction 1.73 0.31 9.74 0.53 
    PAD 1.10 0.22 5.51 0.91 
    Chronic obstructive airways disease 0.37 0.03 3.84 0.40 
    Obesity 2.09 0.48 9.08 0.33 
    Cancer 2.34 1.21 4.52 0.01 
    Diabetes mellitus 1.12 0.53 2.34 0.77 
    Hypertension 1.93 0.93 4.01 0.08 
    Heart failure 1.28 0.93 2.35 0.43 
    Coronary artery bypass graft 0.74 0.25 2.23 0.60 
    Percutaneous coronary intervention 0.30 0.07 1.25 0.10 
 
9.3.3.  Discrimination of MACE using CHADS2-based scores 
For presentations with a CHADS2 score of 0 and ³4, the incidence of subsequent MACE (per 
100 person-years) increased from 27.1 to 120.1 for PAD, 14.2 to 73.4 for CVA, and 4.0 to 69.3 
for CAD, respectively (Figure 9.1). 
Table 9.5 outlines the increase in the risk of MACE for each unit change in the 
CHADS2-based scores. The hazard ratio for every additional CHADS2 point was higher for 
CAD (HR 2.00, 95% CI, 1.95 to 2.05, p<0.01), compared with CVA (HR 1.53, 95% CI, 1.40 
to 1.57, p<0.01) and PAD (HR 1.45, 95% CI, 1.38 to 1.53, p<0.01). When comparing the 
different models for PAD, there was higher hazard ratio for a unit change in the CHADS2 score 
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(HR 1.45, 95% CI, 1.38 to 1.53, p<0.01), compared with CHA2DS2-VASc (HR 1.32, 95% CI, 
1.27 to 1.38, p<0.01), and R2CHADS2 (HR 1.30, 95% CI, 1.25 to 1.35, p<0.01). 
The C-statistic for the CHADS2 score predicting MACE was lower in PAD, (C-statistic 
0.53, 95% CI, 0.51 to 0.56, p=0.01), compared with CVA (C-statistic 0.59, 95% CI, 0.58 to 
0.60, p<0.01) and CAD (C-statistic 0.64, 95% CI, 0.63 to 0.65, p<0.01) (Table 9.6). All 
CHADS2-based models had weak discrimination in PAD and were lower than in CAD. The 
R2CHADS2 score was the best predictor of MACE in CAD (C-statistic 0.67, 95% CI, 0.66 to 
0.68, p<0.01). 
 
Figure 9.1: Incidence rates of MACE according to vascular presentation and CHADS2 
score 
 
MACE incidence rate 





CHADS2 score    
    0 27.1 14.2 4.0 
    1 54.0 33.4 13.0 
    2 or 3 88.8 55.0 26.8 




Table 9.5: Increased risk of MACE by unit change in CHADS2-based scores 
 PAD CVA CAD 
Score HR 95% CI p value HR 95% CI p value HR 95% CI p value 
CHADS2 1.45 1.38 – 1.53 <0.01 1.53 1.49 – 1.57 <0.01 2.00 1.95 – 2.05 <0.01 
CHA2DS2-VASc 1.32 1.27 – 1.38 <0.01 1.41 1.38 – 1.44 <0.01 1.60 1.57 – 1.63 <0.01 
R2CHADS2 1.30 1.25 – 1.35 <0.01 1.38 1.35 – 1.40 <0.01 1.69 1.66 – 1.72 <0.01 
 
 
Table 9.6: C-statistics of CHADS2-based scores in predicting MACE, according to 
vascular presentation 
 C-statistic 95% CI p value 
CHADS2 Score    
        PAD 0.533 0.510 – 0.557 0.01 
        CVA 0.593 0.582 – 0.604 <0.01 
        CAD 0.636 0.626 – 0.646 <0.01 
    
CHA2DS2-VASc Score    
        PAD 0.547 0.523 – 0.571 0.01 
        CVA 0.604 0.593 – 0.616 <0.01 
        CAD 0.627 0.616 – 0.637 <0.01 
    
R2CHADS2 Score    
        PAD 0.536 0.512 – 0.560 0.01 
        CVA 0.604 0.593 – 0.615 <0.01 







This study compared the predictive utility of the CHADS2, R2CHADS2, and CHA2DS2-VASc 
scores after presentations with atherosclerotic disease involving different vascular territories, 
to determine whether prior observations in the coronary circulation could be extended to PAD. 
The CHADS2 risk scores were more predictive of MACE in CAD setting than for PAD, as 
these events occurred less frequently. These findings highlighted the precariousness of PAD 
presentations and suggested that further risk stratification is unnecessary. In this analysis, the 
discriminative aspect of risk scoring was assessed; that is, the differentiation of high and low-
risk presentations. Calibration was not evaluated (i.e., prediction of absolute risk of MACE). 
Nevertheless, with these high event rates, calibration would not strengthen the case for using 
CHADS2-based scores in the management of PAD. 
The worse outcomes in PAD might be connected to the high clinical complexity of 
these presentations, and less medical treatment being prescribed. It is expected that these 
presentations were mostly critical limb ischemia or acute limb ischemia. Treatment of these 
conditions can be complicated, as patients may require urgent lower limb revascularisation, 
amputation, wound care, and the management of concomitant illnesses. These types of hospital 
admissions can be protracted, and patients often require multidisciplinary support [29]. A less 
intensive approach may be adopted in this setting, than with other acute vascular presentations, 
due to concerns regarding adverse reactions. Prior observational studies found that PAD 
patients were less likely to receive optimal risk factor control and guideline-recommended 
therapies compared with coronary artery disease or cerebrovascular disease [10, 12].  
PAD management could change based on recent research [19, 61, 76, 294]. The 
COMPASS study randomised 6,391 individuals with PAD, to either combined rivaroxaban and 
aspirin, rivaroxaban alone, or aspirin alone. Combined rivaroxaban and aspirin significantly 
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reduced the risk of stroke and major adverse limb events, although increasing major bleeding, 
compared to aspirin alone [31, 63]. The SPRINT trial showed that intensive blood pressure 
control could reduce the likelihood of MACE, at the expense of other adverse events, when 
compared to a more conventional approach. While the participants were classified as high risk, 
many components of the CHADS2 score were criteria for exclusion, including heart failure, 
age ³75 years old, diabetes mellitus, and previous stroke [84]. Protein convertase 
subtilisin/kexin type 9 (PCSK9) inhibitors significantly reduced low-density lipoprotein 
cholesterol (LDL-C),  corresponding with MACE reduction across all studied patients, even 
those below traditional targets (<1.8 mmol/L or <70 mg/dL) [146]. Likewise, new medical 
therapies for diabetes and elevated high-sensitivity C-reactive protein can reduce the risk of 
MACE [122, 295-297]. These studies were designed to demonstrate relative efficacy with a 
more intensive treatment strategy. However, they do not define the absolute benefit of therapy 
in the broader population, which could be achieved through risk stratification. 
Clinical decisions require a nuanced consideration for potential treatment risks and 
benefits. A treatment threshold has been described, whereby the benefits of any preventative 
therapy matches the net harm and costs [289]. For instance, if combined rivaroxaban and 
aspirin are at the treatment threshold for PAD, a 1% absolute risk reduction in stroke and major 
adverse limb events would be equivalent to the risk of bleeding, medication, costs, and patient 
preference to avoid an adverse event. COMPASS evaluated people with a stable history of 
PAD [31, 63]. Whereas, the PAD presentations in this study were more critical. These were 
very high-risk conditions that could not be meaningfully risk-stratified with the CHADS2 
scores. Theoretically, people presenting to hospital with PAD had more to gain from combined 
rivaroxaban and aspirin, given such high rates of subsequent MACE. With evidence for 
pharmacotherapies mostly extrapolated from lower risk cohorts [147], there is no consensus 
regarding the role of intensive medical therapy in unstable PAD presentations [29]. ATLAS 
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ACS-2-TIMI-51 examined the efficacy of adding low-dose rivaroxaban to antiplatelets in 
patients with recent acute coronary syndrome [298]. More evidence for the management of 
critical limb ischemia is required, in the same way that acute coronary syndrome is researched 
[29]. While the benefit of combined rivaroxaban and aspirin might be assumed in critical limb 
ischemia, further validation is necessary. There could be a high bleeding risk, as patients with 
critical limb ischemia potentially require several procedures. The relative benefits and risks of 
combined rivaroxaban and aspirin might not be consistent across the entire PAD population.  
The CHADS2 score was predictive of MACE in the CAD setting, which is consistent 
with previous studies [286-288]. For CAD presentations with a CHADS2 score of 0 and ³4, 
the observed incidence of MACE (per 100 person-years) was 4.03 and 69.3, respectively. 
Seemingly, even the lowest risk CAD presentations would be deserving of more intensive 
treatment. However, some preventative therapies, such as PCSK9 inhibitors, are yet to be 
introduced entirely. Some caveats include a lack of long-term safety and efficacy data, as well 
as economic considerations. The European Society of Cardiology stated the cost-effectiveness 
of PCSK9 inhibitor treatment at different LDL-C levels, which focused on the cost per quality 
of life years gained. They recommended PCSK9 inhibitors for the highest risk individuals, 
where LDL-C reduction would be most pronounced [94]. Therefore, there could be greater 
value in implementing new medications in CAD with CHADS2 ³4, (or R2CHADS2 ³4) and 
with all PAD presentations, compared with lower risk presentations. 
CVA was associated with a moderate risk of MACE, somewhere between that for CAD 
and PAD. In the period of observation following CVA, there was an approximately 3-fold 
increase in mortality compared with CAD. The C-statistics suggest that the CHADS2-based 
scores were reasonable predictors of MACE for CVA. In the lowest risk-stratified CVA 
presentation (CHADS2 score 0), the incidence of MACE was comparable to CAD with 
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CHADS2 score 1. Nevertheless, the usefulness of the CHADS2 scores in CVA would depend 
on the therapeutic threshold for implementing a different management strategy. The risks of 
harm associated with antithrombotic and antihypertensive therapy in acute stroke can differ 
significantly from other conditions [299]. Cardiovascular outcome studies typically make a 
distinction of investigating stable cerebrovascular disease, as in COMPASS, where a recent 
stroke (less than one month) was excluded [64]. 
The CHADS2 score is useful in AF because the absolute risk of stroke is low, and each 
component of the score is influential [300]. In this study, a Cox multivariate regression analysis 
was performed on risk factors of MACE in PAD. Of the components of the CHADS2 score, 
age, heart failure, and diabetes mellitus were not clearly associated with MACE. Only 
hypertension and prior cancer were associated with an increased risk of MACE. Therefore, the 
incidence of MACE in PAD was invariably high, and conventional risk factors were not 
strongly predictive of recurrent events. These findings reveal how the CHADS2 scores were 
broadly lacking, and they were unlikely to improve substantially if new risk factors were added.  
The ideal risk model would be simple, accurate, and widely applicable to different 
vascular populations and discriminate those who should and should not receive treatment. 
There are other validated risk scores with good discriminatory power in acute coronary 
syndrome [288, 291]. The CHADS2 score is easy to calculate and widely used for AF. Previous 
studies have found the score to be applicable to both stable and unstable coronary artery disease 
presentations [286, 301, 302]. This type of algorithm can be applied retrospectively to 
cardiovascular outcome studies, such as COMPASS. The goal would be to identify groups at 
high risk of ischemic events, without an equivalent increase in the risk of adverse events, such 
as major bleeding. 
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In this study, CHADS2-based scores were tested in predicting a composite of MACE 
endpoints. The elevated MACE rates observed in PAD were mostly attributable to non-fatal 
stroke and myocardial infarction. In AF, the focus of treatment is in preventing ischaemic 
stroke. Whereas, in PAD, there are separate risks of major adverse limb events, myocardial 
infarction, and mortality. The impact of preventative treatment can vary for each outcome. If 
an algorithm were used to guide the management of PAD, it would need to have adequate 
discrimination for predicting these individual outcomes. In the PAD subgroup of COMPASS, 
combined rivaroxaban and aspirin was associated with a relative risk reduction in MACE, 
ischaemic stroke, and major adverse limb events, but not for myocardial infarction or mortality 
[63]. A meta-analysis combined the randomised controlled trials of intensive blood pressure 
control. A lower blood pressure target was associated with a significant relative risk reduction 
in MACE and stroke, a borderline significant reduction in myocardial infarction, and no 
observed reduction in mortality [303]. PCSK9 inhibitors lowered the likelihood of MACE, 
principally through lesser myocardial infarction and stroke [93]. In the PAD subgroup treated 
with empagliflozin, there was an observed risk reduction in MACE predominantly from lower 
mortality and hospitalisation for heart failure [107]. Therefore, algorithm-based management 
of PAD would need to be relevant to all major adverse events. 
When devising an algorithm, the dynamic nature of risk should be considered. In this 
analysis, CHADS2-based scores were applied to hospital presentations in order to predict 
subsequent MACE. There was a relatively short period of observation for PAD, irrespective of 
the baseline CHADS2 score. As this period of observation lengthens, there is more potential 
for the score to increase. In AF, the delta CHADS2 score (increase in the score between baseline 
and follow-up), has been shown to predict stroke risk [304]. This was highlighted in a study 
where 90% of AF patients without baseline comorbidities developed at least one new risk factor 
before an ischaemic stroke occurred [305]. 
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An individual’s residual risk is highly dependent on the management they receive. The 
CHADS2-based scores evaluate non-modifiable risk factors, such as age, gender, and medical 
history. Notwithstanding, the clinical course of diabetes, hypertension, and stroke can be 
altered, using medical and lifestyle interventions, without affecting the CHADS2 score. An 
ideal algorithm would incorporate risk factor control, as a continuous variable, and could be 
applied for a dynamic perspective of residual risk. The difficulty with incorporating continuous 
variables is that they cannot be applied to all studies. A simplified approach would be to focus 
on the prescription of medications. For instance, antihypertensive or diabetic medication use 
would add modifiability to CHADS2-based algorithms. The HAS-BLED score was developed 
for risk-stratifying bleeding risk in AF patients [306]. A high score is not necessarily a deterrent 
for prescribing anticoagulation. Instead, it provides a dynamic clinician assessment of bleeding 
risk, with the possibility for modifiability [307].  
Several caveats should be noted concerning this observational and retrospective 
analysis. It involved an administrative dataset, which examined a large heterogeneous 
population that presented to the emergency department. Given the real-world dataset, it permits 
the opportunity to study many individuals, reflecting contemporary practice to a higher degree 
than the restrictive and controlled cohorts enrolled in clinical trials. However, such data is 
limited in the information obtained, including patient complexity and the use of procedures and 
medical therapies. Such data can be subject to inaccuracies and potential coding errors. While 
multivariate regression analysis was performed, the possibility of unmeasured confounding 




9.5.  Conclusions 
The CHADS2, CHA2DS2-VASc, and R2CHADS2 scores had weak discrimination for MACE 
that commonly occurred following acute presentations with PAD. New strategies and medical 
therapies are required to improve outcomes in PAD, and there was minimal evidence that 


















10.1. Research overview and aims 
This thesis evaluated associations between clinical factors and cardiovascular mortality and 
morbidity in PAD, which provides new insights into the management of these patients. The 
framework for this research was to draw comparisons between groups to understand outcome 
discrepancies. There are numerous reasons for the disproportionately higher rates of MACE 
and mortality in PAD, compared with atherosclerosis clinically manifested in other territories. 
The breadth of this problem is too extensive to discuss here in its entirety. One aspect that was 
outside of the scope of this research was the impact of health care systems at the population-
level. 
The introductory chapter reviewed the magnitude of the problem and the evidence for 
treatments recommended by the professional bodies. This thesis tackled gaps in the 
understanding of intensive risk factor control; gender differences in cardiovascular events; 
lower limb revascularisation outcomes; dyslipidaemia disorders that associate with PAD; the 
prevalence of PAD in Australia; and the clinical utility of risk scores. 
 
10.2. Individual study findings 
We summarise the individual study findings below while recognising the limitations of these 
post hoc observational analyses. 
 
Chapter 2 examined the impact of intensive individual and multiple risk factor control on 
cardiovascular outcomes in ACCELERATE. 
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• PAD patients had a greater incidence of MACE (17.0% vs 13.3%, p<0.001), and all-
cause mortality (8.2% vs 3.6%, p<0.001), when compared with coronary artery disease 
(CAD)-only. 
• Higher MACE rates for PAD were observed even in the setting of an HbA1c <7.0% 
(12.8% vs 10.7%, p=0.02), LDL-C <70mg/dL (15.7% vs 11.4%, p<0.001), systolic BP 
<130 mmHg (13.8% vs 11.0%, p=0.01), diastolic BP <80 mmHg (15.9% vs 12.0%, 
p<0.001), triglycerides <150 mg/dL (14.1% vs 11.9%, p=0.02), non-smoking (15.6% 
vs 12.3%, p<0.001), and multiple risk factor control (14.0% vs 11.1%, p=0.004), in 
comparison with CAD-only. 
• For PAD patients that achieved optimal glycaemia, LDL-C, systolic BP, diastolic BP, 
triglycerides, BMI, and smoking abstinence, individually or in combination, there was 
no significant relative risk reduction in MACE. 
• Optimal hs-CRP levels were the lone risk factor that correlated with improved 
cardiovascular outcomes (HR 0.78, 95% CI, 0.61 to 0.99, p=0.05). 
• These findings highlight the challenges with altering the natural history of PAD and 
indicate a need for new strategies, including inflammatory control. 
 
Chapter 3 examined for differences in coronary artery plaque burden and progression in PAD 
and non-PAD patients, according to risk factor control. 
• PAD patients had a smaller external elastic membrane volume, but comparable percent 
atheroma volume, compared to non-PAD patients. This could indicate a proclivity for 
negative remodelling in the coronary circulation. We propose that negative remodelling 
is also occurring in the peripheries and is clinically manifested by early ischaemia.  
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• Both PAD and non-PAD groups had a comparable annualised change in percent 
atheroma volume and the number of people classified as having plaque progression and 
regression. We postulate that the underlying cardiovascular risk profile can explain 
differences in plaque observed in other studies. 
• Combined risk factor control and optimal triglycerides were associated with greater 
total atheroma volume regression in non-PAD patients, compared to the PAD group. 
• In PAD patients achieving individual or combined risk factor control, there was no 
significant difference in percent atheroma volume or total atheroma volume change, 
compared with PAD individuals that did not. This suggests resilience to medical 
treatments and is consistent with the clinical observations in chapter two. 
 
Chapter 4 was a systematic review and meta-analysis that combined 14 studies reporting a 
multivariate-adjusted hazard ratio for gender differences in mortality or MACE. 
• Male gender was associated with a greater risk of all-cause mortality (HR 1.13, 95% CI 
1.10 to 1.16, p<0.001) and MACE (HR 1.10, 95% CI 1.06 to 1.14, p<0.001). 
• Higher mortality and MACE rates in men with PAD occurred despite other accepted 
gender disparities. This divergence was potentially more significant in advanced 
diseases, such as critical limb ischaemia or when a lower extremity procedure was 
performed. 
• These results might represent how females benefitted from treatment.  
 




• The rates of MACE in females and males were comparable (16.0% vs 17.4%, p=0.32, 
respectively). Females were significantly less likely to die from any cause than males 
(5.6% vs 9.2%, p=0.01). 
• Male gender was independently predictive of all-cause mortality (adjusted hazard ratio 
[HR] 1.62, 95% CI, 1.11 to 2.38, p=0.01). 
• Female PAD patients that achieved more optimal risk factor control had significantly 
lower all-cause mortality than their male counterparts (4.0% vs 8.6%, p=0.004). 
• Given the disconnect between mortality and non-fatal MACE, major adverse limb 
events might contribute to the observed gender differences.  
• We postulate that women with PAD benefit more from intensive risk factor control than 
men, through a reduction in major adverse limb events. 
 
In chapter 6, propensity-score matched analysis was performed to compare long-term (up to 8 
years) outcomes of endovascular and surgical lower extremity revascularisation. 
• The incidence of complications was as followed: major adverse limb events ([MALE], 
17.9% and 15.3%, p<0.0001), all-cause mortality (29.3% and 29.1%, p=0.89), all-cause 
mortality or MALE (40.4% and 38.3%, p<0.0001), in unmatched surgery and 
endovascular patients, respectively. 
• With a propensity-matched comparison, endovascular repair had a higher rate of all-
cause mortality (HR 1.14, 95% CI 1.10 to 1.19, p<0.001), composite of all-cause 
mortality or MALE (HR 1.12, 95% CI, 1.07 to 1.16, p<0.001), and composite of other 
limb events (HR 1.12, 95 % CI, 1.09 to 1.15, p<0.001), but similar rates of MALE, 
major bleeding, all-cause acute rehospitalisations, compared to surgery. Endovascular 
patients were less likely to require urgent surgical reintervention (HR 0.70, 95% CI, 
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0.63 to 0.78, p<0.001), elective surgical reintervention (HR 0.65, 95% CI, 0.60 to 0.69, 
p<0.001), or experience arterial embolus/ thrombus (HR 0.83, 95% CI, 0.76 to 0.91, 
p<0.001), but at the expense of higher urgent endovascular reintervention (HR 1.18, 95 
% CI, 1.09 to 1.28, p<0.001), elective endovascular intervention (HR 1.49, 95% CI, 
1.42 to 1.56, p<0.001), and minor amputation (HR 1.35, 95% CI, 1.24 to 1.47, 
p<0.001). 
• Male gender was associated with an 8% higher rate of mortality or MALE. 
• Some cardiovascular conditions appeared to be protective, such as a prior percutaneous 
coronary intervention or coronary artery bypass graft operation. This could indicate an 
advantage from completed coronary revascularisation when this precedes PAD 
revascularisation. 
• The high rates of major adverse events emphasise the dangers of revascularisation, and 
some less critical cases might be better managed conservatively.  
• There were many associations between non-PAD comorbidities and MALE or 
mortality, indicating that there are multiple mechanisms likely contributing. Patients 
have complex multidisciplinary needs that continued beyond the revascularisation 
procedure. 
 
Chapter 7 was an exploratory analysis of the Heart of the Heart study. The Indigenous 
participants underwent a clinical assessment that included an ankle-brachial index (ABI) and 
an extensive lipid panel. 
• People with abnormal ABI had a lower median total HDL-mediated cholesterol efflux 
capacity, compared to normal ABI (30.6% [27.3, 34.2] and 31.1% [29.5, 34.2], p=0.02). 
There was a significantly lower adjusted total HDL-mediated cholesterol efflux 
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capacity (adjusted difference -1.40%, 95% CI, -2.46 to -0.24, p=0.02) and ABCA-1 
cholesterol efflux capacity (adjusted difference -1.20%, 95% CI, -2.11 to -0.19, 
p=0.02), when comparing abnormal with normal ABI. 
• This result has potential mechanistic implications underscoring a role for dysfunctional 
HDL in the pathogenesis of PAD. 
•  
Chapter 8 evaluated the usefulness of ABI screening for the Heart of the Heart participants. 
• Of 185 Indigenous participants, 58% had normal, 28% abnormal, and 15% borderline 
ABI, from a single lower limb screened. 
• When applying the National Vascular Disease Prevention Alliance algorithm to non-
normal ABI, the proportion of people that were very low, low, moderate and high risk 
was 53%, 16%, 8% and 23%, respectively. This indicates that cardiovascular risk was 
being grossly underestimated in most affected individuals. 
• These findings suggest that undiagnosed PAD could be contributing to health 
disparities in Indigenous Australians. 
 
In chapter 9, several CHADS2-based scores (CHADS2, CHA2DS2-VASc, R2CHADS2) were 
evaluated for predicting MACE after PAD-related hospital presentations, compared with other 
hospital presentations. 
• For presentations with a CHADS2 score of 0 and ³4, the incidence of subsequent 
MACE (per 100 person-years) increased from 27.1 to 120.1 for PAD, 14.2 to 73.4 for 
cerebrovascular accident (CVA), and 4.0 to 69.3 for CAD, respectively. 
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• The risk of MACE for every additional CHADS2 point was higher for CAD (hazard 
ratio [HR] 2.00, 95% CI, 1.95 to 2.05, p<0.01), compared with PAD (HR 1.45, 95% 
CI, 1.38 to 1.53, p<0.01). 
• The C-statistic for the CHADS2 score predicting MACE was lower in PAD, (C-statistic 
0.53, 95% CI, 0.51 to 0.56, p=0.01), compared with CVA (C-statistic 0.59, 95% CI, 
0.58 to 0.60, p<0.01) and CAD (C-statistic 0.64, 95% CI, 0.63 to 0.65, p<0.01). 
• These results demonstrated the exceptionally high clinical risk of presentations with 
PAD and that further risk stratification did not appear advantageous. 
 
10.3. Overarching conclusions 
Important caveats should be noted regarding these observational and retrospective analyses. 
Some chapters utilised administrative data, which had the potential for coding and data entry 
inaccuracies. Each study had a varying degree of clinical information, and therefore, the group 
comparisons that were made could have been affected by confounding. We formulate the 
following hypotheses regarding PAD, in contrast to other high-risk conditions, such as 
coronary artery disease; although, these require further clarification through randomised and 
prospective studies. 
• PAD patients have a distinct clinical phenotype, relating to functional status, 
cardiovascular risk factors and other medical comorbidities. This high medical 
complexity is a major contributor to cardiovascular mortality and morbidity. 
• The risks and benefits of intensively treating PAD are different, and this partly explains 
the low prescription of proven therapies in observational studies. 
• Concomitant coronary artery atheroma in PAD patients have specific properties that are 
more resilient to the effects of preventative treatments. 
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• PAD-affected women are less likely to experience major adverse limb events and 
mortality, and this is linked to lower utilisation of lower extremity revascularisation and 
a more beneficial impact of preventative treatments. 
• Major adverse limb events are an additional driver of cardiovascular and non-
cardiovascular mortality. 
• There are some enduring advantages of surgical revascularisation, including less all-
cause mortality and endovascular reintervention, compared to an initial endovascular 
approach. 
• Dysfunctional HDL cholesterol is associated with the pathogenesis of PAD and can be 
a therapeutic target. 
• Undiagnosed PAD is contributing to health disparities in Indigenous Australians 
• PAD-related hospital presentations are invariably high-risk, whereby evaluation using 
a clinical risk score is not advantageous. 
 
10.4. Clinical implications and future directions 
10.4.1.  Clinical implications 
The high medical complexity of PAD patients requires multidisciplinary management. As was 
evident from the Steno-2 study, a team approach is the most effective means of delivering risk 
factor modification, and in monitoring for adverse reactions. In chapter 2 and 3, there was no 
convincing benefit from intensive multiple risk factor control, although this data had 
limitations. Further investigation through randomised controlled trials would better 
characterise the effects of multiple risk factor control in PAD. These studies do not negate the 
importance of intensive risk factor control, but they do provide perspective regarding the 
challenges in altering the natural history of this condition. Chapter 9 considered the treatment 
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threshold for prescribing preventative therapies. For example, the risks and benefits of the 
intensive management of dyslipidaemia are distinct from hyperglycaemia. There are 
differences in toxicity, dependent on the medications used and patient-specific factors, thus 
necessitating an individualised decision that is less reliant on broad-based recommendations. 
Other preventative treatments need to be implemented, such as combined antithrombotics 
and new strategies for inflammatory control. Chapter 7 showed a link between lower HDL-
medicated cholesterol efflux capacity and early PAD, and this is another potential target for 
therapeutic modification. A subgroup analysis of PAD in clinical trials of HDL mimetics would 
be of interest. 
The importance of clinical discretion was again evident in chapter 6, where all PAD patients 
had a high risk of mortality and major adverse limb events (MALE), irrespective of the 
revascularisation strategy performed. Peripheral artery revascularisation is sometimes the only 
possible option to resolve lifestyle-limiting claudication. In this setting, the long-term risk of 
mortality, MALE and other limb events need to be weighed against this benefit. There were 
many observed links between non-PAD comorbidities and MALE or mortality, and these 
conditions require management from various healthcare specialists. 
PAD exists across a clinical spectrum, ranging from asymptomatic disease, intermittent 
claudication, and critical limb-threatening ischaemia that requires lower limb revascularisation 
or amputation. Most of the evidence for pharmacotherapies have been extrapolated from lower 
risk cohorts. Chapter 9 highlighted the precarious nature of PAD-related hospital presentations, 
and these types of patients are rarely included in clinical trials. These conditions could not be 
meaningfully risk-stratified with the CHADS2 scores. Theoretically, people presenting to 
hospital with PAD have more to gain from preventative treatments. While the benefit of 
intensive therapies, such as combined rivaroxaban and aspirin, might be assumed, further 
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validation is necessary. More evidence for the management of critical limb ischemia is 
required, in the same way, that acute coronary syndrome is researched. Chapter 8 looked 
beyond the management of established disease at the benefits of screening for early PAD. ABI 
is a simple and non-invasive test with good sensitivity and specificity for detection of 
asymptomatic disease. The role of ABI screening of Indigenous Australians needs further 
clarification, as this could help address the accepted problem of cardiovascular risk 
underestimation in this population. 
Chapter 4, 5 and 6 identified significant gender disparities. Acknowledging there are 
different interactions between risk factors and PAD, according to gender, the impact of 
preventative treatments might differ also. While contemporary clinical trials have investigated 
the effects of medical treatment in preventing major adverse limb events, fewer women are 
usually enrolled. We postulate that women with PAD benefit more from intensive risk factor 
control than men. Research into the effects of intensive risk factor control in PAD, with a 
gender-specific lens, is indicated. An appreciation for these issues could inspire more effective 
health initiatives that are attentive to both gender groups. There may be a role for PAD care 
delivery models that focus separately on men and women, as has been introduced in other 
aspects of cardiovascular medicine. 
 
10.4.2.  Ankle-brachial index screening 
The Heart of the Heart study raised serious questions about the under-diagnosis of Indigenous 
populations living in Central Australia. Current national guidelines do not endorse the use of 
ankle-brachial index screening for asymptomatic people. Local research is required into the 
prevalence of PAD across different populations in Australia. A more extensive study in 
different Australian regions is required. As with Heart of the Heart, detailed clinical 
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information and blood tests should be collected to assess Framingham risk scores and to 
evaluate how an abnormal ABI could resultantly alter management. A longitudinal study, 
where participants are followed for years, would help validate some inferences made about the 
association between an abnormal ankle-brachial index and cardiovascular risk. 
 
10.4.3.  Multifactorial intervention clinical trial 
This research featured observational studies of patient cohorts and administrative datasets. The 
possibilities for new treatment strategies were discussed that need evaluation in a clinical trial. 
We would propose a randomised controlled trial of PAD patients that investigates new 
approaches to care. A central question is the safety, efficacy, and viability of intensive multiple 
risk factor control. The Steno-2 study demonstrated the cardiovascular benefits of 
multifactorial intervention in a 160-patient randomised controlled trial of diabetes patients that 
occurred for 7.8 years [134]. Steno-2 provides a framework for powering a study of multiple 
risk factor control. However, risk factor targets should be based on contemporary ideas, and 
lifestyle modification needs to be tailored towards the challenges of PAD. Some cardiovascular 
targets include systolic blood pressure <130 mmHg, diastolic blood pressure <80 mmHg, 
triglycerides <150 mg/dL, high-sensitivity C-reactive protein <2.0 mg/L, body mass index <25 
kg/m2, and glycated haemoglobin <7.0%. Some functional goals include treadmill walking 
distance and quality of life.  
 
The types of initiatives that could be incorporated include: 
• Specialist physician and nursing consultation for the initiation and titration of 
preventative medical therapies 
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• Routine evaluation of cardiovascular risk factors with patient feedback in the form of 
personalised counselling, progress charts, letters and mobile phone messages 
• Regular treadmill walking program supervised by an exercise physiologist  
• Dietician-led weight loss consultation that includes consistent phone and email-based 
communication centred around the recording of a food journal 
• Motivational interviewing and behavioural psychology strategies that encourage self-
directed goals regarding walking, weight, and risk factors 
• Use of smartphones to monitor walking steps 
• Group-based education and support, in clinics and through social media platforms  
• Pharmacy counselling and review focused on medication compliance and minimisation 
of errors 
 
The efficacy of multifactorial intervention can be assessed through serial measurements of 
walking, quality of life, risk factor control, exploratory laboratory tests, and the incidence of 
adverse events. The outcomes of interest include:  
• Walking distance (maximum walking distance and claudication-onset walking 
distance) using a validated treadmill protocol [308] 
• Quality of life and pain scores using a validated questionnaire [309] 
• Total number of controlled risk factors 
• Ankle-brachial index 
• Inflammatory and lipid risk markers, including high-sensitivity C-reactive protein and 
cholesterol efflux capacity 




A clinical trial of PAD patients designed to test hypotheses generated from this body of work 
could create a road map for the future.  
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